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Abstract 
 
This investigation involved the synthesis of potential CA clan cysteine inhibitors of m-calpain 
and cathepsin B. Inhibitors 2.1.3a-j were based on the SJA-6017 construct containing the          
N-(4-fluorobenzenesulfonyl) moiety at the P3 address region. The inhibitor 2.1.3k was based on   
CAT-0059 a novel dipeptide dialdehyde inhibitor containing the 5-formyl pyrrole moiety at the 
P3 address region. 
 
Chapter 1 introduces proteases in particular m-calpain and cathepsin B implicated in human 
pathologies cataract and tumour metastasis respectably. Structure, disease processes and known 
inhibitors for m-calpain and cathepsin B are presented and described. The chapter also describes 
drug design and rational including the requirement of the β-strand conformation for enzyme 
substrate binding.  
 
Chapter 2 details the synthesis of m-calpain and cathepsin B inhibitors,                  
N-(4-fluorobenzenesulfonyl) peptide aldehyde 2.1.3a-j and the dipeptide dialdehyde 2.1.3k.    
The synthesis involved the preparation of the N-(4-fluorobenzenesulfonyl) α-amino acids  
2.1.8a-f, the N-(4-fluorobenzenesulfonyl) peptide esters of 2.1.10a-g, the peptide alcohols 
2.1.11a-k and the peptide aldehydes 2.1.3a-k. Specific coupling reagents for amide bond 
formation are also discussed. The oxidation of the alcohols 2.1.11a-k with sulfur trioxide and 
pyridine complex are also addressed. The results from molecular modelling and enzymatic 
assays of the inhibitors 2.1.3a-k with m-calpain and cathepsin B are presented and discussed.   
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Chapter 1 
Introduction 
 
1.1 Proteases and the cysteine protease family 
 
The protease super family are a vast group of enzymes that control protein synthesis, turnover 
and function and thereby regulate the normal physiological responses including digestion,1,2 cell 
degradation3,4 tissue remodelling5,6 blood pressure regulation7 and defensive roles.8                 
The proteases are also responsible for disease propagation in numerous pathologies including; 
cancers,9 (tumour metastasis)10,11 viral infections (e.g. HIV),12 cardiovascular diseases,13         
and neurological disorders including Alzheimer’s disease14 (Table 1.1 below).                  
These biochemical processes all involve selective cleavage and catalysis of specific peptide 
(amide) bonds on target substrates (Figure 1.1).  
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Figure 1.1 Peptide bond cleavage from a protease via catalysed hydrolysis  
The majority of proteases are sequence specific therefore to describe these binding positions 
standard (Schechter and Berger) nomenclature is used (Figure 1.2).15,16 
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Figure 1.2 Schechter and Berger nomenclature, substrate/inhibitor P regions with the enzyme 
subsites S regions.15,16 Standard polypeptide substrate sequence where the standard 
substrate/inhibitor regions are designated as P3, P2, P1, P1', P2', P3'. These P regions will bind to 
their corresponding enzyme subsites S3, S2, S1, S1', S2', S3'. 
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Protease classification 
 
The protease super family comprises of five classes,17 cysteine, threonine, serine, aspartic acid, 
and metalloproteases (Table 1.1). The classification system defines the active functional group 
within the active site of each enzyme class. The most common characteristic of the proteases is 
they require a nucleophile for the hydrolysis of a peptide bond.17 However; the catalytic 
mechanisms vary between the classes. For cysteine, threonine and serine proteases the 
nucleophile is a component of the side chain. For aspartic acid and metalloproteases an activated 
water molecule acts as nucleophile.17 
Table 1.1 Protease classification based on catalytic properties, regular function and dysfunctions 
Protease 
Family 
Selected Enzymes Function Dysfunction 
Cysteine Calpains μ and m 
(calcium activated proteases) 
 
 
Cathepsins B, C, F, H, K, L, S, O, 
V, W and X (human cathepsins) 
Papain 
Bone resorption18
Regulation in cell death19,20 
Cytoskeletal remodelling21  
Signal transduction22 
Intracellular lysosomal 
protein degradation23-25 
Defence8 
Cataract26
Muscular dystrophy27 
Alzheimer’s disease14 
 
Tumour invasion and 
metastasis10 
Threonine Proteasome Degradation of ubiquated 
proteins28 
 
Serine Cathepsin G 
Chymotrypsin 
Elastase 
 
Plasma Kallikrein 
Thrombin 
Cellular degradation3,4 
Digestion1 
Elastin degradation29 
Digestion1 
Pro-urokinase activation30 
Procoagulant and 
aniticoagulant31 
 
 
 
 
Cardiovascular 
disease13 
Pulmonary fibrosis32 
Aspartic acid HIV protease 
Cathepsin D and E 
Pepsin 
Renin 
 
Intracellular degradation9 
Digestion2 
Blood pressure regulation7 
HIV replication12
Gastric carcinoma9 
Peptidic ulcers27 
 
 
Metallo Astacin 
Collagenase 
Gelatinase 
Animal morphogenesis33
Tissue remodelling5 
Tissue remodelling6 
 
Arthritis34 
Tumour invasion11 
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The cysteine protease family can be divided into three major clans (see Table 1.2) defined by 
their structure. The CA or papain like clan is the most abundant of the cysteine proteases.      
This clan consists of three major groups; mammalian proteases (e.g., the lysosomal human 
cathepsins B, C, F, H, K, L, O, S, V, W and X), parasitic proteases (e.g., falcipain), and cytosolic 
proteases (e.g., μ-calpain and m-calpain). The PA or picornain family (e.g., PA(C), SARS virus) 
consist of viral proteases which carry more than one of the following amino acids at their active 
sites serine, threonine, or cysteine. The CD or interleukin 1β converting enzyme (ICE-like) 
proteases, is the second most abundant clan and consists of mammalian (e.g., the caspases 1 and 
3) and bacterial proteases (e.g., the gingipains K and R).35,36  
This study will focus on the inhibition of two cysteine proteases of the CA clan, m-calpain and 
cathepsin B. 
 
Table 1.2 Classification of cysteine proteases35,36 
Clan Family Example of cysteine 
proteases 
CA C1 (mammalian) Cathepsins B, C, F, H, K, L, O, 
S, V, W and X 
CA C1 (parasite) Falcipain 
CA C2 (cytosolic) m-calpain, μ-calpain 
PA(C) C3 (viral) Picornain 3C (e.g., Hepatitis A 
virus, human rhinovirus) 
PA(C) C30 (viral) SARS virus 
CD C14 (mammalian) Caspase 1 (ICE) Caspase 3  
CD C25 (bacterial) Gingipain K and R 
 
The general mechanism of catalysis for the cysteine proteases 
Along with a nucleophile in the active site, a proton donor is also required. In the case of 
cysteine and serine proteases histidine acts as donor.37 Shown below in Figure 1.3 is the 
mechanism for the catalysis of a suitable substrate with a cysteine protease. The reaction 
mechanism can be divided into two distinct processes, acylation and deacylation. The first 
reaction requires a powerful nucleophile to attack a carbonyl carbon of the peptide. The weak 
nucleophilic thiol group on cysteine is activated to the thiolate anion.38 
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The reaction begins with the deprotonation of the cysteine’s sulfhydryl functional group by an 
adjacent histidine imidazole group (A) (Figure 1.3). The SH proton on cysteine is transferred to 
the adjacent histidine to form a Wheland intermediate which is stabilised by hydrogen bonding 
with a nearby asparagine or aspartic acid residue (B). The thiolate anion on cysteine undergoes 
nucleophilic attack on to the carbonyl carbon of the peptide substrate. This forms a high energy 
tetrahedral intermediate with a thioethanolate linkage (C). The thioethanolate anion subsequently 
deprotonates the imidazole functionality on histidine to give the thioester; consisting of cysteine 
and the peptide substrate (D). This also affords the first cleaved segment of the substrate as the 
free amine NH2R (D).38 
The commencement of deacylation phase (to yield the free the cysteine protease) begins with the 
hydrolysis of the thioester (E). This reaction involves the proton abstraction of a water molecule 
via the imidazole group on histidine to provide the hydroxyl ion necessary for the nucleophilic 
attack on carbonyl group on the thioester; this gives rise to the second tetrahedral intermediate 
(F). This is followed by a nucleophilic attack from the oxyanion hole to the histidine which 
breaks the Sγ−C bond on cysteine to release the activated enzyme and the second cleaved 
substrate (G) as the free acid. Then protonation of the cysteine’s thiol group (H) from histidine 
gives the deactivated enzyme (A).38-40 
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Figure 1.3 Mechanism for the catalysis of peptides with cysteine proteases38-40 
 
 
1.2 The calpains and m-calpain structure 
 
The calpains are a diverse family of cysteine proteases present in all mammalian species and first 
identified in 1964 from rat brain.41 In the late 1970s the enzymes were isolated and 
characterised.42 They play important beneficial roles in the regulation of bone resorption,18 
signalling transduction pathways,22 remodelling of cytoskeletal attachments to the plasma 
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membrane21 and cell death19,20 (Table 1.1). The catalytic action unlike other proteases is limited 
to the cleavage of amide bonds between domains as opposed to certain amino acids residues      
or sequences. This form of substrate selectivity leaves large substrate fragments suggesting that 
calpains are bio-modulators instead of being involved in a digestive function.43               
However, calpains are known to play an important role in numerous human pathologies 
including cataract,26 Alzheimer’s disease,14 and muscular dystrophy,27 as addressed in Table 1.1. 
 
The calpain family group comprises of a number of different isoforms which can be classified 
into two distinct groups, according to Suzuki and co-workers. The first group are the typical 
calpains comprising of domains I-IV and the atypical calpains displaying alterations in these 
domains.44 All these isoforms are activated by Ca2+; this form of activation is unique to the 
calpain family. The two most abundant isoforms are μ-calpain and m-calpain. The difference 
between the two isoforms is the concentration of Ca2+ required for their activation: 1.0-100 μmol 
and 0.1-1.0 mmol Ca2+ respectively.45 Occurrence of both these isoforms in mammals is 
ubiquitous and the ratios between μ and m-calpain vary from cell to cell.43 
 
m-Calpain is a flat oval disk shaped enzyme made up of a heterodimeric subunit.                  
The crystallographic study of inactivate human lens m-calpain (Figure 1.4) shows it has a total of 
six subunits (I-VI). The larger catalytic subunit (80 KDa) consists of domains I-IV and the 
smaller regulatory subunit (28 KDa) comprises of domains V and VI; both subunits are encoded 
by CAPN 2 and CAPN 4 genes respectively.44 Positioned in the centre of the enzyme in     
Figure 1.4 below (in green folds) is domain I (dI) (an NH2 terminal domain) this represents the 
start of the larger catalytic subunit where d1 acts as the anchoring helix contained in a vacant 
cavity in domain VI (dVI) (orange folds); This domain folds into the first part of catalytic 
domain II (dII), subdomain IIa (dIIa) (shown in gold folds) via a domain I→II linker.            
Both dI and dIIa form a part of the left hand side of the enzymes architecture which resembles 
papain. Then this folds into the second subdomain IIb (dIIb) (shown in red folds). This domain 
has a barrel like structure which descends (via an II→III linker loop) into domain III (dIII) 
indicated by blue folds. This further descends into the calmodulin-like domain IV (dIV) (the 
terminus of the larger catalytic subunit) (yellow folds) through an extended III→IV linker, 
shown in magenta. Domain V (dV) or S domain (30 KDa) coloured in magenta is positioned 
above dIIa. This domain folds into domain VI (dVI) indicated in orange the left-side calmodulin 
domain. The catalytic residues (which form the active catalytic triad) are positioned on the two 
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subdomains dIIa cysteine and dIIb histidine and aspartate or asparagine (not shown);              
(this is common to all calpains).46 
 
            
 
Figure 1.4 Crystallographic construct of human m-calpain in the inactivated state46 
 
The EF-hand motifs (calcium binding proteins) 
 
The EF-hand motifs are one of the most common of the calcium binding proteins that were first 
described by Kretsinger and Nockolds in parvalbumin.47 These motifs receive their name by the 
protein forming the symbolic shape of a human hand, shown in Figure 1.5a. The E helix winds 
down the index finger to link the F helix winding up through the thumb, (coloured light grey) 
known as the apoprotein (closed conformation). The calcium bound state or holoprotein displays 
the open conformation (dark grey). The calcium bound conformer (Figure 1.5b) forms ligands 
between the amino acid side chains of asparagine or aspartic acid (X and Y), asparagine, aspartic 
acid or serine (Z). In addition to a peptide carbonyl oxygen (-Y) and a water molecule at (-X) 
there is also a conserved bidentate ligand at (-Z). This consists of glutamic acid or aspartic acid. 
Figure 1.5c displays a modified EF-hand loop (without calcium) showing the hydrogen bond 
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scaffolding. The calpains consist of two sets of five EF-hand motifs where each set occurs on 
both the large subunit and small subunits.48 These motifs are similar to that occurring in 
calmodulin which are important in the activation of calpains to induce proteolytic activity.46 
 
 
 
Figure 1.5 The EF-hand motif. (a) Symbolic representation (b) Geometry of the calcium ligands 
(c) Modified EF-hand motif displaying hydrogen bonding48 
 
Calpain activation begins with an influx of Ca2+ which binds to the EF-hand motifs and 
subdomains of dIIa and dIIb. These accommodations of calcium collectively cause 
conformational changes in the overall m-calpain construct (see Figures 1.6 and 1.7).            
These changes are thought to be caused (in part) through a rotational turn of Trp288 in dIIb which 
results in twisting of the dIIb subdomain. It is thought that this conformational twisting will 
reduce the initial gap between the catalytic residues of Cys105, His268 and Asp286 from 8.5Å to a 
functionally active distance of 3.7Å which forms the catalytic triad complex.49 
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Figure 1.6 Schematic representation of m-calpains main binding events.50 (a) m-Calpain in the 
inactivated state. (b) m-Calpain in the activated state with Ca2+ bound. 
 
Then once a suitable substrate is found, catalysis as previously mentioned and illustrated in 
Figure 1.3 occurs. For m-calpain the cysteine residue containing the thiol group will participate 
directly in covalent catalytic cleavage of the peptide (amide) bond. The histidine residue, which 
is in close spatial proximity to the cysteine residue, will also take part in the catalytic cleavage 
acting as the proton donor. In addition the other nearby residues with in the active site will 
provide functional groups for general acid–base catalysis. 
 
 
 
 
 
 10
                        
 
Figure 1.7 Crystallographic structures of the calpains (a) Inactivated human m-calpain51          
(b) Activated (calcium induced) rat m-calpain52 baring the serine (Ser) mutant on dIIa (red folds) 
and histidine and aspartic acid on dIIb (blue folds). In the inactivated construct (a) the distance 
between the Cys105 and His262, Asp286 residues is 8.5 Å; this gap is too far to support a 
functionally active catalytic complex. However upon activation with Ca2+ the gap between Cys105 
and His268 closes to 3.7 Å, close enough to perform proteolysis49,51 
 
 
1.3 Mode of action on m-calpain in cataracts  
 
Cataract is a condition where the eye lens is opaque or cloudy. The normal human eye lens 
(Figure 1.8) is designed to allow light to pass through and focus to the back of the retina.       
This direct focusing is achieved through of three types of crystallins (α, β, γ) where the β form is 
the most abundant. The names are given in order from their elution from gel chromatography. 
Existence of these forms and their generic sequences have been confirmed and characterised in 
previous reports.53-58 
Cys 
His
Ser  
His
Asp 
Asp  
(a) (b)
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Figure 1.8 Schematic of the human eye showing the lens50  
 
The crystallins make up 90% of the water soluble proteins of the lens and are arranged in a tight 
aligned packing. This arrangement increases the refractive index and transparency to allow light 
to pass to the retina.59 However this level of transparency may degrade with one or more of the 
following insults, (see Figure 1.9) diabetes,60 ageing,61 oxidants,62 selenite,63 galatose,64 and 
other causes. 
  
 
 
Figure 1.9 Processes of cataract formation initiated from varying outside insults50 
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These insults can lead to increases in Ca2+ concentration in the lens; calpains present in the lens 
can become pathologically over activated and in a deregulatory manner will proteolyse the 
crystallins. The proteolysis will disrupt or truncate the packing order of the soluble crystallins 
resulting in insolubilisation and development of opacity. This leads to a decrease in overall 
reflective index and lens transparency; which causes incoming light to scatter rather than being 
focused to the back of the retina.65 
 
 
1.4 Known inhibitors of the calpains 
 
The search for selective inhibitors of calpain is ongoing. In the past 35 years since the enzymes 
discovery41 a significant number of inhibitors have been either developed from natural or 
synthetic sources. Unfortunately a large number of them show little selectivity for other cysteine 
proteases, for example cathepsin B. This apparent lack of selectivity may be due to summitries of 
the catalytic triad and surrounding subsite regions of the cysteine proteases. Two of first 
identifiable calpain inhibitors to appear was the calcium chelators; EDTA and EGTA.45  
However these where found to be neither potent nor selective for the calpains; a list of calpain 
inhibitors is summarised below. 
 
Naturally derived inhibitors of calpain (from the plant and fungal kingdoms) 
 
 
N
N
O
O
HO
OH
1.4.1. Diketopiperazine     
 HO
N
H O
N
OH
O
N
H O
H
N
O
OH
1.4.2. Tetrapeptide      
 
HO
O
O
OO
HO
1.4.3. Penicillide  
 
The Streptomyces species has yielded many naturally occurring calpain inhibitors; the main 
groups isolated are the diketopiperazines, peptide aldehydes and the pyrazinones. The inhibitors 
diketopiperazine 1.4.1 and tetrapeptide 1.4.2 have an N-methyl tyrosine moiety and exhibit 
 13
moderate potency for the calpains. Extracted from an actinomycete strain of Streptomyces 
griseus these have respective inhibitions for μ-calpain IC50 = 800 nM and 1.2 μM.66 Penicillide 
1.4.3 is a weak calpain inhibitor 7.1 = μM for μ-calpain occurring from the Penicillium species, 
this compound is an example of a non-peptide calpain inhibitor however; the compound has    
28-fold selectivity towards papain.45  
 
Irreversible calpain inhibitors (from chemical synthesis) 
 
 
Irreversible inhibitors (non active site directed)  
 
The majority of irreversible inhibitors target the active site (active site directed); however, there 
are a number of non active site directed inhibitors such as the α-mercaptoacrylate derivatives 
(PD150606 1.4.4 IC50 = 370 nM for m-calpain and IC50 = 0.128 μM for cathepsin B and 
PD151746 1.4.5 IC50 = 5.33 nM for m-calpain and IC50 > 0.200 µM for cathepsin B). These were 
first reported by Wang et al67 and are one of the earliest known non active site directed inhibitors 
to block calcium ions from binding to calcium binding domains in calpains.67 
 I SH
OH
O
1.4.4. PD-150606                                                                       
 
O
OH
SH
H
N
F
1.4.5. PD-151746  
 
Irreversible inhibitors (active site directed) 
 
The rational of irreversible inhibitors of the calpains such as; peptide diazoketones,68,69           
halo methyl ketones,70 Michael acceptors (α and β-vinyl sulfones)71 and other derivates employ 
an activated electrophile which can be displaced within the active site of calpain by a 
nucleophile, for example the cysteine thiolate group. This displacement leads to the formation of 
a covalent bond and can permanently inactivate the enzyme; therefore these activated 
electrophiles can be regarded as active warheads. The majority of the irreversible inhibitors are 
selective towards serine proteases. The development of active irreversible inhibitors for calpain 
is somewhat limited due to the reactive nature of these warheads reacting to other thiol groups 
occurring throughout the human body. 
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The non-peptides SJA-7019 1.4.6 (IC50 = 64 nM for μ-calpain and IC50 = 1.5 nM for cathepsin L 
and SJA-7029 1.4.7 IC50 = 170 nM for m-calpain and IC50 = 4.2 nM for cathepsin L) displayed 
below are highly potent against μ-calpain and m-calpain and cathepsin L these compounds are 
known to prevent extracellular Ca2+ influxes. 
                                                                          
 
 
 
 
 
 
 
Diazomethyl ketones 
 
 
 
 
 
 
These inhibitors are generally selective for the calpains and have no observable activity for the 
serine proteases.68 It has been suggested the mechanism of enzymatic inactivation is generated 
from nucleophilic attack of the carbonyl carbon on the diazo group by thiolate on cysteine to 
give the hemithioketal. (Figure 1.10) Subsequent protonation of the hemithioketal from the 
imidazole group on histidine 1.4.11 (rate determining step) gives concomitant cleavage of 
nitrogen and the thiol ether end product 1.4.12. The compound cbz Leu Leu Tyr-CHN2 1.4.8 
gives a second rate order of inhibition constants for calpain (k2nd rate 230,000 M-1s-1) and 
cathepsin B (k2nd rate 1,300 M-1s-1).69  
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Figure 1.10 Inhibition with diazo methyl ketone inhibitors  
 
Halo methyl ketones 
 
From X-ray crystal structures this group of compounds are known to from irreversible alklating 
adducts with cysteine active site residues of the cysteine proteases for example papain72 and 
cathepsin B73 The compound cbz L-leucine D,L-tyrosine CH2F 1.4.13 has moderate potency for 
the calpains IC50 = 80 nM and a second order constant (k2nd rate 17,000 M-1s-1) for chicken gizzard 
m-calpain.70 The fluoroketones display superior potency compared to the chloro analogues.70 
 
 
O
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O
1.4.13. Cbz L-leucine D,L-tyrosine CH2F  
 
 
Allyl vinyl sulfones 
 
The Michael acceptors (α and β vinyl sulfones) are generally selective for the calpains with the 
β (allyl) analogues displaying the greater potency and selectivity towards to cathepsin B 
compared to the calpains.71 Nevertheless the α-vinyl sulfones are found to be non-reactive 
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towards other thiol proteases occurring through the human body and are only active towards the 
cysteine residue.  
 
The compound cbz-Val-Phe-Avs-Ph (E&Z) 1.4.14 displays reasonable inhibition for μ-calpain 
(IC50 = 3.0 nM for μ-calpain) and no observable inhibition for cathepsin B. Generally the allyl 
vinyl sulfones exhibit greater potency then the vinyl sulfones.71 
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Synthetic reversible calpain inhibitors 
 
Examples of reversible inhibitors that inhibit calpains have been produced from; peptide 
aldehydes,16,74,75 the ketones (α-ketoacids, α-ketoamides, α-ketoesters and α-ketoacids) and 
other derivatives. These moieties inactivate the enzyme in a reversible reaction by the reversible 
formation of a covalent bond. In the case of the peptide aldehydes a hemithioacetal or with the 
ketones a thioketal would form with the cysteine’s thiol group in the active site of calpain.  
 
Peptide aldehydes 
 
Many examples of peptide aldehydes have been synthesised for the calpains in which the 
mechanism of inhibition is illustrated in Figure 1.11 below. This reaction forms a reversible 
covalent adduct which mimics the active transition states of the thiolate complex 1.4.15 
generated from normal substrate proteolysis. This type of inhibitor is considered competitive due 
to tight binding.74 
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Figure 1.11 The mechanism of reversible inhibition of aldehyde inhibitors forming the 
hemithioaceteal74 
 
The compound MDL-28170 1.4.16 also referred to as calpain III inhibitor, IC50 = 7 nM for 
calpain16 and IC50 = 21 nM for cathepsin B. MDL-28170 exhibits good potency for both            
μ-calpain and m-calpain and the cathepsins. The compound 1.4.16 is used as a template 
compound for other potential inhibitors. 
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The aldehyde compound 1.4.17 is a potent and inhibitor for μ-calpain IC50 = 28 nM and             
IC50 >10,000 nM for cathepsin B which exerts good selectivity for μ-calpain over cathepsin B. 
Compound 1.4.17 consists of a P2 = azo-proline moiety at P2 which gives added constraint to the 
inhibitor.75  
 
The calpain inhibitor calpeptin 1.4.18 is a potent, cell penetrating inhibitor which is known to 
stop the activity of μ-calpain proteolysis in rat platelets after 30 min of incubation, IC50 = 40 nM 
for platelet μ-calpain.76,77 
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The ketones, α-ketoacids, α-ketoamides, α-ketoesters 
 
The ketones are generally non selective inhibitors for the cysteine proteases, their order of 
potency for the cysteine proteases decreases from the α-ketoacids > α-ketoamides >                  
α-ketoesters.45,78 The mechanism of inhibition for the ketones α-ketoacids and α-ketoesters is 
given in Figure 1.12 to give products 1.4.20. The reaction with the α-ketoamide gives structure 
1.4.21 shown in Figure 1.13 below.79  
  
 
 
 
 
 
 
R3= Alk ketone 
R3= OH α-ketoacid 
R3= OAlk α-ketoester 
 
Figure 1.12 Inhibition of the ketones, α-ketoacids and α-ketoesters79 
 
 
 
 
 
 
 
Figure 1.13 Inhibition for the α-ketoamides79 
 
A number of ketones inhibitors based from the cathepsin B inhibitor MDL-28170 (1.4.16) were 
synthesised by Li and co-workers78 which found the α-ketoacid 1.4.22 to be one of the most 
potent and selective (selectivity for m-calpain over cathepsin B 790 fold) examples of the 
ketones, IC50 = 5.7 nM, for m-calpain IC50 = 4.5 μM for cathepsin B and IC50 = 7.0 μM, for 
papain.78 
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The α-ketoamide inhibitor 1.4.23 has high potency and a good selectivity (190-fold) for           
m-calpain over cathepsin B, IC50 = 19 nM for m-calpain, IC50 = 3.4 μM for cathepsin B and       
IC50 = 190 μM for papain.78 
 
The compound 1.4.24 is an example of a α-ketoester which gives good inhibition and (180-fold) 
selectivity for m-calpain over cathepsin B IC50 = 180 nM for m-calpain, IC50 = 0.02 μM and          
IC50 = 0.19 μM for papain. α-Ketoesters provide the greatest permeability and selectivity 
compared to the other ketones.78 
 
 
 
 
 
 
 
1.5 The cathepsins and cathepsin B structure 
 
The cathepsins are a large group of ubiquitously expressed proteases that span three main 
protease groups (cysteine, aspartic and serine).80 The largest group is of the cysteine cathepsins 
these consist of 11 lysosomal (human) cathepsins B, C, F, H, K, L, O, S, V, W and X.81          
The other family members of the cathepsins occur in the aspartic family (cathepsin D and E) and 
the serine family (cathepsin G)80 (Table 1.1). In the past 15 years the number of known 
beneficial and pathological roles of human cathepsins has increased two fold. The human 
cathepsins are involved with normal cellular functions for example, protein breakdown in 
lysosomes, normal protein turnover, bone remodelling and antigen processing.81 However, they 
play many significant roles in much human pathology, including Alzheimer’s disease, arthritis, 
atherosclerosis and multiple sclerosis.81  
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Cathepsin B is the most abundant and widely studied of the human cathepsins. The enzyme is 
responsible for the formation of insulin from the precursor proinsulin,82 and intracellular protein 
turnover over. The enzyme has also been implicated in tumour metastasis83 many other human 
pathologies. 
 
Cathepsin B structure  
 
Figure 1.14 Crystallographic construct of human cathepsin B (generated by Steve McNabb).  
The active site (centred) contains the catalytic triad of residues asparagine (bottom left), histidine 
(top left) situated on R domain and cysteine (right) on the L domain 
The overall structure of cathepsin B is a 30 kDa bilobal lysosomal protease (see Figure 1.14) 
which is disc shaped of approximately 50 Å in diameter and 30 Å thick. Cathepsin B has two 
discrete domains; the L and R domain these can interact together through an extended polar 
interface this opens out to the V-shaped active site cleft (see Figure 1.15 below).84 The active 
functional thiol group belonging to cysteine (coloured yellow) can be clearly seen positioned at 
the bottom of the active site cleft. 
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Figure 1.15 V-Shaped active site cleft of cathepsin B (generated by Steve McNabb).        
Colours denoting individual elements. White = carbon, red = oxygen, blue = nitrogen and                
yellow = sulfur 
Human and rat cathepsin B consists of seven disulfide bridges, however bovine cathepsin B 
contains an eighth disulfide bridge. Peptide bond cleavage is catalysed by the Cys29 residue 
which is located in the L domain. Both Cys29 and His199 form an active ion pair at pH 4.0-8.5 
which initiates the peptide bond cleavage analogous to the calpains.  
 
1.6 Inhibitors of cathepsin B 
 
Natural inhibitors from the plant kingdom 
 
There are three main groups of inhibitors that have been isolated from natural sources these are 
the aziridinyls peptides,85 peptide epoxysuccinyls86 and the peptide aldehydes.74,87,88                
The majority of these inhibitors are non selective towards calpain over papain. However with the 
alteration of amino acids at the P1 and P2 address positions selectivity is gained. 
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Natural irreversible inhibitors from the plant kingdom 
 
 
Epoxysuccinyl peptides 
 
The compound E-64 (1.6.1) was first identified and characterised by Hanada and co-workers 
from extracts of Aspergillus japonicus.86 This natural inhibitor contains an epoxide warhead and 
gives reverse binding to an enzymes active site.89 The compound has low selectivity for the 
cathepsins for example cathepsin B IC50 = 55 nM90 (k2nd rate 89,400 M-1s-1)91 and cathepsin L  
IC50 = 68 nM90 (k2nd rate 96,250 M-1s-1).91 E-64 is used as a template compound for the design of 
other potential inhibitors.74  
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Aziridinyl peptides 
 
Mizaridine 1.6.2 extracted from a marine sponge Theonella mirabilis containing the aziridinyl 
war head. This natural product is non selective with inhibition of IC50 = 2.05 μM for cathepsin 
B.85 
 
 
Natural reversible inhibitors from the plant kingdom 
 
Peptide aldehydes 
 
Many peptide aldehydes have been isolated from the plant kingdom such as tokaramide A 1.6.3 
which gives potent inhibition for cathepsin B, IC50 = 62.4 nM. The natural product is extracted 
from the marine sponge Theonella mirabilis containing the aldehyde war head. Tokaramide A   
is known to be a non selective inhibitor.74,87 
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The natural product YM-51084 (1.6.4) is extracted from Streptomyces species known to be a 
potent inhibitor against cathepsin B IC50 = 12.0 nM and cathepsin L IC50 = 9.6 nM.74 
 
The compound leupeptin 1.6.5 has been shown to be a slow tight binder to cathepsin B with a   
Ki value of 4-5 nM. This natural product is one of the most highly potent, non selective, natural 
aldehyde inhibitors known88 and has been used as a template.20  
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Flavones 
 
Dimethylamentoflavone 1.6.6 is extracted from Ginko biloba and Hypericum perforatum          
(St John’s wort). These compounds can be classified as non-peptide inhibitors which are strong 
inhibitors of cathepsin B (IC50 = 550 nM.).92 
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Synthetic irreversible cathepsin B inhibitors 
 
Irreversible cathepsin B inhibitors include the; epoxysuccinyls peptides,89,93 cyclic sulfates,79,94,95 
aziridine peptides,96 thiadiazoles,97 acyloymethyl ketone peptides,98 to name a few.  
 
Expoxysuccinyl peptide 
 
The epoxysuccinyls peptide inhibitors represent a well studied group of inhibitors; this group is 
based on the non selective inhibitor E-64 1.6.1. Many attempts to improve the selectivity of this 
group have been performed but without success, for example E-64c 1.6.7 for rat cathepsin B   
IC50 = 8.70 nM and rat cathepsin L IC50 = 3.5 nM. However, the inhibitor CA-0074 1.6.8 
containing the iso L-leucine-proline moiety, is selective for cathepsin B over cathepsin L with 
respective activities IC50 = 1.94 nM and IC50 = 233 μM.99 Normal substrate binding occurs with 
1.6.8 and cathepsin B preferring the RR ring configuration.89,93 
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Cyclic sulfates 
 
Compound 1.6.9 is a derivative of E-64 in which is highly potent for cathepsin B                  
(IC50 = 0.7 nM). Steric hindrance of the cyclic sulfate may play a role in the lack of inhibition 
observed for the serine proteases and calpain IC50 = 300 nM.79,94,95 
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Aziridine peptides 
 
Other derivatives to the epoxysuccinyls peptides are the azirdines where the synthesis employs 
the electrophilic building block, aziridine-2,3-dicarboxylate. However compared to epoxides the 
aziridines offer greater variability as potential inhibitors, where the nitrogen atom on the 
aziridine ring offers extra derivativation and variability on structural and activity relationship 
(SAR) studies96 Generally, inhibitors synthesised with the aziridine ring are very selective for 
cathepsin B over other cathepsins, in a centralised position. The compound 1.6.10 has the 
nitrogen substituted aziridine ring in a central position which gives good inhibition and 
selectivity. The second order rates of inhibition are as follows, k2nd rate 6,859 (M-1 min-1) for 
cathepsin B and cathepsin L k2nd rate 212 (M-1 min-1).89,96 
 
 
 
 
 
 
 
 
 
Thiadiazoles 
 
Compound 1.6.11 is a moderately potent cathepsin B inhibitor 2.6 μM. This 1,2,4-thiadiazole 
hetrocyclic ring acts as a good thiol trapping pharmacophore and is known to form a disulfide 
adduct upon inhibition.97 
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Acyloymethyl ketone peptides 
 
These groups of compounds use a P1 and P2 address region recognition sequence, in this case 
cbz-Phe-Ala and a space filling leaving group. The compound 1.6.12 has proven to be cathepsin 
B selective over m-calpain with a second order rate of inhibition (k2nd rate 1,600,000 (M-1 s-1)) for 
bovine spleen cathepsin B compared to no observed inhibition for chicken smooth muscle        
m-calpain. It has been proposed that m-calpain may have low tolerance for the bulky space 
filling (arylacyloxy) group.98 
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Synthetic reversible cathepsin B inhibitors 
 
Examples of reversible inhibitor groups are peptide aldehydes,20 nitriles74,100,101 and 
cyclopropenones.102 
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Aldehyde peptides 
 
For the peptide aldehydes the mechanism of inhibition for cathepsin B is analogous to the 
calpains. Many aldehyde inhibitors have been synthesised over the last 15 years however few 
have proven to be cathepsin B selective.74 For example the compound 1.6.13 is a derivative of 
leupeptin 1.6.5 of high potency for the cysteine proteases (cathepsin B IC50 = 4 nM, trypsin    
IC50 = 45 nM, and plasmin IC50 = 13 nM). However like the majority of the aldehydes it is       
non selective.20 
 
Nitrile peptides 
 
Evidential NMR studies show the nitrile mechanism of inhibition is through the formation of the 
reversible thiomidate intermediate100 with mutation studies suggesting 1.6.16 is stabilised with a 
gly19 residue101 (Figure 1.16). An example of the nitrile peptides is the compound 1.6.16 highly 
potent inhibitor of cathepsin B IC50 = 2.0 nM.74 
 
 
 
 
 
 
Figure 1.16 The mechanism of inhibition of cathepsin B from nitriles74 
 
Cyclopropenones 
 
The cyclopropenone ring present in this group of compounds gives rise to amphiphilic 
properties. Reversible inhibitors can be obtained by exploiting the cyclopropenone rings 
electrophilic properties (Figure 1.17). Or conversely the design of inhibitors that allow the 
protonation of the carbonyl group of the cyclopropenone ring to give a stable 2π-aromatic 
hydroxycyclopropenium cation 1.6.17 will give rise to irreversible inhibitors. The compound  
cbz L-valine cyclopropenone-Ph 1.6.17 synthesised by Ando and colleges exhibited high potency 
towards the cysteine proteases such as the calpains, papain, cathepsin B and L.74,102 
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Figure 1.17 The amphiphilic properties of the cyclopropenone ring79,102 
 
 
1.7 Drug design and rational 
 
Since toxicity of irreversible inhibitors is greater than reversible inhibitors, the search for 
reversible, potent, selective, cell permeable calpain and cathepsin B inhibitors is highly sort.   
The reversible inhibitors commonly employ a peptide address region on P2 and P3 for enzyme 
recognition and an electron deficient warhead, for example, an aldehyde.103 
 
Structural activity relationship studies (SAR) on the calpains demonstrated a preference for 
substrate binding of L-valine and L-leucine at the P2 address region. However, Tripathy and       
co-workers75 demonstrated bulk tolerance for the S2 subsite of μ-calpain by synthesising the 
compound 1.4.17 containing the azo-proline moiety at P2 address region.75 The S1 subsite in 
calpains has shown tolerate a wide range of amino acid types bulky groups, for example            
L-phenylalanine in 1.4.16 and 1.4.17, to non-bulky groups such as L-leucine in SJA-6017 1.7.1103 
However studies have demonstrated the S1 subsites incompatibility to amino acids with polar 
groups, for example the insertion of D,L-tyrosine at the P1 address region for the compound 
1.4.13 (k2nd rate 17,000 (M-1 s-1) m-calpain)70 compared to the phenylalanine analogue               
k2nd rate 136,300 (M-1 s-1) for m-calpain.104 Later Chatterjee and co-workers105 inserted L-serine 
into the P1 address region to give compound 1.7.2 k2nd rate 21,000 (M-1 s-1) μ-calpain), compared 
to the serine (THP) protected compound 1.7.3 (k2nd rate 100,000 (M-1 s-1) μ-calpain).                
This confirmed the μ-calpain isoform also had similar incompatibilities to polar amino acids.105 
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The main focus of this study was the synthesis of selective, reversible, first generation peptide 
aldehyde m-calpain and cathepsin B inhibitors. The method adopted throughout this 
investigation was using an aldehyde warhead and variations of α-amino acid residues inserted 
into the P1 and P2 address regions (Figure 1.18). The compounds synthesised in this study where 
based on the SJA-6017 construct103 bearing the N-(4-fluorobenzenesulfonyl) moiety at the P3 
address region.  
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Figure 1.18 The first generation peptide aldehyde construct based on SJA-6017103 
 
The first generation construct consists of three main binding regions and a covalent or             
non covalent warhead region. These binding regions are known as the P1, P2 and the P3 address 
these regions bind to the active site of calpain and cathepsin B via the S1, S2 and the S3 region 
respectively. 
 
The peptide aldehyde SJA-6017 is one of the most well studied calpain inhibitors which was 
originally developed in 1997 by Fukiage et al at Senju Pharmaceutical Corporation Limited.103 
They developed their compound from MDL-28170 1.4.16, and found the inhibitor to be of 
higher permeability and potency compared to the natural epoxide based inhibitor E-64 1.6.1. 
Recently SJA-6017 was found to be active against selenite induced cataract in rats and cataract 
induced porcine lenses.106 Despite SJA-6017’s potency to the calpains, selectivity towards other 
cysteine proteases such as the cathepsins for example cathepsin B is even greater              
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(calpain IC50 = 80 nM and cathepsin B IC50 = 1.6 nM). Permeability is problematic and entry 
into the cell is limited; furthermore bioavailability is compromised by the inhibitor reacting with 
other proteins. To improve the selectivity, potency and bioavailability Senju Pharmaceuticals 
developed further SJA-6017 analogues by varying the P1 and P3 address positions.107     
Solubility was optimised by the insertion of a pyridineethanol moiety at the P3 address region 
and the warhead was made more metabolically stable by using a novel ketoamide with an 
extended P prime cyclopropyl moiety.108 
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Potential first generation inhibitors based on the CAT-0059 construct109 
 
The synthesis of novel calpain inhibitors consisting with the 5-formyl pyrrole moiety were based 
on the calpain inhibitor 5-formyl pyrrole 2-carboxylate L-leucine L-leucinal 1.7.5                  
(IC50 = 25 nM for m-calpain) synthesised by Miyamoto at the University of Canterbury.109 
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Modelling 
 
The potential inhibitors selected for synthesis were the result of modelling preformed by Axel 
Neffe, Blair Stuart and Wangting Jiao using macro model (water simulation) to generate the 
conformers set within a 12 kJ window of the global minimum. The low energy conformers were 
docked into the rigid active site of μ-calpain. From the results of rigid docking studies the 
following parameters were established warhead distance, glide score, and H-bonding contacts. 
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The warhead distance is the distance between the carbonyl carbon of the aldehyde functionality 
of an inhibitor in question to the cysteine sulfur atom in the active site of μ-calpain or    
cathepsin B. In addition the direction angle is also important. For nucleophilic attack from the 
cysteine residue to occur, a distance of <5Å is required. The glide score parameter can be 
translated into the binding energy between the hydrogen bonds of the enzyme and the ligands of 
the inhibitor. However good glide scores may be not necessarily result in a low                  
IC50 concentration.  
 
Requirement of the extended β-strand conformation 
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Figure 1.19 Conformational enzymatic selection of substrate/inhibitor by the proteases110 
 
The significance of the extended β-strand conformation (see Figure 1.19) is necessary to 
facilitate the proteolysis of substrates, inhibitors, including peptide and non peptide forms.     
This was demonstrated by Fairlie et al110 who analysed 266 protease/inhibitor crystal structures 
spanning from the aspartic, serine, cysteine and metalloprotease families. The non-extended 
conformations (random, helix and turns) on substrate/inhibitors have their scissile amide bonds 
protected from proteolysis due to folding of the substrate/inhibitor. Therefore the information 
gleaned from this paper may suggest that enzyme binding affinities can be increased if the 
general methods in the organisation of conformational constraining substrate/inhibitors into the 
extended β-strand conformer.110 
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Figure 1.20 Nomenclature of torsion angles.111,112 Fairlie et al 110 found that the Ramachandran 
plot for ten cyclic HIV-1 protease inhibitors fell in a typical for extended β-strands with torsion 
angles of Φ = -56.9o to -169.5o Ψ = 35.2o to 161.7o and a fixed Ω = 180o 
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Chapter 2 
Results and Discussion 
 
2.1 Synthesis of CA clan inhibitors (m-calpain and cathepsin B) 
 
Throughout the duration of this study the following peptide aldehyde inhibitors have been 
successfully synthesised for the inhibition of m-calpain and cathepsin B (in Table 2.1 below). 
These compounds where selected from vigorous modelling studies involving the μ-calpain and 
cathepsin B active site constructs (addressed in sections 1.7 and 2.5). These synthesised 
inhibitors were based on using a rigid P3 address region of either N-(4-fluorobenzenesulfonyl) 
2.1.1 or 5-formyl pyrrole 2.1.2 moieties. As previously mentioned in Chapter 1 the variations of 
natural and unnatural amino acid residues at the P1 and P2 address region are summarised in 
Table 2.1 below. Note some of these inhibitors can be classified into both themes. 
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The synthesis of the first generation inhibitors commonly involved either the free or                
boc protected α-amino acids 2.1.4 where the carbonyl group was first protected as the ester 
2.1.5, followed by reaction with N-(4-fluorobenzenesulfonyl) sulfonyl chloride 2.1.6.              
The sulfonamide methyl esters 2.1.7 were hydrolysed and the resulting acids 2.1.8 coupled to the 
esters of L-tyrosine, 2.1.9a L-methionine 2.1.9b and L-phenylalanine 2.1.9c. Reduction of the 
corresponding sulfonamide peptide esters 2.1.10 gave the corresponding alcohols 2.1.11 and 
these were oxidised to the target aldehydes 2.1.3. 
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Table 2.1 Synthesised peptide aldehyde inhibitors (variations at P1 and P2 address regions) 
P1 Variations P2 Variations 
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Displayed below is the unsuccessful synthesis of two dipeptide dialdehyde inhibitors these are 
the L-tyrosinal 2.1.3l and the L-phenylalaninal 2.1.3m. These potential inhibitors are included in 
the P1 variation theme containing the 5-formyl pyrrole 2.1.2 functionally at the P3 address region, 
L-valine at P2 and L-tyrosine or L-phenylalanine at P1 respectively. 
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Synthesis of N-(4-fluorobenzenesulfonyl) α-amino acids 2.1.8a-f 
 
Synthesis of 2.1.8a-d 
 
The starting α-amino acids 1-aminocyclohexanecarboxylic acid 2.1.4a, L-phenylglycine 2.1.4b, 
L-cyclohexaglycine 2.1.4c and boc iso L-leucine 2.1.4d were esterified with MeOH and SOCl2 to 
give the methyl ester hydrochlorides 2.1.5a-d (Scheme 2.1). The hydrochloride salts              
were reacted with the sulfonyl chloride 2.1.6 to give in near quantitative yields of the                   
sulfonyl α-amino acid methyl esters 2.1.7a-d. The methyl esters where hydrolysed with aqueous 
sodium hydroxide in THF, under reflux for one day give the corresponding free acids 2.1.8a-d. 
The acids 2.1.8a-d were confirmed with 1H NMR and mass spectra displaying characteristic 
peaks with chemical shifts in deuterated DMSO for 2.1.8b δΗ = 13.10-12.50 for the acid proton 
(COOH). The acid 2.1.8c in CD3OD displayed two multiplets for the CH2’s from δΗ = 1.71-1.56 
and δΗ = 1.28-1.00. Mass spectra for 2.1.8a-d displayed the hydrogen and sodium adducts for 
conformation. 
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2.1.8a R= 1,1 cyclohexane 
2.1.8b R= Ph 
2.1.8c R= cyclohexane  
2.1.8d R= (S)i-Bu 
  
Scheme 2.1 Synthesis of the sulfonamide α-amino acids 2.1.8a-d 
 
Carbonyl group protection via Fisher esterification 
 
Esterification of the following α-amino acids, 2.1.4a-d and L-tyrosine 2.1.12a to their 
corresponding methyl esters was carried out by standard methods using L-methanol and                  
eight equivalents of thionyl chloride (SOCl2). Other esterification reactions involving optimised 
methods where performed on L-methionine 2.1.12b and boc L-methionine 2.1.12c (as detailed 
later).  
 
Esterification was effected under Fisher acid catalysed conditions (Scheme 2.2). The Fisher 
esterification mechanism starts with the reaction of alcohol with thionyl chloride to afford a 
proton source. This proton source takes the form of the methyloxonium ion 2.1.14 which 
protonates the carbonyl group of the α-amino acid 2.1.15 to give the oxonium ion 2.1.16.       
This generates reactive electrophile for the subsequent nucleophilic attack by methanol to give a 
tetrahedral intermediate 2.1.17. This intermediate 2.1.17 will generate the more of the ion 2.1.14 
and the methyoxydiol compound 2.1.18. Protonation of the compound 2.1.18 will lead to 2.1.19 
and subsequent elimination of water to afford 2.1.20. Nucleophilic attack with methanol to gives 
the methyl ester 2.1.21 and regenerate methyloxonium ion 2.1.14. 
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Scheme 2.2 Carbonyl group protection via Fisher esterification 
 
The α-amino acids L-valine and tert L-leucine did not require the esterification step and therefore 
were reacted directly with the sulfonyl chloride 2.1.6 to give the sulfonyl L-valine 2.1.8e and the 
sulfonyl tert L-leucine 2.1.8f (Scheme 2.3), with respective yields of 79% and 77%.                
The compounds where confirmed with 1H NMR and mass spectra (Figures 2.1 and 2.2). 
Compound 2.1.8e, displayed the characteristic peaks of two doublets for the methyl protons on 
L-valine (δΗ = 0.92 and δΗ = 0.88). For compound 2.1.8f a nine proton singlet was observed for 
the equivalent t-butyl protons on tert L-leucine (δΗ = 0.97).  
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The second synthesis involved esterification of the acid 2.1.4a using standard literature 
procedures with MeOH and SOCl2 and gave a quantitative yield of the corresponding methyl 
ester hydrochloride salt (Scheme 2.1). The hydrochloride salt was reacted with the sulfonyl 
chloride 2.1.6 in the presence of DMF to give compound 2.1.7a which was hydrolysed with 
aqueous sodium hydroxide in THF for 21 hr to give in near quantitative yield of 2.1.8a. The acid 
2.1.8a was confirmed with 1H NMR spectra displaying characteristic peaks with chemical shifts 
in deuterated DMSO δΗ = 12.50 for the acid proton (COOH of Chx), and the singlet observed at 
δΗ = 8.01 as the NHC proton.  
 
Boc deprotection via Fisher esterification  
 
This reaction was preformed on the α-amino acids that permitted boc deprotection and 
esterification in one step (Scheme 2.5 below) on boc iso L-leucine 2.1.4d and previously 
mentioned boc L-methionine 2.1.12c. This reaction is similar to Fisher esterification        
(Scheme 2.2) using the proton source of 2.1.14, but nucleophilic attack of MeOH (I) and the 
activated electrophile allows for decomposition of the boc group to carbon dioxide, the              
2-methylpropan-2-ylium cation 2.1.22 and the hydrochloride salt of the α-amino methyl esters 
2.1.9b and 2.1.5d. The cation 2.1.22 reacts with methanol to give butene as the major product 
and the tert-butyl methyl ether 2.1.23 as the minor product and regenerates a proton.               
The tert-butyl methyl ether is easily removed in-vacuo due to its low boiling point. 
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2.1.4d. R= (S)i-Bu 
2.1.12c. R= CH2CH2SCH3 
 
Scheme 2.5 Boc deprotection via Fisher esterification for 2.1.4d and 2.1.12c 
 
Synthesis of L-methionine methyl ester hydrochloride 2.1.9b 
 
Esterification of boc L-methionine and L-methionine was not possible under standard conditions 
using 8 equivalents SOCl2. The 1H NMR spectra was complex. It was necessary to perform a 
number of small scale reactions under varying conditions to optimise reaction conditions.    
These involved the use of two compounds (shown in Scheme 2.6) boc protected L-methionine 
and L-methionine. Four reactions where carried out on each starting material as summarised in 
Tables 2.2 and 2.3. 
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Cl- +H3N
S
O
OMe
RHN
S
O
OH
Under various conditions
2.1.12b and 2.1.12c 2.1.9b  
2.1.12b. R= H 
2.1.12c. R= boc  
 
Scheme 2.6 The esterification of L-methionine 2.1.12b and boc L-methionine 2.1.12c under 
different conditions  
 
Esterification of the α-amino acid (Table 2.2) was unsuccessful. The 1H NMR spectra showed 
the product was present along with other products and starting material. The route was 
abandoned. 
 
Table 2.2 Optimisation reactions for the esterification of L-methionine  
Equivalence of 
L-Met 
SOCl2 MeOH Reaction time 
& temp. 
Puritya (%) 
8 1 4 4 hr, -20°C ? 
66 hr, rt 
65 
1.83 1 6 3 hr, -20°C ? 
13 hr, rt 
97 
1.23 1 8 3 hr, -20°C ? 
13.5 hr, rt 
98 
1.1 1 25 3 hr, -20°C ? 
3 hr, rt 
91 
a Purity estimated on peak heights (1H NMR)  
 
The esterification reaction involving boc L-methionine was successful under the given 
experimental conditions as highlighted in Table 2.3 and detailed in Chapter 3. 
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Table 2.3 Optimisation reactions for the esterification of boc L-methionine 
Equivalence of 
boc L-Met 
SOCl2 MeOH Reaction time 
& temp. 
Puritya (%) 
8 1 4 1 hr, 0°C ?  
19 hr, rt 
95 
1.2 1 24.6 2 hr, -20°C ? 
3 hr, rt 
100 
1.83 1 16.2 2 hr, -20°C ? 
3 hr, rt 
98 
2.4 1 11.2 2 hr, -20°C ? 
3 hr, rt 
93 
a Purity estimated on peak heights (1H NMR) 
 
Synthesis of N-(4-fluorobenzenesulfonyl) peptide alcohols from HATU coupling 
 
The synthesis of sulfonyl peptide alcohols requires the formation of an amide bond, using a 
coupling reagent such as HATU 2.1.24a (2.1.24b). The advantages of HATU over other 
coupling reagents such as HBTU 2.1.25 is the generation (from α-amino acids) of               
highly reactive 3H-[1,2,3]triazolo[4,5-b]pyridin-3-olate esters (COOAt) compared to the                  
1H-benzo[d][1,2,3]triazol-1-olate esters (COOBt) from HBTU. The higher reactivity of the 
COOAt ester coupled with the active participation of the nitrogen atom on the pyridine moiety in 
the amide bond formation offers less enanmtiomersation with higher reported yields.113,114                              
 
 
 
 
 
                             
 
The mechanism for peptide bond formation with HATU (Scheme 2.7) occurs by deprotonation 
of a α-amino acid 2.1.15 under basic conditions of DIPEA. The deprotonated α-amino acid 
reacts with the tetramethylisouronium moiety of HATU 2.1.24b to form a tetrahedral ester 
intermediate 2.1.26. The resulting ester intermediate reacts to form the products in (J). Then the 
following reaction in (J) gives the highly reactive COOAt ester product shown in (K) where an 
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intermolecular reaction in (K) between the free amine functionally of an α-amino acid and       
the pyridine nitrogen gives the amide product 2.1.27, 1,1,3,3-tetramethylurea 2.1.28 and               
3H-[1,2,3]triazolo[4,5-b]pyridin-3-ol (HOAt) 2.1.29. The formation of 1,1,3,3-tetramethylurea is 
the driving force for the decomposition of HATU during amide bond formation in this reaction. 
 
 
N
R1 OH
O
R1 O
O
N
N
N
O
PF6
C
N
N
PF6
O
O
R1
C
N
N
NN
N
N
O
PF6
C
N
R1
O
N
NN
N
N
O
NN
N
N
O
NN
N
N
HO
N
C
N O
R1
N
H
R2
O
R1
O
N
H
H R2
+ +
2.1.28. 
1,1,3,3-Tetramethylurea
2.1.29. 
3H-[1,2,3]Triazolo[4,5-b]pyridin-3-ol
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Scheme 2.7 Synthesis of the peptide bond by application of HATU 2.1.24b coupling reagent 
 
Synthesis of N-(4-fluorobenzenesulfonyl) peptide alcohols from HATU coupling and 
reduction 
 
Synthesis of the sulphonamide peptide alcohols for compounds 2.1.11a-g involved the coupling 
of the hydrochloride salt of the α-amino methyl or ethyl ester 2.1.9a-c to a sulfonyl α-amino acid 
2.1.8a-f, using HATU over 2 days. These reactions obtained yields between 45-92%.              
The resulting methyl or ethyl esters were reduced to alcohols 2.1.11a-g with 1N LiAlH4/THF at 
0oC for 1 hr (Scheme 2.15). Confirmation of these sulfonyl peptide alcohols 2.1.11a-g were 
carried out using a 1D 1H NMR experiment in deuterated DMSO, 13C NMR and mass 
spectrometry. 
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2.1.11a. R1= CH2CH2SCH3 R2= Me R3= 1,1 cyclohexane  
2.1.11b. R1= CH2CH2SCH3 R2= Me R3= Ph 
2.1.11c. R1= CH2CH2SCH3 R2= Me R3= cyclohexane 
2.1.11d. R1=CH2CH2SCH3 R2= Me R3= (S)i-Bu 
2.1.11e. R1= Bn R2= Et R3= i-Pr 
2.1.11f. R1= CH2CH2SCH3 R2= Me R3= t-Bu 
2.1.11g. R1= p-CH2PhOH R2= Me R3= 1,1 cyclohexane  
 
Scheme 2.8 Synthesis of N-(4-fluorobenzenesulfonyl) peptide alcohols from HATU coupling 
and reduction 
 
Synthesis of 2.1.11h and 2.1.11i  
 
The sulfonyl peptide alcohols 2.1.11h and 2.1.11i were directly coupled between sulfonyl         
α-amino acids and unprotected α-amino alcohols L-methioninol 2.1.30 and 2.1.31 (Scheme 2.9). 
The acids 2.1.8a and 2.1.8e were coupled to L-methioninol 2.1.30 in the presence of DIPEA and 
HATU to give 2.1.11h and 2.1.11i. The alcohol 2.1.11i was confirmed with 1H NMR spectra 
(Figure 2.3) with signals displaying chemical shifts in deuterated DMSO δΗ = 7.81 for the singlet 
sulfonamide proton which correlated closely to the singlet sulfonamide proton observed in the 
acid 2.1.8a, and for compound 2.1.11i δΗ = 0.95 and δΗ = 0.91 (3H, d, J = 6.3 Hz, CH3 of Leu) 
3.44-3.40 a multiplet signal for the CH2OH on L-leucinol. Mass spectra displayed the hydrogen 
adduct for confirmation.  
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NaBH4 dissolved in distilled water. Removal of the boc protection with 2N HCl/ether gave the 
hydrochloride salt 2.1.35 which was coupled with compound 2.1.8e in the presence of HATU to 
give the sulfonyl L-valine L-tyrosinol 2.1.11j. 
 
 
Scheme 2.10 Synthesis of N-(4-fluorobenzenesulfonyl) L-valine L-tyrosinol 2.1.11j  
 
The alcohol 2.1.11j was confirmed with 1H NMR spectra (Figure 2.4) with signals displaying 
chemical shifts in deuterated DMSO δΗ = 3.29-3.19 for the two protons (CH2OH) on tyrosine, 
the two methyl (CH3’s) on valine appeared as a multiplet δΗ = 0.88-0.86 as opposed to the two 
doublets observed for the acid precursor 2.1.8e. However, the presence of compound 2.1.11j was 
confirmed with mass spectra observed as the hydrogen adduct within the 5 ppm tolerance range 
required.  
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Scheme 2.11 Boc deprotection of boc L-tyrosinol 2.1.34 to L-tyrosinol hydrochloride 2.1.35 
 
2D gCOSY 
 
2D gCOSY was used to resolve complex multiplets observed from the following        
compounds, 2.1.10e, and 2.1.11b. The compound N-(4-fluorobenzenesulfonyl) L-valine             
L-phenylalanine ethyl ester consisted of two multiplets occurring at δΗ = 4.16-3.99 and 0.91-0.87 
and an unknown triplet at δΗ = 1.10. These were assigned as the NHCH of Phe proton at           
δΗ = 4.16-4.08, OCH2CH3 of Phe protons at δΗ = 4.06-3.99 and OCH2CH3 of Phe δΗ = 1.10 for 
the unknown triplet. 
 
 
 
 
 
 
 
 
 
 
 
 
 
The 2D gCOSY experiment of the alcohol 2.1.11b resolved multiplets occurring the first from  
δΗ = 3.75-3.19 and the second from δΗ = 1.90-1.46. The first multiplet was later assigned as the 
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α-hydrogen on methioninol δΗ = 3.75-3.60 and δΗ = 3.32-3.19 as the CH2OH on methioninol 
and the second multiplet δΗ = 1.90-1.75 and δΗ = 1.60-1.46 as the CHCH2’s on methioninol.  
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5.10
8.72
3.60-3.75
1.75-1.90
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H
H
H
2.28-2.36
1.46-1.60
H H
2.28-2.36
3.30-3.24
3.24-3.18
2.1.11b. N-(4-Fluorobenzenesulfonyl) L-phenylglycine L-methioninol  
 
Table 2.4 shows the HATU coupling yields for the peptide alcohols 2.1.11a-k. This table 
includes the yields from the coupling reactions involving the peptide acids and α-amino alcohol 
or α-amino esters. Overall there was no advantage in using carbonyl group protected α-amino 
esters over the α-amino alcohols and the α-amino alcohols can be used under these coupling 
conditions without esterification.  
 
Table 2.4 HATU coupling yields for the peptide alcohols 2.1.11a-k 
Compound Number Compound Structure Coupling Yield (%) 
2.1.11a 
N
H
S
O
H
N
F
O O
OH
S  
66 
2.1.11b  
N
H
S
O
H
N
F
O O
OH
S  
69 
2.1.11c 
N
H
S
O
H
N
F
O O
OH
S  
66 
2.1.11d  
N
H
S
O
H
N
F
O O
OH
S  
57 
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2.1.11e 
 
 
N
H
S
O
H
N
F
O O
OH
 
64 
2.1.11f  
N
H
S
O
H
N
F
O O
OH
S  
71 
2.1.11g  
N
H
S
O
H
N
F
O O
OH
OH  
73 
2.1.11h 
 
N
H
S
O
H
N
F
O O
OH
S  
56 
 
2.1.11i 
 
 
N
H
S
O
H
N
F
O O
OH
 
82 
2.1.11j  
N
H
S
O
H
N
F
O O
OH
OH  
28 
2.1.11k 
N
H
H
N
H
O O
H
N
OH
S
O
 
84 
 
The yields of the peptide alcohols ranged from 84% for N-(5-pyrrole 2-carboxylate L-valine      
L-methioninol 2.1.11k to 28% for N-(4-fluorophenylsulfonyl) L-valine L-tyrosinol 2.1.11j.     
The synthesis of compound 2.1.11k differed from the synthesis of the sulfonyl derivatives, 
however, the second coupling reaction with EDCI.H2O and HOBt to give a low yield (7%) of 
2.1.11k. The discussion on synthesis of 2.1.11k and its corresponding dialdehyde 2.1.3k is 
address in section 2.2 below. 
 
N
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O O H
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O
2.1.11k. 5-Formyl pyrrole 2-carboxylate L-valine L-methioninol  
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Synthesis of N-(4-fluorobenzenesulfonyl) peptide aldehydes 2.1.3a-j by DMSO oxidation 
 
Oxidation to the target aldehydes was performed through Parikh-Doering oxidation115 of the 
corresponding alcohols. The major advantage to this method is the reaction can be carried out at 
room temperature or below room temperature (0°C-10°C). Unlike Swern involving the reactive 
oxalyl dichloride 2.1.38 to perform the oxidation therefore requiring low temperatures (-78°C) to 
prevent further oxidation.  
 
Cl
O
O
Cl
2.1.38. Oxalyl dichloride  
 
A disadvantage of the Parikh-Doering oxidation is that the reaction for some unknown reason 
requires a minimum of 200 mg alcohol for the reaction to proceed. For smaller scale reactions a 
sacrificial alcohol such as isopropyl alcohol (IPA) can be used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.12 Parikh-Doering oxidation via the formation of an active DMSO.SO3 complex 
 
The first step in the Parikh-Doering oxidation (Scheme 2.12) involves activation of DMSO 
2.1.39 by addition of the SO3.Pyr complex 2.1.40, with DCM as solvent resulting in the 
sulfonium species 2.1.41 where the electrophilic nature of the sulfur atom is increased and 
 53
provides a 1-oxidopyridine-2-sulfonate leaving group. The alcohol reacts at sulfur with 
displacement of the sulfonate anion to give an alkoxydimethylsulfonium salt 2.1.42. This salt 
2.1.42 is deprotonated by DIPEA to form 2.1.43 which reacts through an intramolecular reaction 
to form the aldehyde 2.1.44 and dimethyl sulphide 2.1.45. The oxidations of the sulfonyl peptide 
alcohols 2.1.3a-j are summarised in Scheme 2.13. 
 
 
 
 
 
 
 
 
2.1.3a. R1= 1,1 cyclohexane R2= CH2CH2SCH3  
2.1.3b. R1= Ph R2= CH2CH2SCH3  
2.1.3c. R1= cyclohexane R2= CH2CH2SCH3  
2.1.3d. R1= (S)i-Bu R2= CH2CH2SCH3  
2.1.3e. R1= i-Pr R2= Bn 
2.1.3f. R1= t-Bu R2= CH2CH2SCH3  
2.1.3g. R1= 1,1 cyclohexane R2= p-CH2PhOH  
2.1.3h. R1= i-Pr R2= CH2CH2SCH3 
2.1.3i. R1= 1,1 cyclohexane R2= CH2i-Pr 
2.1.3j. R1= i-Pr R2= p-CH2PhOH 
 
Scheme 2.13 Parikh-Doering oxidation113 of the N-(4-fluorobenzenesulfonyl) peptide alcohols 
2.1.3a-j 
 
The compound 2.1.3a (Figure 2.5) was confirmed with 1H NMR and mass spectra displaying the 
aldehyde proton of Met at δΗ = 9.45, the singlet NH proton of Chx (δΗ = 7.91) and the two 
multiplets of the benzlic group at δΗ = 8.01-7.96 and δΗ = 7.81-7.47 in deuterated DMSO. 
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2.1.3i. (S)-1-(4-Fluorophenylsulfonamido)-N-(4-methyl-1-oxopentan-2-yl)cyclohexanecarboxamide  
 
The compound 2.13d the 2D gCOSY helped to resolved the multiplets occurring from               
δΗ = 1.76-1.51. This multiplet was later assigned as the α-hydrogen on iso L-leucine and a proton 
of the CHCH2’s on methioninal δΗ = 1.76-1.66 and δΗ = 1.60-1.51 for one CH2 on iso L-leucine. 
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2.1.3d. N-(4-Fluorobenzenesulfonyl) L-iso-leucine- L-methioninal  
 
In Table 2.5 the oxidation yields which range from 24% for the aldehyde  2.1.3h to near 
quantitative yield for the sulfonyl tert L-leucine L-methioninal 2.1.3f (99%). 
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Table 2.5 Yields for the peptide aldehydes 
Compound Number Compound Structure Oxidation Yield (%) 
2.1.3a  
N
H
S
O
H
N
F
O O
H
S
O
 
84 
2.1.3b  
N
H
S
O
H
N
F
O O
H
S
O
 
41 
2.1.3c  
N
H
S
O
H
N
F
O O
H
S
O
 
95 
2.1.3d  
N
H
S
O
H
N
F
O O
H
S
O
 
96 
2.1.3e  
N
H
S
O
H
N
F
O O
H
O
 
90 
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N
H
S
O
H
N
F
O O
H
S
O
 
99 
2.1.3g 
N
H
S
O
H
N
F
O O
H
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45 
2.1.3h  
N
H
S
O
H
N
F
O O
H
S
O
 
24 
2.1.3i 
N
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H
N
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O O
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O
 
71 
2.1.3j  
N
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N
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O O
H
O
OH  
70 
2.1.3k  
N
H
H
N
H
O O H
N
H
S
O
O
 
25 
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13C NMR spectra 
 
The sulfonyl compounds containing the 4-fluorinated aromatic N-(4-fluorobenzenesulfonyl) 
group) all displayed the characteristic C-F signal splitting into a doublet with an        
approximate chemical shift (δC) in deuterated DMSO δC = 164.0 and approximate           
coupling constant (J = 250 Hz). This effect can extend throughout the aromatic ring of the                   
N-(4-fluorobenzenesulfonyl) group where it can be observed that carbons positioned further 
away from the fluorine atom show an overall decrease in the J value. Typical chemical shifts and 
coupling constant values found for the other N-(4-fluorobenzenesulfonyl) aromatic carbons are 
summarised in Table 2.6 below.  
 
Table 2.6 Experimental 13C NMR chemical shift (δ) data found for compounds containing the            
N-(4-fluorobenzenesulfonyl) group. 2.1.7a-d, 2.1.8a-f, 2.1.10a-g, 2.1.11a-j and 2.1.3a-j 
Distance from 
the fluorine 
atom 
Functionality Chemical shift 
range deuterated 
DMSO (δ) 
Coupling constant 
range deuterated 
DMSO (J) (Hz) 
 F
 
F-C 164.0-164.2 248.3-251.1 
(doublet) 
F-C=C 116.2-115.9 22.0-23.0 (doublet) 
S-C=C 129.5-129.8 8.7-9.9 (doublet) 
S-C= 137.6-139.8 Singlet-3.3 
     
Other significant chemical shifts (δ) such as aldehydes (CHO), amides (CONH) and the 
carbonyl methyl esters (COOCH3), tertiary butyl groups C(CH3)3 and methyl carbons on valine 
C(CH3)2 and thiol methyl on Met (SCH3) are summarised in Table 2.17 below. 
 
 
The Aldehydes (CHO) 
 
The aldehydes typically display a singlet with a down field chemical shift (δ) ranging from       
δC = 199.7-202.0 in deuterated DMSO. Compounds containing the 5-formyl pyrrole group 
consist of a formyl carbon which can be observed as a singlet in either CD3OD at δC = 182.6 or 
deuterated DMSO at δC = 181.3.  
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Table 2.7 Experimental 13C NMR chemical shift (δ) data for the non-aromatic carbons for 
2.1.7a-d, 2.1.8a-f, 2.1.10a-g, 2.1.11a-j and 2.1.3a-j 
Functionality Chemical shift range DMSO-d6 (δ)  
Aldehydes (CHO) 199.7-202.0 
Carbonyl methyl esters (COOCH3) 168.9-171.9 
Amides (CONH) 168-6-170.8 
Tertiary butyl groups C(CH3)3 26.5-34.1 
Methyl carbons on valine C(CH3)2 CCH3 = 17.9-19.6 
CCH3 = 19.1-20.2 
Thiol methyl on methionine (SCH3) 14.4-15.6 
 
The tertiary butyl group C(CH3)3 (on tert L-leucine)  
 
Compounds containing the group tertiary butyl group C(CH3)3 for example in tert L-leucine 
display the characteristic tall singlet approximately at DMSO δC = 26.6 in deuterated.  
 
Methyl carbons on valine C(CH3)  
 
The experimental chemical shifts (δ) for the methyl carbons on valine C(CH3), where observed 
as non equivalent entities ranging from δC = 17.9-20.2 with a separation of 1 ppm. These peaks 
were not resolved any further and were assigned as CH3 of Val in the experimental Chapter 3. 
 
 
2.2 Synthesis of a novel 5-formyl pyrrole dipeptide dialdehyde inhibitor 
 
The synthesis of the L-methioninal 2.1.3k differed form the synthesis of the other sulfonyl 
analogues, where two coupling reactions were required. The first involved HATU for coupling 
the P2 address region of boc L-valine 2.2.11 to L-methioninol 2.1.30, (Scheme 2.17) then the 
second involved coupling the pre-synthesised acid 2.2.4 (for the P3 address region) and L-valine 
L-methioninol with (EDC.HCl) and 1-hydroxybenzotriazole (HOBt.H2O) (Scheme 2.16).  
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Synthesis of 5-formyl pyrrole 2-carboxylic acid  
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Scheme 2.14 The synthesis of 5-formyl pyrrole 2-carboxylic acid via the Vilsmeier-Haack 
formylation116 
 
Synthesis of the ethyl ester 2.2.4 was prepared by Vilsmeier formylation;116 this initially 
involved the synthesis of the DMF-POCl3 complex 2.2.5 at 0°C (Scheme 2.15a). Then the 
complex was reacted by careful addition of pyrrole 2-carboxylate ethyl ester dissolved in DCE. 
The reaction mixture was heated under reflux at 115°C for 15 min and the reaction mixture was 
refluxed with NaOAc.3H2O at 120°C for 20 min to give the 4 and 5-formyl pyrrole                  
2-carboxylate ethyl esters 2.2.3b and 2.2.3a. This reaction was regioselective yielding a 2:1 ratio 
in favour of the 5 isomer. These acquired regioisomers were separated and their presence 
confirmed with 1H NMR spectra. As expected the two reioisomers displayed markedly different 
spectra. In one case both pyrrole protons displayed similar chemical shifts, this was identified as 
the 5 isomer 2.2.3a (Figure 2.6) (δΗ =  7.03 and δΗ = 6.95). The other spectra displayed an 
apparent separation of the pyrrole protons (Figure 2.7) (δH = 7.90 for the NHCH proton and      
δΗ = 7.22 for the singlet C=CHC proton), this indicated the presence of the 4 isomer 2.2.3b. 
Then after confirmation the ethyl ester 2.2.3a (5 isomer) was hydrolysed with aqueous potassium 
hydroxide to give a quantitative yield of the carboxylic acid.  
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Scheme 2.15a The mechanism for the formation of the Vilsmeier salt  
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.15b The mechanism for the formation of 5-formyl pyrrole 2-carboxylate ethyl ester 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.15c The mechanism for the formation of 4-formyl pyrrole 2-carboxylate ethyl ester 
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EDCI.HCl and HOBt.H2O coupling 
 
As mentioned earlier the synthesis of the m-calpain inhibitor 5-formyl pyrrole 2-carboxylate     
L-valine L-methioninal 2.1.3k required two coupling reactions, the first with HATU and the 
second with EDCI.HCl and HOBt.H2O. The mechanism for EDCI.HCl and HOBt.H2O coupling 
(Scheme 2.16) requires initial activation of the α-amino acid with EDCI.HCl. 2.2.7 to give the 
activated ester (L) with a good leaving group facilitating nucleophilic attack from HOBt to give 
the side product 1-(3-(dimethylamino)propyl)-3-ethylurea 2.2.10 and the complex (M). The free 
amino group of another α-amino peptide effects nucleophilic attack on the carbonyl group (M) to 
give rise to the target peptide 2.1.28 and regenerated HOBt 2.2.9. 
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Scheme 2.16 Mechanism of peptide bond formation with EDCI.HCl and HOBt.H2O for the 
synthesis of 5-formyl pyrrole 2-carboxylate L-valine L-methioninol 2.1.11k 
 
The synthesis of 2.1.11k (Scheme 2.17) requires coupling of L-methioninol 2.1.30 and            
boc L-valine 2.2.11 with HATU to give the boc protected peptide alcohol 2.2.12. Deprotection to 
give the hydrochloride salt 2.1.13 (was confirmed through 1H NMR spectra from the 
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disappearance of the boc peak at δΗ = 1.44 in CD3OD) was coupled with EDCI.HCl-HOBt.H2O 
to give 5-formyl pyrrole 2-carboxylate L-valine L-methioninol 2.1.11k with a 7% yield. 
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Scheme 2.17 The synthesis of 5-formyl pyrrole L-valine L-methioninol 2.1.11k 
 
Synthesis of 5-formyl pyrrole L-valine L-methioninal 2.1.3k 
 
Parikh-Doering oxidation of the alcohol 2.1.11k (Scheme 2.28) was the same as for the             
sulfonyl analogues previously discussed. The crude product resultant from the oxidation reaction 
was purified by column chromatography and identified by 1H NMR spectra and mass 
spectrometry.  The 1H NMR spectrum in deuterated DMSO showed two aldehyde peaks at         
δΗ = 9.74 for the CHO of methioninal and δH = 9.54 CHO for the formyl group on pyrrole.     
The chemical shift for the formyl hydrogen corresponded well to the dipeptide alcohol precursor 
2.1.11k. For mass spectrometry the compound 2.1.3k was identified as the hydrogen adduct in 
CH3CN.  
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Scheme 2.18 Synthesis of 5-formyl pyrrole 2-carboxylate L-valine L-methioninal from      
Parikh-Doering oxidation 
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2.3 Attempted synthesis of dipeptide dialdehydes 
 
Attempted synthesis of 5-formyl pyrrole 2-carboxylate L-valine L-tyrosinal 2.1.3l 
 
In this synthesis, boc L-tyrosine methyl ester 2.1.32 was reduced with NaBH4 to give the 
corresponding alcohol 2.1.34. The boc protecting group was removed using 2N HCl/ether to give 
L-tyrosinol hydrochloride 2.1.35 which was coupled to boc L-valine 2.2.11. This gave             
boc L-valine L-tyrosinol 2.3.1 followed by boc deprotection to give the corresponding 
hydrochloride salt 2.3.2. This salt 2.3.2 was coupled to previously prepared 5-formyl pyrrole     
2-carboxylic acid 2.2.4 using EDCI.HCl-HOBt.H2O. This reaction gave only a 5% yield and 
resulted in us having only 30 mg of the alcohol 2.3.3 to oxidise to aldehyde 2.1.3l. Therefore, the 
oxidation by DMSO activated by SO3.Pyr required the use of a sacrificial alcohol, isopropyl 
alcohol (IPA). The oxidation was unsuccessful and did not provide the target aldehyde 5-formyl 
pyrrole 2-carboxylate L-valine L-tyrosinal 2.1.3l. 
 
There are two possible reasons for the low yields observed in coupling reactions of L-valine      
L-tyrosinol hydrochloride 2.3.2 with 5-formyl pyrrole 2-carboxylic acid 2.2.4 and 5-formyl 
pyrrole 2-carboxylate L-valine L-methioninol 2.2.11k (7% yield) (Scheme 2.17). Firstly, 
electronic: the carboxylic acid proton for the acid 2.2.4 may not be acidic enough to react with 
the coupling reagent and the free amine of L-valine L-tyrosinol hydrochloride 2.3.2. Secondly, 
unwanted side reactions may occur between the formyl carbon functionality of 2.2.4 and one or 
both alcohol groups present in L-tyrosine. 
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Scheme 2.19 Attempted synthesis of 5-formyl pyrrole 2-carboxylate L-valine L-tyrosinal  
 
Second attempted synthesis of 2.1.3l, synthesis of 5-formyl pyrrole 2-carboxylate L-valine 
2.3.6 
 
In this synthesis (see Scheme 2.20), the coupling reaction between L-valine methyl ester 
hydrochloride 2.3.4 with 5-formyl pyrrole 2-carboxylic acid 2.2.4 was attempted with EDCI.HCl 
as the activation agent and HOBt.H2O as the coupling reagent and gave 5-formyl pyrrole           
2-carboxylate L-valine methyl ester 2.3.5 as a white solid in 45% yield. Then the methyl ester 
was hydrolysed to the free acid 5-formyl pyrrole 2-carboxylate L-valine 2.3.6 with aqueous 
sodium hydroxide. Confirmation of the acid 2.3.6 was confirmed with 1H NMR spectra.      Mass 
spectra detected the acid 2.3.6 as both the hydrogen and sodium adducts. 
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Scheme 2.20 Synthesis of 5-formyl pyrrole 2-carboxylate L-valine 2.3.6 
 
The free acid 2.3.6 was reacted with L-tyrosinol hydrochloride 2.1.35 in Scheme 2.21 in the 
presence of HATU to give 5-formyl pyrrole 2-carboxylate L-valine L-tyrosinol 2.3.3 as crude. 
The extent of the impurity in the crude was confirmed with TLC producing many spots of 
unknown compounds and 1H NMR as complex spectra. The compound of interest 2.3.3 could 
not be purified to obtain sufficient alcohol 2.1.3l for oxidation. 
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Scheme 2.21 Synthesis of 5-formyl pyrrole 2-carboxylate L-valine L-tyrosinal 2.1.3l 
 
 67
Third attempted synthesis of 5-formyl pyrrole 2-carboxylate L-valine L-tyrosinal 
 
This third synthesis involved coupling between pre-synthesised L-tyrosine methyl ester 
hydrochloride 2.1.35 and 5-formyl pyrrole 2-carboxylate L-valine 2.3.6 with HATU over 21 hr to 
give a low yield (14%) of 5-formyl pyrrole 2-carboxylate L-valine L-tyrosine methyl ester 2.3.7. 
Then the methyl ester could not be reduced with LiAlH4/THF and gave a complex mixture 
including starting material. Separation on silica (EtOAc/pet ether) was unsuccessful and any 
further synthesis of this target compound 2.1.3l was abandoned. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.22 Attempted synthesis of 5-formyl pyrrole 2-carboxylate L-valine L-tyrosinal 2.1.3l 
via the diol route 
 
Attempted synthesis of 5-formyl pyrrole 2-carboxylate L-valine L-phenylalaninal 2.1.3m 
The attempted synthesis of 2.1.3m (Scheme 2.23) was similar to that of 5-formyl pyrrole              
2-carboxylate L-valine L-tyrosinal 2.1.3l. The only variation to this synthesis was the use of a 
pre-synthesised ethyl ester hydrochloride 2.1.9c as opposed to an esterified methyl ester 
hydrochloride used as the starting material. The coupling reaction between the L-valine 
compound 2.3.6, L-phenylalanine ethyl ester hydrochloride 2.1.9c and HATU was successful to 
give the ethyl ester 2.3.9 as an orange solid. Reduction reaction of the ethyl ester with LiAlH4 in 
THF over 17 hr produced a complex mixture including starting ethyl ester; chromatography on 
silica give a 29% yield of the diol 2.3.8b as a white solid. The oxidation of the diol using DMSO 
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and 8 equivalents of SO3.Pry was unsuccessful. The 1H NMR spectra in deuterated DMSO of the 
reaction mixture was complex. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.23 Attempted synthesis of 5-formyl pyrrole 2-carboxylate L-valine L-phenylalaninal 
 
 
2.4 Future work  
 
Comparing the unsuccessful synthesis of the L-tyrosinal 2.1.3l in Schemes 2.19, 2.21 and 2.22 
with the successful synthesis of the closely related sulfonyl alcohol 2.1.11j; may indicate a 
possible side reaction occurring with the phenolic alcohol in the L-tyrosinol and the 5-formyl 
pyrrole moiety. This was not clarified experimentally, however, to prevent this potential reaction 
occurring it would be possible to start with L-tyrosine with its phenolic alcohol protected with a 
benzyl group 2.4.1. Then esterification may be possible to the methyl ester 2.4.2 under basic 
conditions with MeI and K2CO3. Subsequently the methyl ester 2.4.2 would be coupled to         
5-formyl pyrrole 2-carboxylate L-valine 2.3.6 using HATU as coupling reagent. The methyl ester 
2.4.3 could be reduced to the L-tyrosine protected diol 2.4.4 with LiAlH4/THF.                   
Next a deprotection step with H2/Pd on C of the L-tyrosine protected diol 2.4.4 should afford     
5-hydroxymethyl pyrrole 2-carboxylte L-valine L-tyrosinol 2.3.8a. The finial oxidation step with 
DMSO and 8 equiv. of SO3.Pyr should afford the target aldehyde 2.1.3l.  
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Scheme 2.24 Suggested synthesis of 5-formyl pyrrole 2-carboxylate L-valine  
L-tyrosinal 
 
 
2.5 Computational modelling and biological activity  
 
The peptide alcohols 2.1.11a-k and peptide aldehydes 2.1.3a-k were docked to μ-calpain and 
cathepsin B using computational modelling (all modelling studies were preformed by Wangting 
Jiao and Steve McNabb). The modelling results are displayed in Table 2.8, 2.10, 2.12 and 
include glide scores, warhead distance in Å, hydrogen bond contacts to μ-calpain (labelled [A], 
[B] and [C] where [A] and [B] are hydrogen bonds formed between an inhibitor and Gly208 of the 
enzyme and [C] is a hydrogen bond formed between an inhibitor and Gly271 of the enzyme), 
hydrogen bond contacts to cathepsin B (labelled [A, B] and [C]where [A] and [B] are hydrogen 
bonds formed between an inhibitor and Gly74 of the enzyme and C is a hydrogen bond formed 
between an inhibitor and Gly198 of the enzyme), and any extra hydrogen bonds. 
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Table 2.8 Molecular modelling results of peptide alcohols 2.1.11a-k docked to μ-calpain and 
[cathepsin B]. 
Compound Glide Score H-bonds 
A,B,C 
Extra H-
bonds 
Warhead 
Distance (Å) 
N
H
S
O
H
N
F
O O
OH
S
2.1.11a  
-5.37 
[-4.55] 
0 
[A] 
3 
[1] 
4.08 
[5.78] 
 
N
H
S
O
H
N
F
O O
OH
S
2.1.11b  
-5.54 
[-6.79] 
C 
[0] 
2 
[3] 
3.95 
[3.77] 
 
N
H
S
O
H
N
F
O O
OH
S
2.1.11c  
-4.94 
[-6.01] 
A,C 
[A,B,C] 
0 
[1] 
3.67 
[3.52] 
 
N
H
S
O
H
N
F
O O
OH
S
2.1.11d  
-4.72 
[-6.33] 
A,B,C 
[A,B,C] 
1 
[F] 
3.34 
[3.25] 
 
N
H
S
O
H
N
F
O O
OH
2.1.11e  
-5.95 
[-4.13] 
A,B,C 
[A,B,C] 
1 
[F] 
3.57 
[4.19] 
 
N
H
S
O
H
N
F
O O
OH
S
2.1.11f  
-2.89 
[-5.64] 
0 
[B,C] 
2 
[F,+1] 
3.99 
[3.67] 
 
N
H
S
O
H
N
F
O O
OH
OH
2.1.11g  
-5.17 
 
0 
 
2 
 
3.89 
 
N
H
S
O
H
N
F
O O
OH
S
2.1.11h  
-4.914 
[-5.54] 
A,B,C  
[A,B,C] 
0 
[F,+1] 
4.090 
[3.49] 
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N
H
S
O
H
N
F
O O
OH
2.1.11i  
-1.149 B, C, C 0 3.423 
 
N
H
S
O
H
N
F
O O
OH
OH
2.1.11j  
-4.799 
[-4.90] 
A,B,C 
[A, C] 
0 
[0] 
3.917 
[4.38] 
N
H
H
N
H
O O H
N
OH
S
O
2.1.11k  
-5.677 A,B,C 0 3.505 
 
 
Peptide alcohols 
 
Alcohol 2.1.11d gave the best modelling results for both μ-calpain and cathepsin B (Table 2.8) 
as indicated by the smallest warhead distance between the alcohol and the active site cysteine, 
3.34 Å and 3.25 Å respectively. A strong F-H hydrogen bond was predicted for compounds 
2.1.11d, 2.1.11e, 2.1.11f and 2.1.11h to Asp69 of cathepsin B. No evidence of an F-H hydrogen 
bond between any of the compounds and μ-calpain was revealed by molecular modelling 
inferring that the observed F-H hydrogen bond is unique to cathepsin B.  
 
The peptide alcohols 2.1.11a-k were assayed against ovine m-calpain (purified from ovine lung 
tissue) and cathepsin B using a fluorescence-based assay to determine in-vitro potency and 
selectivity (assays were performed by Dr’s Matthew Jones and Janna Mehrtens). The assay 
results are summarised in Table 2.9. The peptide alcohol 2.1.11e was the most potent inhibitor of 
m-calpain and cathepsin B (IC50 = 2.3 μM for m-calpain and IC50 = 75 nM for cathepsin B) with 
good selectivity (30.75 fold) for cathepsin B over m-calpain. The compound was also assayed 
against μ-calpain and shown to be a good inhibitor (IC50 =1.5 μM for μ-calpain). The selectivity 
of compound 2.1.11e for cathepsin B over m-calpain may be due to the predicted formation of 
the F-H bond between the P3 address region and Asp69 of cathepsin B (Figure 2.8).                  
The modelling results indicate that compound 2.1.11e forms a β-strand conformation in the 
enzymes active site with hydrogen bond to Gly74 [A and B], Gly278 [C] and an extra F-H bond to 
Asp69. 
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Table 2.9 Biological activity of peptide alcohols 2.1.11a-k  
Compound P3 P2 P1 IC50 
(μM) 
m-Cal 
IC50 
(μM) 
Cath B 
Selectivity 
(mC/CB) 
2.1.11a pFPhSO2 Chx L-MetCH2OH >50  >50  Zero 
2.1.11b pFPhSO2 L-Pgl L-MetCH2OH 19  >50  0.38 
2.1.11c pFPhSO2 L-Chg L-MetCH2OH >50  27 1.85 
2.1.11d pFPhSO2 L-Ile L-MetCH2OH 25.7 >50  0.51 
2.1.11e pFPhSO2 L-Val L-PheCH2OH 2.3 
1.5a 
0.075 30.75 
2.1.11f pFPhSO2 L-Tle L-MetCH2OH >50  14  3.57 
2.1.11g pFPhSO2 Chx L-TyrCH2OH 50  NAb  
2.1.11h pFPhSO2 L-Val L-MetCH2OH >50  >50  Zero 
2.1.11i pFPhSO2 Chx L-LeuCH2OH >50  NAb  
2.1.11j pFPhSO2 L-Val L-TyrCH2OH >50  >50  Zero 
2.1.11k 5-CHO 
pyrrole 
L-Val L-MetCH2OH NAb NAb  
a
 Enzyme assay with μ-calpain (nM) 
b Not assayed 
 
 
 
 
Figure 2.8 Modelling results of compound N-(4-fluorobenzenesulfonyl) L-valine                       
L-phenylalaninol 2.1.11e in the active site of cathepsin B. 
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Peptide aldehydes 
 
The modelling results for the peptide aldehydes 2.1.3a, 2.1.3e, 2.1.3g, 2.1.3h, 2.1.3i, 2.1.3j and 
2.1.3k are shown in Table 2.10. Five hydrogen bonds, [A,B,C] and two extra H bonds including 
a F-H bond, are formed between compound 2.1.3h and cathepsin B. The modelling results 
indicate three hydrogen bonds [A, B, C] are formed between compound 2.1.3e and μ-calpain 
with the aldehyde warhead in close proximity (3.497 Å) to the active site cysteine. 
 
Table 2.10 Molecular modelling results of the peptide aldehydes 2.1.3a, 2.1.3e, 2.1.3g, 2.1.3h, 
2.1.3i, 2.1.3j and 2.1.3k docked to μ-calpain and [cathepsin B] 
Compound 
 
Glide Score 
 
H-bonds 
A,B,C 
Extra H-
bonds 
Warhead 
Distance (Å) 
N
H
S
O
H
N
F
O O
H
S
O
2.1.3a  
-6.512 
[-4.61] 
A,C 
[A,B,C] 
1 
[0] 
4.016 
[3.38] 
 
N
H
S
O
H
N
F
O O
H
O
2.1.3e  
-6.080 
[-3.32] 
A,B,C 
[A,B,C] 
0 
[F,+1] 
3.497 
[3.64] 
 
N
H
S
O
H
N
F
O O
H
OH
O
2.1.3g  
-5.322 A, B 3 3.958 
 
N
H
S
O
H
N
F
O O
H
S
O
2.1.3h  
-4.914 
[-5.54] 
 
A,B,C 
[A,B,C] 
0 
[F,+1] 
4.090 
[3.49] 
 
N
H
S
O
H
N
F
O O
H
O
2.1.3i  
-1.149 B,C,C 0 3.423 
 
N
H
S
O
H
N
F
O O
H
O
OH
2.1.3j  
-4.799 
[-4.90] 
A,B,C 
[A,C] 
0 
[0] 
3.917 
[4.38] 
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N
H
H
N
H
O O H
N
H
S
O
O
2.1.3k  
-5.677 A,B,C 0 3.505 
 
 
The peptide aldehydes 2.1.3a, 2.1.3e, 2.1.3g, 2.1.3h, 2.1.3i, 2.1.3j and 2.1.3.k were assayed 
against ovine m-calpain (purified from ovine lung tissue) and cathepsin B using a     
fluorescence-based assay to determine in vitro potency and selectivity (Table 2.11). The results 
revealed three potent inhibitors 2.1.3e, 2.1.3h and 2.1.3k with IC50 constants in the nM range for 
the calpains. The compounds 2.1.3e, 2.1.3h 2.1.3j was highly potent against cathepsin B.        
The compound 2.1.3a was the most potent inhibitor for both isoforms of the calpains and 
cathepsin B (IC50 = 93 nM for m-calpain, 12 nM for μ-calpain and IC50 = 16 nM for cathepsin 
B). The most selective inhibitor was compound 2.1.3a, displaying a 41 fold selectivity for 
cathepsin B over m-calpain. 
 
Table 2.11 Biological activity of peptide aldehydes 2.1.3a, 2.1.3e, 2.1.3g, 2.1.3h, 2.1.3i, 2.1.3j 
and 2.1.3.k. (P1 variations) 
Compound  P3 P2 P1 IC50 
(nM) m-
cal 
IC50 
(nM) 
Cath B 
Selectivity 
(mC/CB) 
2.1.3a pFPhSO2 Chx L-Met-H 9300 228 40.79 
2.1.3e pFPhSO2 L-Val L-Phe-H 93 
12a 
16 4.5 
2.1.3g pFPhSO2 Chx L-Tyr-H 1530 NAb  
2.1.3h pFPhSO2 L-Val L-Met-H 94 57 1.65 
2.1.3i pFPhSO2 Chx L-Leu-H 2280  NAb  
2.1.3j pFPhSO2 L-Val L-Tyr-H NAb 27  
2.1.3k 5-CHO 
pyrrole 
L-Val L-Met-H 135 NAb  
a Enzyme assay with μ-calpain (nM) 
b Not assayed  
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The selectivity obtained for 2.1.3a for cathepsin B over m-calpain may be a consequence of 
numerous effects. A factor that may account for this apparent selectivity is the formation of a 
stable β-strand when docked into the active site of cathepsin B in Figure 2.9. This is in sharp 
contrast the docking results of compound 2.1.3a in the active site of μ-calpain (not shown) where 
the β-strand fails to form.  
 
 
 
Figure 2.9 Compound (S)-1-(4-fluorophenylsulfonamido)-N-(4-(methylthio)-1-oxobutan-2-
yl)cyclohexanecarboxamide docked in the active site of cathepsin B showing hydrogen bonds 
[A] and [B] to Gly74 and hydrogen bond [C] to Gly198 
 
The dipeptide dialdehyde inhibitor 5-formyl pyrrole 2-carboylate L-valine L-methioninal 2.1.3k 
displayed good inhibition against m-calpain (IC50 = 135 nM). This was 5.4 fold less potent than 
the template m-calpain inhibitor CAT-0059 1.7.5 synthesised by Shigeru Miyamoto23,109            
(IC50 = 25 nM). Modelling results of inhibitor 2.1.3k docked to μ-calpain suggests the compound 
binds in a unique way to enzyme’s active site compared to the sulfonyl analogues; this unique 
binding mode is illustrated in Figures 2.10 and 2.11 below. 
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Figure 2.10 5-Formyl pyrrole 2-carboylate L-valine L-methioninal 2.1.3k docked in the active 
site of μ-calpain 
 
Computational modelling of 2.1.3k to the active site of μ-calpain predicts a shunted binding 
conformation as shown in Figure 2.10. The compound 2.1.3k adopts a conformation where 
hydrogen bond [A] is replaced by a hydrogen bond formed between the pyrrole NH and Gly208. 
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R1 and R2= α-amino acid 
 
Figure 2.11 Compounds N-(4-fluorobenzenesulfonyl) analogues (left) and   
5-formyl pyrrole L-valine L-methioninal 2.1.3k (right), showing the hydrogen bond interactions 
[A], [B] and [C] with glycine residues 
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Evaluation of the variations of α-amino acids at P1 address region 
  
The methionine containing compounds 2.1.3a, 2.1.3h and 2.1.3k were potent inhibitors of both 
m-calpain and cathepsin B. Compound 2.1.3h exhibited a 1.65 fold increase in potency for 
cathepsin B IC50 = 57 nM over m-calpain IC50 = 94 nM. The phenylalanine compound 2.1.3e 
displayed excellent binding to the assayed enzymes.  
 
Table 2.12 Modelling results for peptide aldehyde inhibitors 2.1.3a, 2.1.3b, 2.1.3c, 2.13d, 2.1.3f 
and 2.1.3h to m-calpain and [cathepsin B]  
Compound Glide score H-bonds 
A,B,C 
Extra H-
bonds 
War Head 
Distance (Å) 
N
H
S
O
H
N
F
O O
H
S
O
2.1.3a  
-6.512 
[-4.61] 
A,C 
[A,B,C] 
1 
[0] 
4.016 
[3.38] 
 
N
H
S
O
H
N
F
O O
H
S
O
2.1.3b  
-3.925 
[-6.79] 
C,C 
[0] 
1 
[3] 
3.759 
[3.77] 
 
N
H
S
O
H
N
F
O O
H
S
O
2.1.3c  
-4.785 
[-6.01] 
A,C 
[A,B,C] 
0 
[1] 
3.502 
[3.52] 
 
N
H
S
O
H
N
F
O O
H
S
O
2.1.3.d  
-5.371 
[-5.79] 
A,B,C 
[B,C] 
0 
[F] 
3.841 
[3.70] 
 
N
H
S
O
H
N
F
O O
H
S
O
2.1.3f  
-4.943 
[-6.01] 
B,C 
[A,B,C] 
1 
[0] 
5.491 
[3.67] 
 
N
H
S
O
H
N
F
O O
H
S
O
2.1.3h  
-4.914 
[-5.54] 
A,B,C 
[A,B,C] 
0 
[F,+1] 
4.090 
[3.49] 
 
 78
Table 2.12 shows the modelling results for the P2 variations 2.1.3a, 2.1.3b, 2.1.3c, 2.13d, 2.1.3f 
and 2.1.3h. Computational modelling predicted compound 2.1.3d had a closer warhead distance 
to Cys115 of μ-calpain (3.841 Å) compared to compound 2.1.3h (4.090 Å). This could be 
attributed to an extra CH2 group on the side chain of iso L-leucine giving rise to extra extension 
into the enzymes active site. This may suggest enhanced inhibition for iso L-leucine at P2 address 
region over its L-valine derivate 2.1.3h. In addition the modelling suggested 2.1.3d would take 
on the β-strand conformation (Figure 2.12). However, the assay results for the aldehyde 2.1.3h 
was 3.36 fold more potent than the compound 2.1.3d at 317 nM (Table 2.13). In this case the 
assay results did not concur with the modelling predictions made for the P2 preferences of         
μ-calpain.  
 
Figure 2.12 N-(4-fluorobenzenesulfonyl) iso L-leucine L-methioninal docked in the active site of 
μ-calpain 
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Table 2.13 Biological activity of peptide aldehydes 2.1.3a, 2.1.3.b, 2.1.3c, 2.1.3d, 2.1.3f and 
2.1.3h (P2 variations)  
Compound P3 P2 P1 IC50 
(nM) 
m-cal 
IC50 
(nM) 
Cat B 
Selectivity 
(mC/CB) 
2.1.3a pFPhSO2 Chx L-Met-H 9300 228 40.79 
2.1.3b pFPhSO2 L-Pgl L-Met-H 315 122 2.58 
2.1.3c pFPhSO2 L-Chg L-Met-H 5000 400 12.5 
2.1.3d pFPhSO2 L-Ile L-Tyr-H 317 260 1.22 
2.1.3f pFPhSO2 L-Tle L-Met-H 14500 2800 5.18 
2.1.3h pFPhSO2 L-Val L-Met-H 94 57 1.65 
 
 
The enzyme assay results for the P2 variations compounds 2.1.3a, 2.1.3.b, 2.1.3c, 2.1.3d, 2.1.3f 
and 2.1.3h are shown in table (Table 2.13). The results reveal that compounds 2.1.3b, 2.1.3d and 
2.1.3h are highly potent with IC50’s in the nM range for m-calpain. Compound 2.1.3h was more 
potent against m-calpain (IC50 = 94 nM) compared to cathepsin B (IC50 = 57 nM). 
 
The aldehyde 2.1.3f displayed low potency against m-calpain and cathepsin B (IC50 = 14.5 μM 
and 2.8 μM respectably) (Table 2.13). The modelling studies suggested 2.1.3f bound to            
m-calpain but didn’t display a hydrogen bonding interactions between NH of tert L-leucine and 
the carbonyl group on Gly208. However, the Gly208 residue did form a hydrogen bond to the 
aldehyde warhead on the L-methioninal moiety as seen in Figure 2.13. The computational 
modelling reveals the influence of the extra methyl group on tert L-leucine moiety of 2.1.3f.   
The incorporation of this group results in a reverse binding mode in the active site of μ-calpain 
and gives an unfavourable warhead distance of 5.491 Å. 
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Figure 2.13 Compound N-(4-fluorobenzenesulfonyl) tert L-leucine L-methioninal 2.1.3f docked 
in the active site of μ-calpain revealing a reverse binding mode 
 
Evaluation of the variations of α-amino acids at P2 address region 
 
m-Calpain was found to favour L-valine, iso L-leucine and L-phenylglycine at the P2 address 
region with compound 2.1.3h (containing L-valine) being the most active inhibitor. The inclusion 
of the bulky unnatural amino acids L-cyclohexaglycine (Chg), tert L-leucine (Tle) and              
1,1 cyclohexane (Chx) resulted in poor enzyme inhibition of m-calpain. These assays results 
suggest the S2 subsite has a low tolerance for bulky amino acids.  
 
The S2 subsite of cathepsin B seems to have a higher tolerance (gleaned from assay results) for 
the inclusion of unnatural amino acids used in this investigation such as Chg, with inhibition 
concentrations in the nM range. However, in agreement with the m-calpain assay results the 
inclusion of a tert L-leucine residue in compound 2.1.3f results in decreased potency compared 
to compound 2.1.3h that contains L-valine at P2.  
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2.6 Conclusion 
 
The CA clan cysteine proteases m-calpain and cathepsin B are implicated in a number of human 
pathologies including cataract26 and tumour metastases10 respectably. It’s thought inhibiting 
these enzymes may arrest disease progression.117 In this investigation the successful synthesis 
peptide aldehydes 2.1.3a-j based on the SJA-6017 1.7.1117 was completed. A potent dipeptide 
dialdehyde inhibitor 2.1.3k (IC50 = 135 nM m-calpain) was successfully synthesised using   
CAT-0059 1.7.3 as template.103 The variations at the P1 position produced the most potent 
inhibitors against the tested enzymes. The compound 2.1.3e was the most potent inhibitor for    
μ-calpain and m-calpain with respective IC50 concentrations 16 nM and 93 nM. The aldehyde 
2.1.3h (IC50 = 94 nM for m-calpain) was also a highly active inhibitor. The best cathepsin B 
inhibitors were the sulfonyl L-valine L-phenylalaninal 2.1.3e IC50 16 = nM and the L-tyrosinal 
2.1.3j IC50 = 27 nM. Despite their high potency, none of these inhibitors 2.1.3d, 2.1.3i, and 2.1.3j 
where selective for the enzyme assayed. However selectivity for cathepsin B was marginally 
improved with the inclusion of bulky aliphatic α-amino acids in the P2 position of the inhibitor. 
For example the peptide alcohol 2.1.11c gave a 13 fold selectivity for cathepsin B                  
(IC50 = 5.0 μM for m-calpain and IC50 = 400 nM for cathepsin B). The synthesis of an m-calpain 
selective inhibitor was not achieved in this study. Compound 2.1.3k demonstrated a shunted 
binding conformation to μ-calpain where the pyrrole NH replaced hydrogen bond [A]. 
Computational modelling predicted the existence of an extra F-H bond for the peptide alcohols 
2.1.11b, 2.1.11d, 2.1.11g, 2.1.11j and the peptide aldehydes 2.1.3b, 2.1.3d and 2.13j which were 
unique to for cathepsin B and seemed to aid binding. 
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Chapter 3 
Experimental 
 
 
3.1 General experimental methods and procedures  
 
Dichloromethane, ethyl acetate, petroleum ether and triethylamine were distilled over 
CaH2. THF was dried over sodium or potassium metal wire utilising a wetness indictor, 
benzylphenone. Product mixtures from reactions (when required) were examined by TLC using 
Polygram SIL G/UV254 plastic backed silica plates and EtOAc/petroleum ether, EtOAc/MeOH 
or DCM/MeOH solvent mixtures. Visualisation was achieved by ultra violet light (UV) or using 
either KMnO4 or phosphomolybdic acid (PMA) solution. The KMnO4 solution was prepared 
with KMnO4 (3 g), K2CO3 (20 g), NaOH (5.0 mL; 0.05 N) and water (300 mL). The PMA 
solution was prepared with phosphomolybdic acid (12 g) in ethanol (250 mL). Crude mixtures 
(not including compounds with polar groups such as CO2H and hydrochloride salts) of >200 mg 
where either loaded onto a column with dichloromethane or dry loaded onto silica using a Buchi 
rotary evaporator. Separation was achieved by using a Buchi C-660 fraction collector. 
The common name for compounds is mentioned first followed by the systematic name 
generated from ChemDraw Ultra v. 9.0. Melting points were obtained with an Electrotherm 
melting apparatus using Samco 100 mm soda glass capillary tubes. Experimental melting points 
are reported to the nearest 1oC after any literature melting points when known. 
 
Infrared (IR) experiments were carried out on a Shimadzu FTIR-8201PC Fourier Transform 
Infrared Spectrophotometer and referenced to KBr and reported to the nearest ν max 1.0 cm.-1
  
Nuclear Magnetic Resonance (NMR). The NMR solvents used in this study (CDCl3, CD3OD 
and (CD3)2SO)) were supplied by Cambridge Isotope Laboratories. 1H NMR experiments 
including 1H and GCOSY spectra were obtained from either a Varian UNITY operating at 300 
Hz or a Varian INOVA Unity operating at 500 Hz. The operating temperature used on both 
instruments was 23oC, however occasionally a temperature of 25oC was also used. The INOVA 
was equipped with a variable temperature and inverse-detection 5 mm probe or a                 
triple-resonance indirect detection PFG. 13C NMR spectra were recorded on a Varian UNITY 300 
NMR spectrometer equipped with a variable temperature direct broadband 5 mm probe, 
operating at 75 MHz. The operating temperatures used were 23oC, however occasionally a 
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temperature of 25oC was also used. Chemical shifts are expressed in parts per million (ppm) on 
the δ scale and reported to the nearest 1H δH = 0.01 and for 13C δC = 0.1. CDCl3 is referenced to 
CHCl3 at δH = 7.25 (1H); CD3OD referenced to CHD2OD at δH = 3.31 (1H) and CD3OD             
at δC = 49.3 (13C); (CD3)2SO referenced to CD3(CHD2)SO at δH = 2.50 (1H) and (CD3)2SO        
at δC = 39.6 (13C). 
 
High Resolution Mass Spectra (HRMS) were performed on a Micromass LCT spectrometer 
using a probe voltage of 3,200V, with an operating temperature of 150°C and a source 
temperature of 80°C. The carrier solvent was 50:50 mixture of CH3CN/H2O at a flow rate         
of 20 µL/minute. Typically, 10 µL of a 10 µg/mL solution was injected. Leucine enkephalin was 
used as the lock mass internal standard at [M+H]+ = m/z 527.2771. Mass spectrometry 
measurements were reported to m/z = 0.0001 and within a tolerance range of 5.0 ppm from its 
calculated mass. 
 
 
3.2 Experimental 
 
1-(Methoxycarbonyl)cyclohexanaminium chloride 
 
Cl- +H3N
O
OMe
H2N
O
OH
2.1.4a 2.1.5a  
A solution containing 1-aminocyclohexanecarboxylic acid 4.000 g (27.935 mmol, 1 equiv.) in 
MeOH (65 mL) was cooled to -20oC in a NaCl ice bath. SOCl2 (16 mL) (223.479 mmol,                  
8 equiv.) added dropwise over 20 min and the reaction mixture stirred for 1 hr at -20oC               
and allowed to return to room temperature and stirred for 1 day. The solution                  
was diluted with MeOH (200 mL) and the solvent removed in-vacuo to give                  
1-(methoxycarbonyl)cyclohexanaminium chloride 5.410 g (27.935 mmol, 100%) as a white 
solid. lit. m.p. 210-212oC118 m.p. 209oC; 1H NMR ((CD3)2SO) (300 MHz) δH = 8.87 (3H, s, 
CNH3+), 3.86 (3H, s, OCH3), 2.10-1.51 (10H, m, CH2’s); (HRMS) (CH3OH) calcd. for the free 
amine C8H16NO2 [M + H]+: 158.1181, found 158.1186. 
 
Methyl 1-(4-fluorophenylsulfonamido)cyclohexanecarboxylate 
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N
H
S
O
OMe
F
O O
Cl- +H3N
O
OMe
Cl
S
F
O O
2.1.6
2.1.7a2.1.5a  
A solution containing 1-(methoxycarbonyl)cyclohexanaminium chloride 4.77 g (24.666 mmol,   
1 equiv.) in DMF (15 mL) and DIPEA (9.5 mL) (54.266 mmol, 2.2 equiv.) was cooled to 0oC in 
a ice bath. N-(4-Fluorobenzenesulfonyl) chloride 5.760 g (29.598 mmol, 1.2 equiv.) added       
over 15 min and the reaction mixture was left stirring for 1 day at room temperature.               
The mixture was partitioned between EtOAc (50 mL) and HCl (50 mL; 1N), and the aqueous 
phase was washed twice with EtOAc (50 mL). The combined organic phases were washed with 
saturated NaHCO3 (50 mL) and saturated brine (50 mL) and dried with anhydrous Na2SO4 and 
the solvent removed in-vacuo. Flash chromatography on silica (EtOAc/petroleum ether 1:3,      
Rf = 0.35) gave methyl 1-(4-fluorophenylsulfonamido)cyclohexanecarboxylate 6.768 g (21.459 
mmol, 87%) as a white solid. m.p. 139oC; 1H NMR ((CD3)2SO) (300 MHz) δH = 8.20 (1H, s, 
NHC), 7.93-7.89 (2H, m, ArH), 7.54-7.48 (2H, m, ArH), 3.49 (3H, s, OCH3 of Chx), 1.91-1.75 
(4H, m, CH2’s of Chx), 1.39-1.25 (6H, m, CH2’s of Chx); (HRMS) (CH3OH) calcd. for 
C14H19FNO4S [M + H]+: 316.1019, found 316.1030. 
 
1-(4-Fluorophenylsulfonamido)cyclohexanecarboxylic acid 
 
 
N
H
S
O
OMe
F
O O
N
H
S
O
OH
F
O O
2.1.7a 2.1.8a  
 
To methyl 1-(4-fluorophenylsulfonamido)cyclohexanecarboxylate 6.570 g (20.833 mmol,           
1 equiv.) in THF (30 mL), a solution of NaOH (10.0 mL; 5.208 N) was added slowly over 5 min. 
The mixture was heated to 65oC in a silica oil bath and stirred for 21 hr. The mixture was 
concentrated to half its original volume on a rotary evaporator and the resulting residue dissolved 
in 80 mL of distilled water. The aqueous phase was washed twice with EtOAc (80 mL) and the 
organic phase discarded. The reaction mixture was partitioned between EtOAc (80 mL) and HCl 
(80 mL; 1N) and the aqueous phase washed twice with EtOAc (80 mL). The combined organic 
phases were washed with saturated brine (80 mL) and dried with anhydrous Na2SO4 and the 
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solvent removed in-vacuo to give 1-(4-fluorophenylsulfonamido)cyclohexanecarboxylic acid 
5.613 g (18.630 mmol, 89%) as a white solid. m.p. 215oC; 1H NMR ((CD3)2SO) (300 MHz)     
δH = 12.50 (1H, s, COOH of Chx), 8.01 (1H, s, NHC of Chx) 7.95-7.90 (2H, m, ArH) 7.52-7.46 
(2H, m, ArH) 1.90-1.76 (4H, m, CH2’s of Chx) 1.50-1.20 (6H, m, CH2’s of Chx); (HRMS) 
(CH3OH) calcd. for C13H17FNO4S [M + H]+: 302.0862, found 302.0877.  
 
L-Methionine methyl ester hydrochloride [(S)-1-methoxy-4-(methylthio)-1-oxobutan-2-
aminium chloride]  
 
 
Cl- +H3N OMe
S
OH
N
OH
S
O
O
O
2.1.12c 2.1.9b  
 
A solution of boc L-methionine 12.500 g (50.134 mmol, 1 equiv.) in MeOH (108 mL) was 
cooled to -20oC in a NaCl ice bath. SOCl2 (4.4 mL) (60.161 mmol, 1.2 equiv.) added dropwise 
over 15 min. The reaction mixture was stirred for 2 hr at -20oC and allowed to come to room 
temperature for an additional 3 hr. The solution was diluted with MeOH (400 mL) and the 
solvent removed in-vacuo to give L-methionine methyl ester hydrochloride 10.012 g         
(50.134 mmol, 100%) as a white solid. lit. m.p. 145-149oC119 m.p. 153oC; 1H NMR (CD3OD)     
(300 MHz) δH = 4.05 (1H, t, J = 6.5 Hz, CHCO), 3.68 (3H, s, OCH3), 2.52-2.47 (2H, m, SCH2), 
2.09-1.94 (5H, m, CHCH2CH2 and SCH3); (HRMS) (CH3OH) calcd. for C6H14NO2S [M + H]+: 
164.0745, found 164.0740. 
 
(S)-Methyl 2-(1-(4-fluorophenylsulfonamido)cyclohexanecarboxamido)-4-
(methylthio)butanoate 
 
N
H
S
O
OH
F
O O
Cl- +H3N OMe
S
O
N
H
S
O
H
N
F
O O
OMe
S
O
2.1.8a
2.1.9b
2.1.10a  
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To a solution (S)-methyl 2-(1-(4-fluorophenylsulfonamido)cyclohexanecarboxamido)-4-
(methylthio)butanoate 1.800 g (5.974 mmol, 1 equiv.) in DMF (10 mL) kept under N2,                 
L-methionine methyl ester hydrochloride 1.312 g (6.571 mmol, 1.1 equiv.) added followed by 
DIPEA (2.3 mL) (13.143 mmol, 2.2 equiv.). HATU 2.498 g (6.571 mmol, 1.1 equiv.) added over 
15 min and the reaction stirred for 2 days at room temperature. The reaction mixture was 
partitioned between EtOAc (25 mL) and HCl (25 mL; 1N), and the aqueous phase was washed 
twice with EtOAc (25 mL). The combined organic phases were washed with saturated       
NaHCO3 (25 mL) and saturated brine (25 mL) and dried with anhydrous Na2SO4 and the   
solvent removed in-vacuo. Flash chromatography on silica (EtOAc/petroleum ether                  
1:1, Rf = 0.43) gave (S)-methyl 2-(1-(4-fluorophenylsulfonamido)cyclohexanecarboxamido)-4-
(methylthio)butanoate 2.460 g (5.509 mmol, 92%) as a white solid. m.p. 113oC; IR ν max (KBr) 
1717 (COOCH3), 1663 (CONH); 1H NMR (CD3OD) (300 MHz) δH = 7.96-7.91 (2H, m, ArH), 
7.80 (1H, d, J = 7.5 Hz, NHCH of Met), 7.31-7.24 (2H, m, ArH), 4.57-4.50 (1H, m, NHCH of 
Met), 3.73 (3H, s, OCH3 of Met), 2.70-2.54 (2H, m, SCH2 of Met), 2.21-1.73 (9H, m, CH2’s of 
Chx, SCH3 of Met and CHCH2CH2 of Met), 1.42-1.00 (6H, m, CH2’s of Chx); 13C NMR 
((CD3)2SO) δC = 173.6, 172.2, 164.1 (d, J = 249.4 Hz, F-C=), 139.5 (=C-S), 129.6 (2C, d,           
J = 9.3 Hz, C=C-S), 116.1 (2C, d, J = 22.6 Hz, F-C=C), 61.7, 52.0, 51.4, 33.7, 32.2, 30.7, 29.6, 
24.8, 21.1, 14.7 (SCH3 of Met); (HRMS) (CH3OH) calcd. for C19H28FN2O5S2 [M + H]+: 
447.1424, found 447.1439. 
 
(S)-1-(4-Fluorophenylsulfonamido)-N-(1-hydroxy-4-(methylthio)butan-2-
yl)cyclohexanecarboxamide 
 
N
H
S
O
H
N
F
O O
OH
S
N
H
S
O
H
N
F
O O
OMe
S
O
2.1.10a 2.1.11a  
 
A two necked round bottom flask containing a solution of 2.1.10a 2.222 g (4.976 mmol,             
1 equiv.) in THF (7.2 mL) kept under N2, was cooled to 0oC in a ice bath. Then a solution of 
LiAlH4/THF (5.5 mL; 1N) added dropwise over 3 min. The reaction mixture was stirred at 0oC 
for 1 hr and allowed to come to room temperature and stirred for a further 17 hr. The reaction 
mixture was partitioned between EtOAc (25 mL) and KHSO4 (25 mL; 1N), and the aqueous 
phase was washed twice with CHCl3 (10 mL). The combined organic phases were washed with 
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saturated brine and dried with anhydrous MgSO4 and the solvent removed in-vacuo.                  
Flash chromatography on silica (EtOAc/petroleum ether 3:1, Rf = 0.28) gave (S)-1-(4-
fluorophenylsulfonamido)-N-(1-hydroxy-4-(methylthio)butan-2-yl)cyclohexanecarboxamide 
1.367 g (3.266 mmol, 66%) as an opaque solid. m.p. 108oC; IR ν max (KBr) 3514 (H2COH), 
1651 (CONH), 1030 (H2COH); 1H NMR (CD3OD) (300 MHz) δH = 7.96-7.91 (2H, m, ArH), 
7.30-7.25 (2H, m, ArH), 4.01-3.98 (1H, m, NHCH of Met), 3.61-3.51 (2H, m, CH2OH of Met), 
2.66-2.51 (2H, m, SCH2 of Met), 2.08 (1H, s, SCH3 of Met), 1.93-1.80 (6H, m, CH2’s of Chx 
and CHCH2CH2 of Met), 1.43-1.05 (6H, m, CH2’s of Chx); 13C NMR ((CD3)2SO) δC  = 173.4 
(CONH of Chx), 164.0 (d, J = 248.9 Hz, F-C=), 139.8 (d, J = 2.8 Hz, =C-S), 129.6 (2C, d,         
J = 9.4 Hz, C=C-S), 116.1 (2C, d, J = 22.5 Hz, F-C=C), 62.9, 62.0, 50.3, 33.4, 32.6, 30.8, 30.1, 
24.8, 21.2, 14.8 (SCH3 of Met); (HRMS) (CH3OH) calcd. for C18H28FN2O4S2 [M + H]+: 
419.1475, found 419.1484. 
 
(S)-1-(4-Fluorophenylsulfonamido)-N-(4-(methylthio)-1-oxobutan-2-
yl)cyclohexanecarboxamide 
 
 
N
H
S
O
H
N
F
O O
H
S
O
N
H
S
O
H
N
F
O O
OH
S
2.1.11a 2.1.3a  
(S)-1-(4-Fluorophenylsulfonamido)-N-(1-hydroxy-4-(methylthio)butan-2-
yl)cyclohexanecarboxamide 975 mg (2.330 mmol, 1 equiv.) in DMSO (8 mL) and DCM         
(11 mL) was kept under N2 and DIPEA (1.6 mL) (9.318 mmol, 4 equiv.) was added. A separate 
vial containing SO3.Pyr 1.483 g (9.318 mmol, 4 equiv.) dissolved in DMSO (4 mL) was heated 
and added slowly to the reaction mixture over 5 min. The reaction was stirred for 2 hr at room 
temperature. The reaction mixture was partitioned between EtOAc (20 mL) and HCl                
(20 mL; 1N), and the aqueous phase washed twice with EtOAc (20 mL). The combined organic 
phases were washed with saturated NaHCO3 (20 mL) and saturated brine (20 mL) and           
dried with anhydrous Na2SO4. The solvent was removed in-vacuo, to give (S)-1-(4-
fluorophenylsulfonamido)-N-(4-(methylthio)-1-oxobutan-2-yl)cyclohexanecarboxamide 820 mg 
(1.969 mmol, 84%) as white solid. m.p. 137oC; IR ν max (KBr) 1719 (COH), 1650 (CONH); 1H 
NMR ((CD3)2SO) (300 MHz) δH = 9.45 (1H, s, CHO of Met), 8.13 (1H, d, J = 6.9 Hz, NHCH of 
Met), 8.01-7.96 (2H, m, ArH), 7.91 (1H, s, NHC of Chx), 7.81-7.47 (2H, m, ArH), 4.15-4.08 
(1H, m, NHCH of Met), 2.69-2.51 (2H, m, SCH2 of Met), 2.20-2.06 (4H, m, CHCH2CH2 of Met 
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and SCH3 of Met), 1.98-1.83 (5H, m, CHCH2CH2 of Met and CH2’s of Chx), 1.40-1.25 (6H, m, 
CH2’s of Chx); 13C NMR ((CD3)2SO) δC = 201.1 (CHO of Met), 174.2 (CONH of Chx), 164.0 
(d, J = 248.9 Hz, F-C=), 139.7 (d, J = 2.8 Hz, =C-S), 129.5 (2C, d, J = 9.4 Hz, C=C-S), 116.1 
(2C, d, J = 22.5 Hz, F-C=C), 61.5, 57.7, 33.3, 32.8, 29.5, 27.6, 24.7, 21.1, 14.5 (SCH3 of Met); 
(HRMS) (CH3CN) calcd. for C18H26FN2O4S2 [M + H]+: 417.1318, found 417.1310.  
 
L-Phenylglycine methyl ester hydrochloride [(S)-2-methoxy-2-oxo-1-phenylethanaminium 
chloride] 
 
Cl- +H3N
O
OMeH2N
O
OH
2.1.4b 2.1.5b  
 
L-Phenylglycine 3.000 g (19.845 mmol, 1 equiv.) in MeOH (46 mL) was cooled to 0oC and 
SOCl2 (11.5 mL) (158.762 mmol, 8 equiv.) added dropwise over 15 min. The reaction mixture 
was stirred the first hr at 0oC and for a further 21 hr at room temperature. MeOH (50 mL) added 
and the solvent removed in-vacuo to give L-phenylglycine methyl ester hydrochloride 4.000 g 
(19.845 mmol, 100%) as a white solid. lit. m.p. 200oC120 m.p. 198oC; 1H NMR (CD3OD)                  
(300 MHz) δH = 9.04 (3H, b s, CHNH3), 7.53-7.47 (5H, m, ArH), 5.24 (1H, s, CHCO), 3.79 
(3H, s, OCH3); (HRMS) (CH3OH) calcd. for C9H12NO2 [M + H]+: 166.0868, found 166.0860.  
 
N-(4-Fluorobenzenesulfonyl) L-phenylglycine methyl ester [(S)-methyl 2-(4-
fluorophenylsulfonamido)-2-phenylacetate] 
 
N
H
S
O
OMe
F
O O
Cl
S
F
O O
Cl- +H3N
O
OMe
2.1.5b 2.1.7b
2.1.6
 
L-Phenylglycine methyl ester hydrochloride 3.000 g (14.877 mmol, 1 equiv.) in DMF (17 mL) 
was cooled to 0oC in an ice bath and DIPEA (5.7 mL) (32.729 mmol, 2.2 equiv.) added followed 
by the addition of N-(4-fluorobenzenesulfonyl) chloride 3.475 g (17.853 mmol, 1.2 equiv.) over          
15 min. The reaction mixture was stirred for 1 day and partitioned between EtOAc (50 mL) and 
HCl (50 mL; 1N). The aqueous phase was washed twice with EtOAc (50 mL). The organic 
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phases were combined and washed with saturated NaHCO3 (50 mL), saturated brine (50 mL) and 
dried with anhydrous Na2SO4. Solvent was removed in-vacuo and the product was recrystallised 
(EtOAc/petroleum ether 1:3, Rf = 0.29) to give N-(4-fluorobenzenesulfonyl) L-phenylglycine 
methyl ester 3.36 g (10.392 mmol, 70%) as a white solid. m.p. 135oC; IR ν max (KBr) 1734 
(COOCH3); 1H NMR ((CD3)2SO) (300 MHz) δH = 9.08 (1H, d, J = 9.3, Hz, NHCH of Pgl),  
7.89-7.84 (2H, m, FArH) 7.44-7.36 (7H, m, 2 x FArH and 5 x ArH of Pgl), 5.16 (1H, d,              
J = 9.3 Hz, NHCH of Pgl), 3.58 (3H, s, OCH3 of Pgl); 13C NMR ((CD3)2SO) δC = 170.2, 
(COCH3 of Pgl), 164.2 (d, J = 249.4 Hz, F-C=), 137.4 (d, J = 2.7 Hz, =C-S), 135.7 (NHCHC= 
of Pgl), 129.7 (2C, d, J = 9.3 Hz, C=C-S), 128.7 (2C, s, C=C-C of Pgl), 128.4 (C=C-C of Pgl), 
127.5 (2C, s, C=C-C of Pgl), 116.1 (2C, d, J = 22.5 Hz, F-C=C), 59.6 (NHCH of Pgl),           
52.5 (OCH3 of Pgl); (HRMS) (CH3OH) calcd. for C15H15FNO4S [M + H]+: 324.0706,                  
found 324.0714. 
 
N-(4-Fluorobenzenesulfonyl) L-phenylglycine [(S)-2-(4-fluorophenylsulfonamido)-2-
phenylacetic acid] 
 
N
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O O
2.1.7b 2.1.8b  
 
To N-(4-fluorobenzenesulfonyl) L-phenylglycine methyl ester 3.00 g (9.278 mmol, 1 equiv.) in 
THF (30.0 mL), NaOH (10.0 mL; 2.320 N) added over 5 min. The reaction mixture was heated 
to 65oC and stirred for 1 day. The mixture was concentrated to half its original volume on a 
rotary evaporator and distilled water (50 mL) added. The aqueous phase was washed twice with 
EtOAc and the solution was partitioned between EtOAc (50 mL) and HCl (50 mL; 1N), the 
aqueous phase was washed twice with EtOAc (50 mL). The combined organic phases were 
washed with saturated brine (50 mL) and dried with anhydrous Na2SO4 and the solvent removed 
in-vacuo to give N-(4-fluorobenzenesulfonyl) L-phenylglycine 2.675 g (8.648 mmol, 93%) as a 
white solid. lit. m.p. 158-160oC121 m.p. 166oC. 1H NMR ((CD3)2SO) (300 MHz) δH = 13.09 (1H, 
b s, COOH), 8.91 (1H, d, J = 9.3 Hz, NHCH of Pgl), 7.89-7.85 (2H, m, FArH), 7.42-7.36 (7H, 
m, 2 x FArH and 5 x ArH of Pgl), 5.03 (1H, d, J = 9.6 Hz, NHCH of Pgl); (HRMS) (CH3OH) 
calcd. for C14H13FNO4S [M + H]+: 310.0549 found 310.0535. 
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N-(4-Fluorobenzenesulfonyl) L-phenylglycine L-methionine methyl ester [(S)-methyl 2-((S)-
2-(4-fluorophenylsulfonamido)-2-phenylacetamido)-4-(methylthio)butanoate] 
 
N
H
S
O
OH
F
O O
2.1.8b
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O
H
N
F
O O
OMe
O
S
Cl- +H3N OMe
S
O
2.1.9b
2.1.10b  
 
To N-(4-fluorobenzenesulfonyl) L-phenylglycine 2.253 g (7.283 mmol, 1 equiv.) in DMF        
(15 mL) kept under N2, L-methionine methyl ester hydrochloride 1.600 g (8.012 mmol,            
1.1 equiv.) added. DIPEA (2.8 mL) (16.023 mmol, 2.2 equiv.) added and HATU 3.046 g    
(8.012 mmol, 1.1 equiv.) added over 15 min and the mixture stirred for 2 days at room 
temperature. The mixture was partitioned between EtOAc (50 mL) and HCl (50 mL; 1N), and 
the aqueous phase was washed twice with EtOAc (50 mL). The combined organic phases were 
washed with saturated NaHCO3 (50 mL) and saturated brine (50 mL) and dried with anhydrous 
Na2SO4. The solvent was removed in-vacuo. Flash chromatography on silica (EtOAc/petroleum 
ether 2:3, Rf = 0.23) gave N-(4-fluorobenzenesulfonyl) L-phenylglycine L-methionine methyl 
ester 1.718 g (3.780 mmol, 52%) as a white solid. m.p. 150oC; IR ν max (KBr) 1728 (COOH3), 
1649 (CONH); 1H NMR ((CD3)2SO) (300 MHz) δH = 8.81 (1H, d, J = 9.6 Hz, NHCH), 8.74 
(1H, d, J = 7.5 Hz, NHCH), 7.91-7.80 (2H, m, FArH), 7.44-7.29 (7H, m, 2 x FArH and 5 x ArH 
of Pgl), 5.19 (1H, J = 9.6 Hz, NHCH of Pgl), 4.33-4.26 (1H, m, NHCH of Met), 3.60 (3H, s, 
OCH3 of Met), 2.44-2.39 (2H, m, SCH2 of Met), 2.12 (3H, s, SCH3 of Met), 1.97-1.82 (2H, m, 
CHCH2CH2 of Met); 13C NMR ((CD3)2SO) δC = 171.6, (COCH3 of Met), 168.9 (CONH of Pgl), 
164.1 (d, J = 251.1 Hz, F-C=), 137.6, 137.2, 129.6 (2C, d, J = 9.4 Hz, C=C-S), 128.2 (2C, s, 
C=C-C of Pgl), 127.7 (C=C-C of Pgl), 127.2 (2C, s, C=C-C of Pgl), 115.9 (2C, d, J = 22.6 Hz, 
F-C=C), 59.1 (NHCH of Pgl), 52.0, 51.0, 30.4 (CH2 of Met), 29.4 (CH2 of Met), 14.5 (SCH3 of 
Met); (HRMS) (CH3OH) calcd. for C20H24FN2O5S2 [M + H]+: 455.1111 found 455.1104. 
 
N-(4-Fluorobenzenesulfonyl) L-phenylglycine L-methioninol [(S)-2-(4-
fluorophenylsulfonamido)-N-((S)-1-hydroxy-4-(methylthio)butan-2-yl)-2-phenylacetamide] 
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2.1.10b 2.1.11b  
 
N-(4-Fluorobenzenesulfonyl) L-phenylglycine L-methionine methyl ester 1.600 g (3.520 mmol,   
1 equiv.) in THF (7.2 mL) under N2, was cooled to 0oC and a solution of LiAlH4/THF (3.9 mL; 
1N) added dropwise over 5 min. The reaction mixture was stirred at 0oC for 1 hr and allowed to 
warm to room temperature and stirred for a further 17 hr. The reaction mixture was partitioned 
between EtOAc (40 mL) and KHSO4 (40 mL; 1N), the aqueous phase was washed twice with 
CHCl3 (10 mL). The separate organic phase was washed with saturated brine (40 mL) and dried 
with anhydrous Na2SO4 the solvent was removed in-vacuo. Flash chromatography on silica 
(EtOAc/petroleum ether 7:3 Rf = 0.45,) gave N-(4-fluorobenzenesulfonyl) L-phenylglycine           
L-methioninol 1.034 g (2.424 mmol, 69%) as a white solid. m.p. 163oC; IR ν max (KBr) 1647 
(CONH), 1063 (H2COH); 1H NMR ((CD3)2SO) (300 MHz) δH = 8.72 (1H, d, J = 9.3 Hz, NHCH 
of Pgl), 8.13 (1H, d, J = 8.4 Hz, NHCH of Met), 7.90-7.85 (2H, m, FArH), 7.42-7.32 (7H, m,     
2 x FArH and 5 x ArH of Pgl), 5.10 (1H, d, J = 9.9 Hz, NHCH of Pgl), 4.78-4.74 (1H, m, 
CH2OH of Met), 3.75-3.60 (1H, m, NHCH of Met), 3.32-3.19 (2H, m, CH2OH of Met),       
2.36-2.28 (2H, m, SCH2 of Met), 2.09 (3H, s, SCH3 of Met), 1.90-1.75 (1H, m, CHCH2CH2 of 
Met), 1.60-1.46 (1H, m, CHCH2CH2 of Met); 13C NMR ((CD3)2SO) δC = 168.6, (CONH of Pgl), 
164.0 (d, J = 249.4 Hz, F-C=), 137.9, 137.7, 129.6 (2C, d, J = 9.9 Hz, C=C-S), 128.2 (2C, s, 
C=C-C of Pgl), 127.6 (C=C-C of Pgl), 127.1 (2C, s, C=C-C of Pgl), 115.9 (2C, d, J = 22.5 Hz, 
F-C=C), 62.6 (CH2OH of Met), 59.5 (NHCH of Pgl), 50.2 (NHCH of Met), 30.5 (CH2 of Met), 
29.9 (CH2 of Met), 14.7 (SCH3 of Met); (HRMS) (CH3OH) calcd. for C19H24FN2O4S2 [M + H]+: 
427.1162 found 427.1156. 
 
N-(4-Fluorobenzenesulfonyl) L-phenylglycine L-methioninal [(S)-2-(4-
fluorophenylsulfonamido)-N-((S)-4-(methylthio)-1-oxobutan-2-yl)-2-phenylacetamide] 
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N-(4-Fluorobenzenesulfonyl) L-phenylglycine L-methioninol 843 mg (1.977 mmol, 1 equiv.) was 
dissolved in DMSO (18 mL) and DCM (18 mL) and then DIPEA (1.4 mL) (7.906 mmol,            
4 equiv.) added to the solution. Then in a separate vial containing SO3.Pyr 1.258 g (7.906 mmol, 
4 equiv.) dissolved in DMSO (5 mL), the solution was heated and added slowly to the reaction 
mixture over 3 min. The reaction was left stirring for 2 hr at room temperature. Then the reaction 
mixture was partitioned between EtOAc (20 mL) and HCl (20 mL; 1N), the aqueous phase was 
washed twice more with EtOAc (20 mL). The combined organic phases where washed with 
saturated NaHCO3 (20 mL) and saturated brine (20 mL) and dried with anhydrous Na2SO4.     
The solvent was evaporated to dryness in-vacuo to give a brown crude. Flash chromatography on 
silica (EtOAc/pet ether 2:1, Rf = 0.65) gave N-(4-fluorobenzenesulfonyl) L-phenylglycine           
L-methioninal 354 mg (0.813 mmol, 41%) as white yellow solid. m.p. 47oC; IR ν max (KBr) 
1734 (CHO), 1653 (CONH); 1H NMR ((CD3)2SO) (300 MHz) δH = 9.28 (1H, s, CHO of Met), 
8.85-8.82 (2H, m, NHCH), 7.90-7.80 (2H, m, FArH), 7.49-7.25 (7H, m, FArH and ArH of Pgl), 
5.19 (1H, d, J = 9.3 Hz, NHCH of Pgl), 4.17-4.08 (1H, m, NHCH of Met), 2.36-2.30 (2H, m, 
SCH2 of Met), 2.04 (3H, s, SCH3 of Met), 1.85-1.56 (2H, m, CHCH2CH2 of Met); 13C NMR 
((CD3)2SO) δC = 200.0 (CHO of Met), 169.6 (CONH of Pgl), 164.1 (d, J = 248.9 Hz, F-C=), 
137.5, 137.3, 129.8 (2C, d, J = 9.8 Hz, C=C-S), 129.6, 128.3 (2C, s, C=C-C of Pgl), 127.8 
(C=C-C of Pgl), 127.2 (2C, s, C=C-C of Pgl), 116.0 (2C, d, J = 23.1 Hz, F-C=C), 59.3, 57.4, 
29.2 (CH2 of Met), 27.3 (CH2 of Met), 14.4 (SCH3 of Met); (HRMS) (CH3CN) calcd. for 
C19H22FN2O4S2 [M + H]+: 425.1005 found 425.1007. 
 
L-Cyclohexaglycine methyl ester hydrochloride [(S)-1-cyclohexyl-2-methoxy-2-
oxoethanaminium chloride] 
 
Cl- +H3N
O
OMeH2N
O
OH
2.1.4c 2.1.5c  
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A solution of L-cyclohexaglycine 1.000 g (6.361 mmol, 1 equiv.) in MeOH (15 mL) was cooled 
to -20oC in a NaCl ice bath, SOCl2 (3.7 mL) (50.887 mmol, 8 equiv.) added over 15 min, and the 
mixture was stirred for 1 hr at -20oC and for 18 hr at room temperature. MeOH                  
2 x (50 mL) added and the solvent removed in-vacuo to give L-cyclohexaglycine methyl ester 
hydrochloride 1.321 g (6.361 mmol, 100%) as a white solid. m.p. 181oC; 1H NMR (CD3OD) 
(300 MHz) δH = 3.87 (1H, d, J = 5.1 Hz, CHCO), 3.83 (3H, s, OCH3), 1.90-1.69 (6H, m, CH2’s 
and CH2CHCH2), 1.34-1.10 (5H, m, CH2’s); (HRMS) (CH3OH) calcd. for C9H18NO2 [M + H]+: 
172.1338 found 172.1345. 
 
N-(4-Fluorobenzenesulfonyl) L-cyclohexaglycine methyl ester [(S)-methyl 2-cyclohexyl-2-(4-
fluorophenylsulfonamido)acetate] 
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2.1.5c
2.1.6
2.1.7c  
 
L-Cyclohexaglycine methyl ester hydrochloride 1.163 g (5.599 mmol, 1 equiv.) in DMF (10 mL) 
was and cooled to 0oC in an ice bath and DIPEA (2.1 mL) (12.318 mmol, 2.2 equiv.) added.        
N-(4-fluorobenzenesulfonyl) chloride 1.308 g (6.719 mmol, 1.1 equiv.) added over 15 min and 
the reaction stirred for 20 hr at room temperature. The mixture was partitioned between EtOAc 
(25 mL) and HCl (25 mL; 1N), and the aqueous phase washed twice with EtOAc (25 mL).     
The combined organic phases were washed with saturated NaHCO3 (25 mL) and saturated brine     
(25 mL) and dried with anhydrous Na2SO4 the solvent was removed in-vacuo. The product            
was attained by recrystallisation (EtOAc/petroleum ether 1:3, Rf = 0.37) to give                  
N-(4-fluorobenzenesulfonyl) L-cyclohexaglycine methyl ester 1.289 g (3.913 mmol, 70%) as a 
white solid. m.p. 129oC; IR ν max (KBr) 1732 (COOCH3); 1H NMR (CD3OD) (300 MHz)        
δH = 7.81-7.76 (2H, m, ArH), 7.23-7.17 (2H, m, ArH), 3.59 (1H, d, J = 6.9 Hz, NHCH of Chg), 
3.32 (3H, s, OCH3 of Chg), 1.65-1.40 (6H, m, CH2’s of Chg and CH2CHCH2 of Chg), 1.20-0.91 
(5H, m, CH2’s of Chg); 13C NMR ((CD3)2SO) δC = 171.2 (COOCH3 of Chg), 164.2 (d,                
J = 248.9 Hz, F-C=), 137.4 (d, J = 2.8 Hz, =C-S), 129.7 (2C, d, J = 9.3 Hz, C=C-S), 116.2 (2C, 
d, J = 22.5 Hz, F-C=C), 60.9 (NHCH of Chg), 51.7 OCH3 of Chg), 28.9 (CH2 of Chg), 28.3 
(CH2 of Chg), 25.6 (CH2 of Chg), 25.4 (CH2 of Chg), 25.3 (CH2 of Chg); (HRMS) (CH3OH) 
calcd. for C15H21FNO4S [M + H]+: 330.1175 found 330.1180. 
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N-(4-Fluorobenzenesulfonyl) L-cyclohexaglycine [(S)-2-cyclohexyl-2-(4-
fluorophenylsulfonamido)acetic acid] 
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2.1.7c 2.1.8c  
To N-(4-fluorobenzenesulfonyl) L-cyclohexaglycine methyl ester 1.142 g (3.467 mmol, 1 equiv.) 
in THF (30 mL) was treated with a solution of NaOH (10.0 mL; 0.867 N) 346.7 mg            
(8.668 mmol, 2.5 equiv.) which added over 5 min. The mixture was heated to 65oC in a silica oil 
bath and stirred for 2 days. The mixture was reduced to half its original volume on a rotary 
evaporator and was diluted with distilled water (50 mL). The reaction mixture was partitioned 
between EtOAc (25 mL) and HCl (25 mL; 1N) and the aqueous phase washed twice with EtOAc          
(25 mL). The combined organic phases were washed with saturated brine (25 mL) and dried with 
anhydrous Na2SO4 and the solvent removed in-vacuo to give N-(4-fluorobenzenesulfonyl)                  
L-cyclohexaglycine 1.032 g (3.272 mmol, 94%) as a white solid. m.p. 150oC; 1H NMR (CD3OD) 
(300 MHz) δH = 7.90-7.85 (2H, m, ArH), 7.27-7.21 (2H, m, ArH), 3.63 (1H, d, J = 6.0 Hz, 
NHCH of Chg), 1.71-1.56 (6H, m, CH2’s of Chg and CH2CHCH2 of Chg), 1.28-1.00 (5H, m, 
CH2’s of Chg).  
 
N-(4-Fluorobenzenesulfonyl) L-cyclohexaglycine L-methionine methyl ester [(S)-methyl 2-
(S)-2-cyclohexyl-2-(4-fluorophenylsulfonamido)acetamido)-4-(methylthio)butanoate] 
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To N-(4-fluorobenzenesulfonyl) L-cyclohexaglycine 843 mg (2.673 mmol, 1 equiv.) dissolved in 
DMF (10 mL) kept under N2, L-methionine methyl ester hydrochloride 587 mg (2.940 mmol,     
1.1 equiv.) added and dissolved. DIPEA (1.0 mL) (5.881 mmol, 2.2 equiv.) added and HATU 
1.118 g (2.940 mmol, 1.1 equiv.) added slowly over 15 min and the reaction was stirred for        
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2 days at room temperature. The reaction mixture was partitioned between EtOAc (20 mL) and 
HCl (20 mL; 1N), the aqueous phase was washed twice with EtOAc (20 mL). The combined 
organic phases were washed with saturated NaHCO3 (20 mL) and saturated brine (20 mL) and 
dried with anhydrous Na2SO4 the solvent was removed in-vacuo. Flash chromatography on silica 
(EtOAc/petroleum ether 1:2, Rf = 0.31) gave N-(4-fluorobenzenesulfonyl) L-cyclohexaglycine       
L-methionine methyl ester 665 mg (1.444 mmol, 54%) as a white solid. m.p. 158oC; IR ν max 
(KBr) 1730 (COOCH3), 1646 (CONH); 1H NMR ((CD3)2SO, 298 K) (300 MHz) δH =  8.38 (1H, 
d, J = 7.5 Hz, NHCH), 8.02 (1H, d, J = 9.3 Hz, NHCH), 7.92-7.87 (2H, m, ArH), 7.49-7.43 (2H, 
m, ArH), 4.20-4.12 (1H, m, NHCH of Met), 3.70-3.64 (4H, m, NHCH of Chg and OCH3 of 
Met), 2.42-2.28 (2H, m, SCH2 of Met), 2.11 (3H, s, SCH3 of Met), 1.96-1.58 (8H, m, 
CHCH2CH2 of Met, CH2’s of Chg and CH2CHCH2 of Chg), 1.30-0.91 (5H, m, CH2’s of Chg); 
13C NMR ((CD3)2SO) δC = 171.9 (COOCH3 of Met), 170.2 (CONH of Chg), 164.1 (d,                
J = 248.9 Hz, F-C=), 137.8 (d, J = 2.8 Hz, =C-S), 129.5 (2C, d, J = 9.3 Hz, C=C-S), 115.9 (2C, 
d, J = 22.0 Hz, F-C=C), 60.5 (NHCH of Chg), 51.9, 50.8, 30.4, 29.4, 28.8, 28.3, 25.9, 25.5, 14.5 
(SCH3 of Met); (HRMS) (CH3OH) calcd. for C20H30FN2O5S2 [M + H]+: 461.1580                
found 461.1600. 
 
N-(4-Fluorobenzenesulfonyl) L-cyclohexaglycine L-methioninol [(S)-2-cyclohexyl-2-(4-
fluorophenylsulfonamido)-N-((S)-1-hydroxy-4-(methylthio)butan-2-yl)acetamide] 
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N-(4-Fluorobenzenesulfonyl) L-cyclohexaglycine methyl ester 602 mg (1.307 mmol, 1 equiv.) in 
THF (7.2 mL) under N2, was cooled to 0oC and LiAlH4/THF (1.4 mL; 1N) added dropwise over  
5 min. The mixture was stirred at 0oC for 1 hr and was allowed to come to room temperature and 
stirred for a further 17 hr. The mixture was partitioned between EtOAc (20 mL) and            
KHSO4 (20 mL; 1N) and the aqueous phase washed twice with CHCl3 (5 mL). The organic 
phases were washed with saturated brine (20 mL) and dried with anhydrous Na2SO4 the solvent 
was removed in-vacuo. Flash chromatography on silica (EtOAc/petroleum ether 7:3, Rf = 0.35) 
gave N-(4-fluorobenzenesulfonyl) L-cyclohexaglycine L-methioninol 373 mg (0.862 mmol, 66%) 
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as a white solid. m.p. 188oC; IR ν max (KBr) 3528 (H2COH), 1640 (CONH), 1061 (H2COH);         
1H NMR ((CD3)2SO) (300 MHz) δH = 7.95-7.89 (3H, m, ArH and NHCH), 7.75 (1H, d,              
J = 8.4 Hz, NHCH), 7.48-7.42 (2H, m, ArH), 4.74 (1H, t, J = 5.3 Hz, CH2OH of Met), 3.70-3.56 
(2H, m, NHCH of Met and NHCH of Chg), 3.38-3.33 (1H, m, CH2OH of Met), 3.23-3.16 (1H, 
m, CH2OH of Met), 2.30-2.08 (5H, m, SCH2 of Met and SCH3 of Met), 1.75-1.37 (8H, m, 
CHCH2CH2 of Met, CH2’s of Chg and CH2CHCH2 of Chg), 1.33-0.85 (5H, m, CH2’s of Chg); 
13C NMR ((CD3)2SO) δC = 169.6 (CONH of Chg) 164.0 (d, J = 248.3 Hz, F-C=), 137.9 (=C-S), 
129.5 (2C, d, J = 9.4 Hz, C=C-S), 116.0 (2C, d, J = 22.0 Hz, F-C=C), 62.8, 61.0, 50.0 (NHCH 
of Met), 30.4, 29.8, 29.0, 28.3, 25.9, 25.5, 14.6 (SCH3 of Met); (HRMS) (CH3OH) calcd. for 
C19H30FN2O4S2 [M + H]+: 433.1631 found 433.1622. 
 
N-(4-Fluorobenzenesulfonyl) L-cyclohexaglycine L-methioninal [(S)-2-cyclohexyl-2-(4-
fluorophenylsulfonamido)-N-((S)-4-(methylthio)-1-oxobutan-2-yl)acetamide] 
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To N-(4-fluorobenzenesulfonyl) L-cyclohexaglycine L-methioninol 321 mg (0.742 mmol,           
1 equiv.) in DMSO (3 mL) and DCM (5 mL), DIPEA (0.5 mL) (2.968 mmol, 4 equiv.) added.           
A separate vial containing SO3.Pyr 472 mg (2.968 mmol, 4 equiv.) in DMSO (2 mL) was heated 
and added over 3 min. The reaction was left stirring for 2 hr at room temperature. The mixture 
was partitioned between EtOAc (10 mL) and HCl (10 mL; 1N), and the aqueous phase was 
washed twice with EtOAc (10 mL). The combined organic phases were washed with saturated       
NaHCO3 (10 mL) and saturated brine (10 mL) and dried with anhydrous Na2SO4. The solvent 
was removed in-vacuo to give N-(4-fluorobenzenesulfonyl) L-cyclohexaglycine L-methioninal       
303 mg (0.704 mmol, 95%) as light yellow solid. m.p. 168oC; IR ν max (KBr) 1735 (CHO), 
1643 (CONH); 1H NMR ((CD3)2SO) (300 MHz) δH = 9.24 (1H, s, CHO of Met), 8.51 (1H, d,     
J = 6.6 Hz, NHCH), 8.09 (1H, d, J = 9.3 Hz, NHCH), 7.94-7.89 (2H, m, ArH), 7.50-7.44 (2H, 
m, ArH), 4.09-4.02 (1H, m, NHCH of Met), 3.71-3.66 (1H, t, J = 8.0 Hz, NHCH of Chg),   
2.43-2.31 (2H, m, SCH2 of Met), 2.09-1.96 (4H, SCH3 of Met and CHCH2CH2 of Met),       
1.80-1.55 (7H, m, CHCH2CH2 of Met, CH2’s of Chg and CH2CHCH2 of Chg), 1.33-0.90 (5H, 
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m, CH2’s of Chg); 13C NMR ((CD3)2SO) δC = 200.1 (CHO of Met), 170.7 (CONH of Chg), 
164.2 (d, J = 249.4 Hz, F-C=), 137.8 (=C-S), 129.7 (2C, d, J = 8.8 Hz, C=C-S), 116.0 (2C, d,               
J = 22.5 Hz, F-C=C), 60.7 (NHCH of Chg), 57.5 (NHCH of Met), 29.4, 29.0, 28.4, 27.5, 25.9, 
25.5, 20.9, 14.5 (SCH3 of Met); (HRMS) (CH3CN) calcd. for C19H28FN2O4S2 [M + H]+: 
431.1475 found 431.1496.  
 
Iso L-leucine methyl ester hydrochloride [(2S,3S)-1-methoxy-3-methyl-1-oxopentan-2-
aminium chloride] 
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2.1.4d 2.1.5d  
 
A solution of boc iso L-leucine hemi hydrate 4.000 g (16.646 mmol, 1 equiv.) in MeOH            
(39 mL) was cooled to 0oC in an ice bath and SOCl2 (9.7 mL) (133.167 mmol, 8 equiv.) added 
dropwise over 20 min. The mixture was stirred for 1 hr at 0oC and then for 2 days at room 
temperature. MeOH (400 mL) added and the solvent removed evaporated down to dryness          
in-vacuo to give iso L-leucine methyl ester hydrochloride 3.024 g (16.646 mmol, 100%) as a 
light yellow brown solid. lit. m.p. 98-100oC122 m.p. 95-96oC; 1H NMR (CD3OD) (300 MHz)          
δH = 8.45 (3H, b s, NH3+), 3.98 (1H, d, J = 3.6 Hz, NHCH), 3.79 (3H, s, OCH3), 1.98-1.93 (1H, 
m, CHCH3), 1.54-1.45 (1H, m, CHCH2CH3), 1.37-1.27 (1H, m, CHCH2CH3), 0.97 (3H, d,         
J = 4.2 Hz CHCH3), 0.94 (3H, m, CH2CH3); (HRMS) (CH3OH) calcd. for C7H16NO2 [M + H]+: 
146.1181, found 146.1181. 
 
N-(4-Fluorobenzenesulfonyl) iso L-leucine methyl ester [(2S,3S)-methyl 2-(4-
fluorophenylsulfonamido)-3-methylpentanoate]  
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2.1.5d 2.1.7d
2.1.6
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Iso L-leucine methyl ester 2.500 g (13.686 mmol, 1 equiv.) was dissolved in DMF (15 mL) and 
DIPEA (5.2 mL) (30.109 mmol, 2.2 equiv.). The solution was cooled to 0°C in an ice bath and 
was subsequently treated with the slow addition (over 10 min) of N-(4-fluorobenzenesulfonyl) 
chloride 3.196 g (16.423 mmol, 1.2 equiv.), the reaction mixture was left stirring for 1 day at 
room temperature. The reaction mixture was partitioned between EtOAc (50 mL) and HCl      
(50 mL; 1N), the aqueous phase was washed twice with EtOAc (50 mL). The combined organic 
phases were washed with saturated NaHCO3 (50 mL) and saturated brine (50 mL) and dried with 
anhydrous Na2SO4 the solvent was removed in-vacuo. Flash chromatography on silica 
(EtOAc/petroleum ether 1:3, Rf = 0.46) gave N-(4-fluorobenzenesulfonyl) iso L-leucine methyl 
ester 3.243 g (10.691 mmol, 78%) as a white solid. m.p. 83oC; 1H NMR ((CD3)2SO) (300 MHz) 
δH = 8.45 (1H, d, J = 9.6 Hz, NHCH of Ile), 7.92-7.88 (2H, m, ArH), 7.54-7.48 (2H, m, ArH), 
3.69 (1H, app t, J = 7.2 Hz, NHCH of Ile), 3.45 (3H, s, OCH3 of Ile), 1.81-1.72 (1H,  m, CHCH3 
of Ile), 1.52-1.42 (1H, m, CH2CH3 of Ile), 1.26-1.16 (1H, m, CH2CH3 of Ile), 0.87 (3H, d,           
J = 4.2 Hz, CHCH3 of Ile), 0.84 (3H, t, J = 3.6 Hz, CH2CH3 of Ile); (HRMS) (CH3OH) calcd. for 
C13H19FNO4S [M + H]+: 304.1019, found 304.1018. 
 
N-(4-Fluorobenzenesulfonyl) L-iso-leucine [(2S,3S)-2-(4-fluorophenylsulfonamido)-3-
methylpentanoic acid] 
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2.1.7d 2.1.8d  
 
To N-(4-fluorobenzenesulfonyl) iso L-leucine methyl ester 2.955 g (9.741 mmol, 1 equiv.) in 
THF (30 mL), NaOH (10 mL; 2.435 N) added over 5 min. The reaction mixture was heated to 
65oC and stirred for 1 day. The mixture was concentrated to half its original volume using a 
rotary evaporator. Distilled water (50 mL) added and the mixture partitioned between EtOAc      
(50 mL) and HCl (50 mL; 1N). The aqueous phase was washed twice with EtOAc (50 mL).          
The combined organic phases were washed with saturated brine (50 mL) and dried with 
anhydrous Na2SO4 the solvent was removed in-vacuo to give N-(4-fluorophenylsulfonyl)         
iso L-leucine 2.550 g (8.813 mmol, 90%) as a white solid. m.p. 114oC; 1H NMR ((CD3)2SO) 
(300 MHz) δH = 12.65 (1H, b s, COOH of Ile), 8.20 (1H, d, J = 9.6 Hz, NHCH of Ile), 7.94-7.89 
(2H, m, ArH), 7.51-7.45 (2H, m, ArH), 3.64 (1H, app t, J = 6.3 Hz, NHCH of Ile), 1.80-1.71 
(1H, m, CHCH3 of Ile), 1.48-1.40 (1H, m, CH2CH3 of Ile), 1.26-1.14 (1H, m, CH2CH3 of Ile), 
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0.90-0.83 (6H, m, 2 x CH3 of Ile); (HRMS) (CH3OH) calcd. for C13H17FNO4S [M + H]+: 
290.0862, found 290.0873. 
 
N-(4-Fluorobenzenesulfonyl) iso L-leucine L-methionine methyl ester [(S)-methyl 2-
((2S,3S)-2-(4-fluorophenylsulfonamido)-3-methylpentanamido)-4-(methylthio)butanoate] 
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To N-(4-fluorobenzenesulfonyl) iso L-leucine 2.305 g (7.966 mmol, 1 equiv.) dissolved in DMF 
(15 mL) kept under N2, L-methionine methyl ester hydrochloride 1.750 g (8.763 mmol,            
1.1 equiv.) added DIPEA (3.1 mL) (17.525 mmol, 2.2 equiv.) and HATU 3.332 g (8.763 mmol, 
1.1 equiv.) added slowly over 15 min. The reaction was stirred for 2 days at room temperature 
and the mixture partitioned between EtOAc (50 mL) and HCl (50 mL; 1N). The aqueous phase 
was washed twice with EtOAc (50 mL). The combined organic phases were washed with 
saturated NaHCO3 (50 mL) and saturated brine (50 mL) and dried with anhydrous Na2SO4 the 
solvent was removed in-vacuo. Flash chromatography on silica (EtOAc/petroleum ether 1:2,     
Rf = 0.23) gave N-(4-fluorobenzenesulfonyl) iso L-leucine L-methionine methyl ester 1.553 g 
(3.574 mmol, 45%) as a white solid. m.p. 146oC; IR ν max (KBr) 1734 (COOCH3), 1649 
(CONH); 1H NMR ((CD3)2SO) (300 MHz) δH = 8.42 (1H, d, J = 7.2 Hz, NHCH of Met) 8.07     
( 1H, d, J = 9.3 Hz, NHCH of Ile), 7.92-7.87 (2H, m, ArH), 7.49-7.43 (2H, m, ArH), 4.13-4.11 
(1H, m, NHCH of Met), 3.70-3.64 (4H, m, NHCH of Ile and OCH3 of Met), 2.39-2.33 (2H, m, 
SCH2 of Met), 2.11-1.68 (4H, m, CHCH3 of Ile, 0.5 x CH2CH3 of Ile and CHCH2CH2 of Met), 
1.20-1.10 (1H, m, CH2CH3 of Ile), 0.90 (3H, d, J = 6.6 Hz, CHCH3 of Ile), 0.85 (3H, t,               
J = 7.5 Hz, CH2CH3 of Ile); 13C NMR ((CD3)2SO) δC = 171.9 (COOCH3 of Met), 170.4 (CONH 
of Ile), 164.1 (d, J = 248.9 Hz, F-C=), 137.8 (d, J = 3.3 Hz, =C-S), 129.6 (2C, d, J = 9.4 Hz, 
C=C-S), 115.9 (2C, d, J = 22.6 Hz, F-C=C), 60.0 (NHCH of Ile), 51.9, 50.9, 37.1, 30.5 (CH2 of 
Met), 29.4 (CH2 of Met), 24.2, 15.0, 14.6, 10.6 (CH2CH3 of Ile); (HRMS) (CH3OH) calcd. for 
C18H28FN2O5S2 [M + H]+: 435.1424, found 435.1438.  
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N-(4-Fluorobenzenesulfonyl) iso L-leucine L-methioninol [(2S, 3S)-2-(4-
fluorophenylsulfonamido)-N-(S)-1-hydroxy-4-(methylthio)butan-2-yl)-3-
methylpentanamide] 
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N-(4-Fluorobenzenesulfonyl) iso L-leucine L-methionine methyl ester 1.330 g (3.061 mmol,         
1 equiv.) in THF (7.2 mL) under N2 was cooled to 0oC in an ice bath. LiAlH4/THF (3.4 mL; 1N) 
added dropwise over 5 min. The reaction mixture was stirred at 0oC for 1 hr and warmed to room 
temperature and stirred for a further 17 hr. The mixture was partitioned between EtOAc (25 mL) 
and KHSO4 (25 mL; 1N), the aqueous phase was washed twice with CHCl3 (10 mL).              
The separate organic phases were washed with saturated brine (25 mL) and dried with anhydrous 
Na2SO4 the solvent was removed in-vacuo. Flash chromatography on silica (EtOAc/petroleum 
ether 3:2, Rf = 0.25) gave N-(4-fluorobenzenesulfonyl) iso L-leucine L-methioninol 711 mg 
(1.749 mmol, 57%) as a white solid. m.p. 168oC; IR ν max (KBr) 1639 (CONH), 1059 
(H2COH); 1H NMR ((CD3)2SO) (300 MHz) δH = 8.00-7.89 (3H, m, NHCH and 2 x ArH), 7.76 
(1H, d, J = 8.4 Hz, NHCH), 7.49-7.43 (2H, m, ArH), 4.74 (1H, t, J = 5.4 Hz, CH2OH of Met), 
3.63-3.58 (2H, m, NHCH of Met and NHCH of Ile), 3.40-3.32 (1H, m, CH2OH of Met),      
3.23-3.18 (1H, m, CH2OH of Met), 2.29-2.21 (1H, m, SCH2 of Met), 2.09 (3H, s, SCH3 of Met), 
1.75-1.40 (4H, m, CHCH3 of Ile, 0.5 x CH2CH3 of Ile and CHCH2CH2 of Met), 1.14-1.10 (1H, 
m, CH2CH3 of Ile), 0.87 (3H, d, J = 3.0 Hz, CHCH3 of Ile), 0.86-0.82 (3H, m, CH2CH3 of Ile); 
13C NMR ((CD3)2SO) δC = 169.9 (CONH of Ile), 164.1 (d, J = 248.3 Hz, F-C=), 137.9 (=C-S), 
129.6 (2C, d, J = 9.3 Hz, C=C-S), 116.0 (2C, d, J = 22.6 Hz, F-C=C), 62.8 (CH2OH of Met), 
60.6 (NHCH of Val), 50.1 (NHCH of Met), 37.2, 30.5 (CH2 of Met), 29.9 (CH2 of Met), 24.3, 
15.3, 14.7, 10.8 (CH2CH3 of Ile); (HRMS) (CH3OH) calcd. for C17H28FN2O4S2 [M + H]+: 
407.1475, found 407.1484.  
 
N-(4-Fluorobenzenesulfonyl) iso L-leucine L-methioninal [(2S,3S)-2-(4-
fluorophenylsulfonamido)-3-methyl-N-((S)-4-(methylthio)-1-oxobutan-2-yl)pentanamide] 
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N-(4-Fluorobenzenesulfonyl) iso L-leucine- L-methioninol 593 mg (1.459 mmol, 1 equiv.) was 
dissolved in DMSO (7 mL) and DCM (9 mL) and DIPEA (1.0 mL) (5.835 mmol, 4 equiv.) 
added. A separate vial containing SO3.Pyr 929 mg (5.835 mmol, 4 equiv.) dissolved in DMSO  
(4 mL), was heated and added slowly to the reaction mixture over 3 min. The reaction was left 
stirring for 2 hr at room temperature and partitioned between EtOAc (20 mL) and HCl (20 mL; 
1N). The aqueous phase was washed twice with EtOAc (20 mL) and the combined organic 
phases were washed with saturated NaHCO3 (20 mL) and saturated brine (20 mL) and dried with 
anhydrous Na2SO4. The solvent was removed in-vacuo, to give N-(4-fluorobenzenesulfonyl)    
iso L-leucine L-methioninal 564 mg (1.394 mmol, 96%) as off white solid. m.p. 151oC; IR ν max 
(KBr) 1730 (CHO), 1643 (CONH); 1H NMR ((CD3)2SO) (300 MHz) δH = 9.24 (3H, s, CHO of 
Met), 8.53 (1H, d, J = 6.6 Hz, NHCH of Met), 8.14 (2H, d, J = 9.3 Hz, NHCH of Ile), 7.95-7.90 
(2H, m, ArH), 7.51-7.45 (2H, m, ArH), 4.03-3.98 (1H, m, NHCH of Met), 3.70 (1H, t,                
J = 8.6 Hz, NHCH of Ile), 2.48-2.33 (2H, m, SCH2 of Met), 2.10 (3H, s, SCH3 of Met),        
2.02-1.94 (1H, m, CHCH2CH2 of Met), 1.76-1.66 (2H, m, CHCH3 of Ile and CHCH2CH2 of 
Met), 1.60-1.51 (1H, m, CH2CH3 of Ile), 1.22-1.12 (1H, m, CH2CH3 of Ile), 0.92 (3H, d,             
J = 6.9 Hz, CHCH3 of Ile), 0.87 (3H, d, J = 7.4 Hz, CH2CH3 of Ile); 13C NMR ((CD3)2SO)       
δC = 200.1 (CHO of Met), 170.8 (CONH), 164.1 (d, J = 249.4 Hz, F-C=), 137.7 (d, J = 3.3 Hz, 
=C-S), 129.7 (2C, d, J = 9.3 Hz, C=C-S), 116.0 (2C, d, J = 22.6 Hz, F-C=C), 60.1 (NHCH of 
Val), 57.5 (NHCH of Met), 37.0, 29.4 (CH2 of Met), 27.4 (CH2 of Met), 24.3, 15.3, 14.5, 10.6 
(CH2CH3 of Ile); (HRMS) (CH3CN) calcd. for C17H26FN2O4S2 [M + H]+: 405.1318,            
found 405.1334.  
 
N-(4-Fluorobenzenesulfonyl) L-valine [(S)-2-(4-fluorophenylsulfonamido)-3-
methylbutanoic acid] 
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Five batches of this compound were synthesised. L-valine 1.17 g (10 mmol, 1 equiv.) dissolved 
in distilled water (10 mL) and was cooled to 0oC in an ice bath. Anhydrous Na2CO3 2.32 g         
(22 mmol, 2.2 equiv.) added and the mixture stirred for 20 minutes. N-(4-fluorobenzenesulfonyl) 
chloride 2.30 g (12 mmol, 1.2 equiv.) added to this mixture in three portions over one hour and 
the mixture allowed to return to room temperature and stirred for 2 days. Then the mixture was 
acidified with HCl (2.5 mL; 9N) to a pH 1.5. This initially gave a clear solution then a white 
precipitate formed within 5 min. This precipitate was filtered using a sintered glass                
filter and washed with HCl (3 mL; 1N). The product was dried in-vacuo to give                  
N-(4-fluorobenzenesulfonyl) L-valine 2.17 g (7.9 mmol, 79%) a white solid. lit. m.p. 116-
118oC123 m.p. 131oC. 1H NMR ((CD3)2SO) (500 MHz) δH = 8.17 (1H, d, J = 9.5 Hz, NHCH of 
Val), 7.95-7.92 (2H, m, ArH), 7.49-7.45 (2H, m, ArH), 3.63 (1H, dd, J = 8.5 Hz and 6.3 Hz, 
NHCH of Val), 2.06-2.02 (1H, m, CH(CH3)2 of Val), 0.92 (3H, d, J = 6.5, CH3 of Val), 0.88 
(3H, d, J = 6.5 Hz CH3 of Val); (HRMS) (CH3OH) calcd. for C11H14FNO4SNa [M + Na]+: 
298.0525, found 298.0536. 
  
N-(4-Fluorobenzenesulfonyl) L-valine L-phenylalanine ethyl ester [(S)-ethyl 2-((S)-2-(4-
fluorophenylsulfonamido)-3-methylbutanamido)-3-phenylpropanoate] 
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To N-(4-fluorobenzenesulfonyl) L-valine 1.634 g (5.936 mmol, 1 equiv.) in DMF (10 mL) kept 
under N2, L-phenylalanine ethyl ester hydrochloride 1.500 g (6.530 mmol, 1.1 equiv.) added. 
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Then DIPEA (2.3 mL) (13.059 mmol, 2.2 equiv.) and HATU 2.483 g (6.530 mmol, 1.1 equiv.) 
added over 15 min and the reaction was stirred for 2 days at room temperature. The mixture was 
partitioned between EtOAc (25 mL) and HCl (25 mL; 1N), and the aqueous phase washed twice 
with EtOAc (25 mL). The combined organic phases were washed with saturated NaHCO3        
(25 mL) and saturated brine (25 mL) and dried with anhydrous Na2SO4 the solvent was removed              
in-vacuo. Flash chromatography on silica (EtOAc/petroleum ether 9:11, Rf = 0.44) gave                  
N-(4-fluorobenzenesulfonyl) L-valine L-phenylalanine ethyl ester 1.776 g (3.942 mmol, 66%) as 
a white yellow solid. m.p. 132oC; IR ν max (KBr) 1724 (COOCH2CH3), 1649 (CONH);           
1H NMR ((CD3)2SO) (300 MHz) δH = 8.46 (1H, d, J = 6.6 Hz, NHCH of Phe), 7.98 (1H, d,        
J = 9.6 Hz, NHCH of Val), 7.84-7.80 (2H, m, FArH), 7.42-7.32 (5H, m, 2 x FArH and 3 x ArH 
of Phe), 7.25-7.23 (2H, m, ArH of Phe), 4.16-3.99 (2H, m, NHCH of Phe and OCH2CH3 of 
Phe), 3.68 (1H, app t, J = 7.2 Hz, NHCH of Val), 2.95-2.80 (2H, m, CHCH2ArH of Phe),     
1.95-1.88 (1H, m, CH(CH3)2 of Val), 1.10 (3H, t, J = 6.9 Hz, OCH2CH3 of Phe), 0.91-0.87 (6H, 
m, CH(CH3)2 of Val); 13C NMR ((CD3)2SO) (75 MHz) δC = 171.2 (COOCH2 of Phe), 170.2 
(CONH of Val), 164.1 (d, J = 248.3 Hz, F-C=), 137.7, 136.9, 129.7 (2C, d, J = 9.3 Hz, C=C-S), 
129.1 (2C, s, C=C-C of Phe), 128.4 (2C, s, C=C-C of Phe), 126.8 (C=C-C of Phe), 115.9 (2C, d, 
J = 22.5 Hz, F-C=C), 61.4, 60.5, 54.0 (NHCH of Phe), 37.0 (CHCH2ArH of Phe), 31.1 
(CH(CH3)2 of Val), 19.1 (CH3 of Val), 18.3 (CH3 of Val), 13.9 (OCH2CH3 of Phe); (HRMS) 
(CH3OH) calcd. for C22H28FN2O5S [M + H]+: 451.1703 found 451.1712. 
 
N-(4-Fluorobenzenesulfonyl) L-valine L-phenylalaninol [(S)-2-(4-
fluorophenylsulfonamido)-N-((S)-1-hydroxy-3-phenylpropan-2-yl)-3-methylbutanamide] 
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N-(4-Fluorobenzenesulfonyl) L-valine L-phenylalanine ethyl ester 1.533 g (3.403 mmol,              
1 equiv.) in THF (7.2 mL) under N2, was cooled to 0oC in an ice bath. LiAlH4/THF (3.7 mL; 1N) 
added dropwise over 5 min. The mixture was stirred at 0oC for 1 hr and returned to room 
temperature and stirred for a further 17 hr. The mixture was partitioned between EtOAc (25 mL) 
and KHSO4 (25 mL; 1N) and the aqueous phase washed twice with CHCl3 (10 mL). The organic 
phases were washed with saturated brine (25 mL) and dried with anhydrous Na2SO4 the solvent 
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was removed in-vacuo. Flash chromatography on silica (EtOAc/petroleum ether 3:2, Rf = 0.49) 
gave N-(4-fluorobenzenesulfonyl) L-valine L-phenylalaninol 896 mg (2.193 mmol, 64%) as a 
white solid. m.p. 185-187oC (decomp.); IR ν max (KBr) 3591 (H2COH), 1641 (CONH), 1036 
(H2COH); 1H NMR ((CD3)2SO) (300 MHz) δH = 7.90-7.80 (4H, 2 x FArH and                  
2 x NHCH), 7.40-7.22 (7H, m, 2 x FArH and 5 x ArH of Phe), 4.78 (1H, t, J = 5.3 Hz, CH2OH 
of Phe), 3.80-3.70 (1H, m, NHCH of Phe), 3.60 (1H, t, J = 8.1 Hz, NHCH of Val), 3.30-3.20 
(2H, m, CH2OH of Phe), 2.78-2.72 (1H, m, CHCH2ArH of Phe), 2.51-2.44 (1H, m, CHCH2ArH 
of Phe), 1.92-1.85 (1H, m, CH(CH3)2 of Val), 0.86-0.84 (6H, m, CH(CH3)2 of Val); 13C NMR 
((CD3)2SO) δC = 169.6 (CONH of Val), 164.1 (d, J = 248.3 Hz, F-C=), 139.0 (CH2-C= of Phe), 
137.7 (=C-S), 129.7 (2C, d, J = 9.3 Hz, C=C-S), 129.2 (2C, s, C=C-C of Phe), 128.3 (2C, s, 
C=C-C of Phe), 126.1 (C=C-C of Phe), 115.9 (2C, d, J = 22.5 Hz, F-C=C), 62.0, 61.7, 52.6 
(NHCH of Phe), 36.4 (CHCH2ArH of Phe), 31.1 (CH(CH3)2 of Val), 19.2 (CH3 of Val), 18.1 
(CH3 of Val); (HRMS) (CH3OH) calcd. for C20H26FN2O4S [M + H]+: 409.1597 found 409.1586. 
 
N-(4-Fluorobenzenesulfonyl) L-valine L-phenylalaninal [(S)-2-(4-
fluorophenylsulfonamido)-3-methyl-N-((S)-1-oxo-3-phenylpropan-2-yl)butanamide] 
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N-(4-Fluorobenzenesulfonyl) L-valine L-phenylalaninol 748 mg (1.831 mmol, 1 equiv.) was 
dissolved in DMSO (8 mL) and DCM (11 mL) and DIPEA (1.3 mL) (7.325 mmol, 4 equiv.) 
added. A separate vial containing SO3.Pyr 1.166 g (7.325 mmol, 4 equiv.) in DMSO (5 mL) was 
heated and added over 3 min. The mixture was stirred for 2 hr at room temperature. The mixture 
was partitioned between EtOAc (20 mL) and HCl (20 mL; 1N), and the aqueous phase washed 
twice with EtOAc (20 mL). The combined organic phases were washed with saturated NaHCO3 
(20 mL) and saturated brine (20 mL) and dried with anhydrous Na2SO4. The solvent was 
removed in-vacuo to give N-(4-fluorobenzenesulfonyl) L-valine L-phenylalaninal 673 mg   
(1.656 mmol, 90%) as white yellow solid. lit. m.p. 109.9-111.1oC107 m.p. 144oC (decomp.);           
IR ν max (KBr) 1730 (CHO), 1638 (CONH); 1H NMR ((CD3)2SO) (300 MHz) δH = 9.18 (1H, s, 
CHO of Phe), 8.54 (1H, d, J = 6.3 Hz, NHCH of Phe), 8.02 (1H, d, J = 8.7 Hz, NHCH of Val), 
7.89-7.84 (2H, m, FArH), 7.69-7.25 (7H, m, 2 x FArH and 5 x ArH of Phe), 4.14-4.11 (1H, m, 
NHCH of Phe), 3.69 (1H, t, J = 7.7 Hz, NHCH of Val), 3.15-3.09 (1H, m, CHCH2ArH of Phe), 
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2.77 (1H, m, CHCH2ArH of Phe), 1.93-1.86 (1H m, CH(CH3)2 of Val), 0.88 (3H, d, J = 3.6 Hz, 
CH3 of Val), 0.86 (3H, d, J = 3.6 Hz, CH3 of Val); 13C NMR ((CD3)2SO) δC = 199.7 (CHO of 
Phe), 170.7 (CONH of Val), 164.1 (d, J = 248.9 Hz, F-C=), 137.6 (d, J = 2.8 Hz, =C-S), 137.6 
(CH2-C= of Phe), 129.7 (2C, d, J = 9.3 Hz, C=C-S), 129.2 (2C, s, C=C-C of Phe), 128.4 (2C, s, 
C=C-C of Phe), 128.3, 126.5, 115.9 (2C, d, J = 22.5 Hz, F-C=C), 61.3, 59.9, 33.4 (CHCH2ArH 
of Phe), 31.0 (CH(CH3)2 of Val), 19.2 (CH3 of Val), 17.9 (CH3 of Val); (HRMS) (CH3CN) 
calcd. for C20H24FN2O4S [M + H]+: 407.1441 found 407.1439.  
 
N-(4-Fluorobenzenesulfonyl) tert L-leucine [(S)-2-(4-fluorophenylsulfonamido)-3,3-
dimethylbutanoic acid] 
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Tert L-leucine 1.75 g (13.341 mmol, 1 equiv.) was dissolved in (20 mL) of distilled water and 
was cooled to 0oC in an ice bath. Anhydrous Na2CO3 3.099 g (29.350 mmol, 2.2 equiv.) was 
added to the solution and the mixture stirred until the carbonate was dissolved.                  
N-(4-fluorobenzenesulfonyl) chloride 3.116 g (16.010 mmol, 1.2 equiv.) added in three portions 
over one hour and the mixture allowed to return to room temperature and stirred for 3 days.    
The mixture was acidified with HCl (4 mL; 9 N) to a pH 1.5 to give a clear solution which in 10 
min to give a white precipitate. The precipitate was filtered with a sintered glass filter to give                  
N-(4-fluorobenzenesulfonyl) tert L-leucine 2.985 g (10.317 mmol, 77%) a white solid.           
m.p. 205oC; IR ν max (KBr) 1701 (COOH); 1H NMR (CD3OD) (300 MHz) δH = 7.91-7.86 (2H, 
m, ArH), 7.27-7.21 (2H, m, ArH), 3.51 (1H, s, NHCH of Tle), 0.97 (9H, s, C(CH3)2 of Tle);   
13C NMR (CD3OD) δC = 173.7 (COOH of Tle), 166.7 (d, J = 250.7 Hz, F-C=), 138.5 (d,             
J = 3.1 Hz, =C-S), 131.6, (2C, d, J = 9.3 Hz, C=C-S), 117.2 (2C, d, J = 22.7 Hz, F-C=C), 66.2 
(NHCH of Tle), 35.3, (C(CH3)3 of Tle), 27.3 (3C, s, C(CH3)3 of Tle); (HRMS) (CH3OH) calcd. 
for C12H17FNO4S [M + H]+: 290.0862, found 290.0852. 
 
N-(4-Fluorobenzenesulfonyl) tert L-leucine L-methionine methyl ester [(S)-methyl 2-((S)-2-
(4-fluorophenylsulfonamido)-3,3-dimethylbutanamido)-4-(methylthio)butanoate] 
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To N-(4-fluorobenzenesulfonyl) tert L-leucine 2.305 g (7.966 mmol, 1 equiv.) dissolved in DMF 
(15 mL) kept under N2, L-methionine methyl ester hydrochloride 1.750 g (8.763 mmol,            
1.1 equiv.) added. DIPEA (3.1 mL) (17.525 mmol, 2.2 equiv.) added and HATU 3.332 g    
(8.763 mmol, 1.1 equiv.) was slowly added over 15 min. The reaction mixture was stirred for     
two days at room temperature and partitioned between EtOAc (50 mL) and HCl (50 mL; 1N).       
The aqueous phase was washed twice with EtOAc (50 mL) and the combined organic phases 
were washed with saturated NaHCO3 (50 mL) and saturated brine (50 mL, dried with anhydrous 
Na2SO4 and the solvent removed in-vacuo. Flash chromatography on silica (EtOAc/petroleum 
ether 1:2, Rf = 0.28) gave N-(4-fluorobenzenesulfonyl) tert L-leucine L-methionine methyl ester 
2.724 g (6.269 mmol, 79%) as a white solid. m.p. 98oC; IR ν max (KBr) 1742 (COOCH3), 1665 
(CONH); 1H NMR (CD3OD) (300 MHz) δH = 8.22 (1H, d, J = 6.3 Hz, NHCH), 7.91-7.86 (2H, 
m, ArH), 7.28-7.22 (2H, m, ArH), 4.19-4.17 (1H, m, NHCH of Met), 3.66 (3H, s, OCH3 of 
Met), 3.56 (1H, s, NHCH of Tle), 2.29-2.06 (2H, m, SCH2 of Met), 2.05 (3H, s, SCH3 of Met), 
1.87-1.82 (1H, m, CHCH2CH2 of Met), 1.72-1.68 (1H, m, CHCH2CH2 of Met), 0.98 (9H, s, 
C(CH3)3 of Tle); 13C NMR ((CD3)2SO) δC = 171.8 (COOCH3 of Met), 169.3 (CONH of Tle), 
164.1 (d, J = 249.5 Hz, F-C=), 137.8 (d, J = 3.3 Hz, =C-S), 129.7 (2C, d, J = 9.3 Hz, C=C-S), 
115.9 (2C, d, J = 22.6 Hz, F-C=C), 63.5 (NHCH of Tle), 51.9, 51.0, 34.4 (C(CH3)3 of Tle), 30.4 
(CH2 of Met), 29.4 (CH2 of Met), 26.5 (3C, s, C(CH3)3 of Tle) 14.6 (SCH3 of Met); (HRMS) 
(CH3OH) calcd. for C18H28FN2O5S2 [M + H]+: 435.1424, found 435.1416. 
 
N-(4-Fluorobenzenesulfonyl) tert L-leucine L-methioninol [(S)-2-(4-
fluorophenylsulfonamido)-N-((S)-1-hydroxy-4-(methylthio)butan-2-yl)-3,3-
dimethylbutanamide] 
 
 107
 
N
H
S
O
H
N
F
O O
OH
S
N
H
S
O
H
N
F
O O
OMe
S
O
2.1.10f 2.1.11f  
 
N-(4-Fluorobenzenesulfonyl) tert L-leucine L-methionine methyl ester 2.400 g (5.523 mmol,        
1 equiv.) dissolved in THF (7.2 mL) under N2 was cooled to 0oC. LiAlH4/THF (6.1 mL; 1N) 
added dropwise over 5 min. The reaction mixture was stirred at 0oC for 1 hr and returned to 
room temperature and stirred for a further 17 hr. The reaction mixture was partitioned between 
EtOAc (50 mL) and KHSO4 (50 mL, 1N), and the aqueous phase was washed twice with       
CHCl3 (10 mL). The organic phase was washed with saturated brine (50 mL) and dried with 
anhydrous Na2SO4 the solvent was removed in-vacuo. Flash chromatography on silica 
(EtOAc/petroleum ether 3:2, Rf = 0.39) gave N-(4-fluorobenzenesulfonyl) tert L-leucine                
L-methioninol 1.605 g (3.948 mmol, 71%) as a white solid. m.p. 183oC; IR ν max (KBr) 1641 
(CONH), 1030 (H2COH); 1H NMR ((CD3)2SO) (300 MHz) δH = 7.96-7.91 (2H, m, ArH), 7.86 
(1H, d, J = 9.9 Hz, NHCH), 7.72 (1H, d, J = 8.4 Hz, NHCH), 7.47-7.41 (2H, m, ArH), 4.71 (1H, 
t, J = 5.1 Hz, CH2OH of Met), 3.62-3.59 (2H, m, NHCH of Tle and NHCH of Met), 3.38-3.33 
(1H, m, CH2OH of Met), 3.23-3.15 (1H, m, CH2OH of Met), 2.16-2.12 (2H, m, SCH2 of Met), 
2.07 (3H, s, SCH3 of Met); 1.75-1.65 (1H, m, CHCH2CH2 of Met), 1.40-1.30 (1H, m, 
CHCH2CH2 of Met), 0.97 (9H, s, C(CH3)3 of Tle); 13C NMR ((CD3)2SO) δC = 168.7 (CONH of 
Tle), 164.1 (d, J = 248.9 Hz, F-C=), 138.0 (d, J = 2.7 Hz, =C-S), 129.6 (2C, d, J = 9.4 Hz,   
C=C-S), 116.0 (2C, d, J = 22.5 Hz, F-C=C), 63.9, 62.7, 50.1 (NHCH of Met), 34.1 (C(CH3)3 of 
Tle), 30.3 (CH2 of Met), 29.9 (CH2 of Met), 26.7 (3C, s, C(CH3)3 of Tle), 14.6 (SCH3 of Met); 
(HRMS) (CH3OH) calcd. for C17H28FN2O4S2 [M + H]+: 407.1475, found 407.1476. 
 
N-(4-Fluorobenzenesulfonyl) tert-leucine L-methioninal [(S)-2-(4-
fluorophenylsulfonamido)-3,3-dimethyl-N-((S)-4-(methylthio)-1-oxobutan-2-
yl)butanamide] 
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N-(4-Fluorobenzenesulfonyl) tert L-leucine-L-methioninol 1.363 g (3.353 mmol, 1 equiv.) was 
dissolved in DMSO (28 mL) and DCM (28 mL) and DIPEA (2.3 mL) (13.410 mmol, 4 equiv.) 
added. A separate vial containing SO3.Pyr 2.135 g (13.410 mmol, 4 equiv.) dissolved in DMSO 
(7 mL), was heated and added to the reaction mixture over 3 min. The reaction was left stirring 
for 2 hr at room temperature. The mixture was partitioned between EtOAc (25 mL) and HCl   
(25 mL; 1N), the aqueous phase was washed twice with EtOAc (25 mL). The combined organic 
phases were washed with saturated NaHCO3 (25 mL) and saturated brine (25 mL) and dried with 
anhydrous Na2SO4. The solvent was removed in-vacuo to give N-(4-fluorobenzenesulfonyl)    
tert L-leucine L-methioninal 1.343 g (3.319 mmol, 99%) as a white solid. m.p. 49-50oC;            
IR ν max (KBr) 1732 (CHO), 1663 (CONH); 1H NMR ((CD3)2SO) (300 MHz) δH = 9.18 (1H, s, 
CHO of Met), 8.48 (1H, d, J = 6.0 Hz, NHCH), 8.03 (1H, d, J = 10.2 Hz, NHCH), 7.98-7.93 
(2H, m, ArH), 7.51-7.45 (2H, m, ArH), 3.95-3.90 (1H, m, NHCH of Met), 3.71 (1H, d,               
J = 9.6 Hz, NHCH of Tle), 2.40-2.30 (2H, m, SCH2 of Met), 2.10 (3H, s, SCH3 of Met),        
2.00-1.85 (1H, m, CHCH2CH2 of Met), 1.73-1.62 (1H, m, CHCH2CH2 of Met), 1.03 (9H, s, 
C(CH3)3 of Tle; 13C NMR ((CD3)2SO) δC = 199.9 (CHO of Met), 169.7 (CONH of Tle), 164.2 
(d, J = 249.4 Hz, F-C=), 137.8 (d, J = 3.3 Hz, =C-S), 129.7 (2C, d, J = 9.375 Hz, C=C-S), 129.6, 
116.0 (2C, d, J = 22.6 Hz, F-C=C), 63.6 (NHCH of Tle), 57.5 (NHCH of Met), 34.1 (C(CH3)3 of 
Tle), 29.4 (CH2 of Met), 27.4 (CH2 of Met), 26.6 (3C, s, C(CH3)3 of Tle), 14.4 (SCH3 of Met); 
(HRMS) (CH3CN) calcd. for C17H26FN2O4S2 [M + H]+: 405.1318, found 405.1331. 
 
L-Tyrosinol methyl ester hydrochloride [(S)-3-(4-hydroxyphenyl)-1-methoxy-1-oxopropan-
2-aminium chloride] 
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To a solution of L-tyrosine 1.500 g (8.278 mmol, 1 equiv.) in MeOH (19.2 mL), at -20oC was 
slowly added SOCl2 (4.8 mL) (66.225 mmol, 8 equiv.) over 15 min and the mixture stirred for    
1 hr at 0°C and was returned to room temperature and stirred for a further 18 hr. MeOH         
(100 mL) added and the solvent removed in-vacuo to give L-tyrosine methyl ester hydrochloride 
1.774 g (7.657 mmol, 93%) as a white solid. lit. m.p. 190oC124 m.p. 192oC. 1H NMR ((CD3)2SO) 
(300 MHz) δH = 9.60 (1H, s, PhOH), 8.75 (3H, s, CHNH3+) 7.10 (2H, d, J = 8.4 Hz, ArH), 6.82 
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(2H, d, J = 8.4 Hz, ArH), 4.25-4.21 (1H, m, COCH), 3.75 (3H, s, OCH3) 3.20-3.04 (2H, m, 
CHCH2ArH); (HRMS) (CH3OH) calcd. for the free amine C10H14NO3 [M + H]+: 196.0974, 
found 196.0972. 
 
(S)-Methyl 2-(1-(4-fluorophenylsulfonamido)cyclohexanecarboxamido)-3-(4-
hydroxyphenyl)propanoate 
 
N
H
S
O
H
N
F
O O
OMe
O
OH
Cl- +H3N OMe
OH
O
N
H
S
O
OH
F
O O
2.1.8a
2.1.9a
2.1.10g  
 
To a solution of 1-(4-fluorophenylsulfonamido)cyclohexanecarboxylic acid 1.800 g            
(5.974 mmol, 1 equiv.) in DMF (10 mL) kept under N2 L-tyrosine methyl ester hydrochloride 
1.522 g (6.571 mmol, 1.1 equiv.) added. DIPEA (2.3 mL) (13.143 mmol, 2.2 equiv.) added 
followed by the slow addition of HATU 2.498 g (6.571 mmol, 1.1 equiv.) over 15 min and the 
reaction stirred for 2 days at room temperature. The reaction mixture was partitioned between 
EtOAc (40 mL) and HCl (40 mL; 1N), and the aqueous phase washed twice with EtOAc         
(40 mL). The combined organic phases were washed with saturated NaHCO3 (40 mL) and               
saturated brine (40 mL) and dried with anhydrous MgSO4 and the solvent                  
removed in-vacuo. Flash chromatography on silica (EtOAc/petroleum ether 1:1,                   
Rf = 0.29) gave (S)-methyl 2-(1-(4-fluorophenylsulfonamido)cyclohexanecarboxamido)-3-(4-
hydroxyphenyl)propanoate 2.315g (4.838 mmol, 81%) as a light yellow solid. m.p. 57-58oC. IR 
ν max (KBr) 1736 (COOCH3), 1655 (CONH), 1040 (ArCOH); 1H NMR ((CD3)2SO, 298 K) 
(300 MHz) δH = 9.33 (1H, s, PhOH of Tyr), 7.92-7.87 (3H, m, FArH and NH), 7.50-7.43 (3H, 
m, FArH and NH), 7.04 (2H, d, J = 8.4 Hz, ArH of Tyr), 6.78-6.74 (2H, m, ArH of Tyr),     
4.27-4.20 (1H, m, NHCH of Tyr), 2.91 (2H, d, J = 6.6 Hz, CHCH2ArH of Tyr), 1.87-1.72 (4H, 
m, CH2’s of Chx), 1.42-1.25 (6H, m, CH2’s of Chx); 13C NMR ((CD3)2SO) δC = 173.1 (CONH 
of Chx), 171.8 (COOCH3 of Tyr), 164.1 (d, J = 249.5 Hz, F-C=), 156.4 (HO-C= of Tyr), 139.2 
(d, J = 2.8 Hz, =C-S), 130.4 (2C, s, HO-C=C-C of Tyr), 129.8 (2C, d, J = 9.4 Hz, C=C-S), 126.7 
(CH2-C= of Tyr), 116.1 (2C, d, J = 22.6 Hz, F-C=C), 115.3 (2C, s, HO-C=C of Tyr), 61.6, 54.1, 
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51.9, 36.5, 32.9, 24.9, 21.1; (HRMS) (CH3OH) calcd. for C23H28FN2O6S [M + H]+: 479.1652, 
found 479.1647. 
 
(S)-1-(4-Fluorophenylsulfonamido)-N-(1-hydroxy-3-(4-hydroxyphenyl)propan-2-
yl)cyclohexanecarboxamide 
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A solution of (S)-methyl 2-(1-(4-fluorophenylsulfonamido)cyclohexanecarboxamido)-3-(4-
hydroxyphenyl)propanoate 2.200 g (4.597 mmol, 1 equiv.) in THF (9.2 mL) under N2, was 
cooled to 0oC in an ice bath. LiAlH4/THF (5.1 mL; 1N) added dropwise slowly over 5 min and 
the mixture stirred at 0oC for 1 hr and allowed to come to room temperature and stirred for a 
further 17 hr. The mixture was partitioned between EtOAc (50 mL) and KHSO4 (50 mL; 1N), 
and the aqueous phase was washed twice with CHCl3 (10 mL). The organic phase was washed 
with saturated brine (50 mL) and dried with anhydrous Na2SO4 the solvent removed                  
in-vacuo. Flash chromatography on silica (EtOAc/petroleum ether 3:1, Rf = 0.35) gave                  
(S)-1-(4-fluorophenylsulfonamido)-N-(1-hydroxy-3-(4-hydroxyphenyl)propan-2-
yl)cyclohexanecarboxamide 1.522 g (3.378 mmol, 73%) as a yellow solid. m.p. 77oC; IR ν max 
(KBr) 1651 (CONH), 1040 (H2COH); 1H NMR ((CD3)2SO) (300 MHz) δH = 9.22 (1H, s, PhOH 
of Tyr), 7.97-7.92 (2H, m, FArH), 7.85 (1H, s, NHC of Chx), 7.51-7.45 (2H, m, FArH),       
7.12-7.07 (3H, m, ArH of Tyr and NHCH of Tyr), 6.74 (2H, d, J = 8.4 Hz, ArH of Tyr), 4.77 
(1H, t, J = 5.1 Hz, CH2OH of Tyr), 3.85-3.75 (1H, m, NHCH of Tyr), 3.42-3.27 (2H, m, CH2OH 
of Tyr), 2.81-2.74 (1H, m, CHCH2ArH of Tyr), 2.65-2.58 (1H, m, CHCH2ArH of Tyr),        
1.85-1.65 (4H, m, CH2’s of Chx), 1.36-1.20 (6H, m, CH2’s of Chx); 13C NMR ((CD3)2SO)        
δC = 173.2 (CONH of Chx), 164.2 (d, J = 250.0 Hz, F-C=), 155.8 (HO-C= of Tyr), 139.7     
(=C-S), 130.4 (2C, s, HO-C=C-C of Tyr), 129.8 (2C, d, J = 9.9 Hz, C=C-S), 129.2 (CH2-C= of 
Tyr), 116.2 (2C, d, J = 22.5 Hz, F-C=C), 115.3 (2C, s, HO-C=C of Tyr), 62.1, 61.9, 52.9, 35.7, 
33.6, 32.8, 25.0, 21.3; (HRMS) (CH3OH) calcd. for C22H28FN2O5S [M + H]+: 451.1703,      
found 451.1725. 
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(S)-1-(4-Fluorophenylsulfonamido)-N-(1-(4-hydroxyphenyl)-3-oxopropan-2-
yl)cyclohexanecarboxamide 
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(S)-1-(4-Fluorophenylsulfonamido)-N-(1-hydroxy-3-(4-hydroxyphenyl)propan-2-
yl)cyclohexanecarboxamide 1.170 g (2.597 mmol, 1 equiv.) was dissolved in DMSO (10 mL) 
and DCM (14 mL), DIPEA (1.8 mL) (10.388 mmol, 4 equiv.) added. A vial containing SO3.Pyr 
1.653 g (10.388 mmol, 4 equiv.) dissolved in DMSO (5 mL), was heated and added slowly to the 
reaction mixture over 3 min. The reaction was left stirring for 2 hr at room temperature.          
The reaction mixture was partitioned between EtOAc (25 mL) and HCl (25 mL; 1N) and the 
aqueous phase washed twice with EtOAc (25 mL). The combined organic phases were washed 
with saturated NaHCO3 (25 mL) and saturated brine (25 mL) and dried with anhydrous Na2SO4. 
The solvent was removed in-vacuo. Flash chromatography on silica (EtOAc/petroleum ether 2:1,     
Rf = 0.50) gave (S)-1-(4-fluorophenylsulfonamido)-N-(1-(4-hydroxyphenyl)-3-oxopropan-2-
yl)cyclohexanecarboxamide 520 mg (1.159 mmol, 45%) as an off white solid. m.p. 86oC.         
IR ν max (KBr) 1730 (CHO), 1657 (CONH), 1041 (ArCOH); 1H NMR ((CD3)2SO) (300 MHz) 
δH = 9.42 (1H, s, CHO of Tyr), 9.29 (1H, s, PhOH of Tyr), 7.96-7.89 (4H, m, FArH and             
2 x NH), 7.50-7.44 (2H, m, FArH), 7.09-7.06 (2H, m, ArH of Tyr), 6.75-6.72 (2H, m, ArH of 
Tyr), 4.19-4.11 (NHCH of Tyr), 3.08-3.01 (1H, m, CHCH2ArH of Tyr), 2.89-2.82 (1H, m, 
CHCH2ArH of Tyr), 1.85-1.70 (4H, m, CH2’s of Chx), 1.40-1.20 (6H, m, CH2’s of Chx);        
13C NMR ((CD3)2SO) δC = 200.9 (CHO of Tyr), 173.9 (CONH of Chx), 164.1 (d, J = 249.4 Hz, 
F-C=), 156.1 (HO-C= of Tyr), 139.6 (d, J = 2.7 Hz, =C-S), 130.4 (2C, s, HO-C=C-C= of Tyr), 
129.7 (2C, d, J = 8.7 Hz, C=C-S), 127.5 (CH2-C= of Tyr), 116.1 (2C, d, J = 23.0 Hz, F-C=C), 
115.2 (2C, s, HO-C=C- of Tyr), 61.6, 60.3, 33.1, 33.0, 24.8, 21.2; (HRMS) (CH3CN) calcd. for 
C22H26FN2O5S [M + H]+: 449.1546, found 449.1537. 
 
N-(4-Fluorobenzenesulfonyl) L-valine L-methioninol [(S)-2-(4-fluorophenylsulfonamido)-N-
((S)-1-hydroxy-4-(methylthio)butan-2-yl)-3-methylbutanamide] 
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N-(4-Fluorobenzenesulfonyl) L-valine, 1.800 g (6.538 mmol, 1 equiv.) was dissolved in (90 mL) 
of DMF kept under argon. L-methioninol 972 mg (7.192 mmol, 1.1 equiv.) added and the 
mixture stirred for 5 min until it was completely dissolved. The mixture was treated with the 
base DIPEA (2.5 mL) (14.38 mmol, 2.2 equiv.). HATU 2.735 g (7.192 mmol, 1.1 equiv.) added 
to the mixture slowly over 15 min and the mixture stirred for 24 hr at room temperature.       
Mixture was partitioned between EtOAc (40 mL) and HCl (40 mL; 1N), the aqueous phase was 
washed twice with EtOAc (40 mL). The combined organic phases were washed with saturated      
NaHCO3 (40 mL) saturated brine (40 mL) and dried with anhydrous MgSO4 and the solvent 
removed in-vacuo. Flash chromatography on silica (EtOAc/petroleum ether 1:4, Rf = 0.45) gave            
N-(4-fluorobenzenesulfonyl) L-valine L-methioninol 1.440 g (3.67 mmol, 56%) as a white solid. 
m.p. 177oC; IR ν max (KBr) 3520 (H2COH), 1638 (CONH), 1057 (H2COH); 1H NMR 
((CD3)2SO) (300 MHz) δH = 7.94-7.89 (3H, m, ArH and NHCH), 7.74 (1H, d, J = 8.1 Hz, 
NHCH), 7.48-7.42 (2H, m, ArH), 4.74 (1H, t, J = 5.3 Hz, CH2OH of Met), 3.66-3.55 (2H, m, 
NHCH of Met and NHCH of Val), 3.36-3.19 (2H, m, CH2OH of Met), 2.29-2.17 (2H, m, SCH2 
of Met), 2.08 (3H, s, SCH3 of Met), 1.92-1.77 (2H, m, CH(CH3)2 of Val and CHCH2CH2 of 
Met), 1.46-1.42 (1H, m, CHCH2CH2 of Met), 0.90 (3H, d, J = 6.6 Hz, CH3 of Val), 0.87 (3H, d, 
J = 6.6 Hz, CH3 of Val); 13C NMR ((CD3)2SO) δC = 169.8 (CONH of Val), 164.1 (d,                  
J = 248.9 Hz, F-C=), 137.8 (=C-S), 129.6 (2C, d, J = 8.8 Hz, C=C-S), 116.0 (2C, d, J = 22.5 Hz, 
F-C=C), 62.9, 61.7, 50.1 (NHCH of Met), 31.2, 30.5, 29.9, 19.2 (CH3 of Val), 18.2 (CH3 of 
Val), 14.6 (SCH3 of Met); (HRMS) (CH3OH) calcd. for C16H26FN2O4S2 [M + H]+: 393.1318, 
found 393.1331.  
 
N-(4-Fluorobenzenesulfonyl) L-valine L-methioninal [(S)-2-(4-fluorophenylsulfonamido)-3-
methyl-N-((S)-4-(methylthio)-1-oxobutan-2-yl)butanamide]  
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To a solution of N-(4-fluorobenzenesulfonyl) L-valine L-methioninol 1.300 g (3.315 mmol,         
1 equiv.) in DMSO (20 mL) and DCM (6 mL), DIPEA (2.3 mL) (13.26 mmol, 4 equiv.). A vial 
containing SO3.Pyr 2.111 g (13.26 mmol, 4 equiv.) dissolved in DMSO (10 mL) was heated and 
added slowly over 5 min to the reaction mixture. This mixture was stirred for 2 hr at room 
temperature. The reaction mixture was partitioned between EtOAc (25 mL) and HCl (25 mL; 
1N), and the aqueous phase was washed twice with EtOAc (25 mL). The combined organic 
phases were washed with saturated NaHCO3 (25 mL) and saturated brine (25 mL) and dried with          
anhydrous MgSO4 and the solvent was removed in-vacuo. Flash chromatography on                  
silica (EtOAc/petroleum ether 1:4, Rf = 0.65) gave N-(4-fluorobenzenesulfonyl) L-valine                  
L-methioninal 343 mg (0.879 mmol, 24%) as a white solid. m.p. 159oC; IR ν max (KBr) 1724 
(CHO), 1643 (CONH); 1H NMR ((CD3)2SO) (300 MHz) δH = 9.26 (1H, s, CHO of Met), 8.49 
(1H, d, J = 6.6 Hz, NHCH), 8.09 (1H, d, J = 9.3 Hz, NHCH), 7.94-7.89 (2H, m, ArH), 7.50-7.44 
(2H, m, ArH), 4.06-4.02 (1H, m, NHCH of Met), 3.66 (1H, app t, J = 7.1 Hz, NHCH of Val), 
2.44-2.36 (2H, m, SCH2 of Met), 2.09-1.91 (5H, m, SCH3 of Met, CH(CH3)2 of Val and 
CHCH2CH2 of Met), 1.74-1.65 (1H, m, CHCH2CH2 of Met), 0.95-0.89 (6H, CH(CH3)2 of Val); 
13C NMR ((CD3)2SO) δC = 200.1 (CHO of Met), 170.8 (CONH of Val), 164.1 (d, J = 249.5 Hz, 
F-C=), 137.7 (=C-S), 129.7 (2C, d, J = 9.3 Hz, C=C-S), 116.0 (2C, d, J = 22.5 Hz, F-C=C), 61.4 
(NHCH of Val), 57.4 (NHCH of Met), 31.0, 29.4, 27.4, 19.1 (CH3 of Val), 18,2 (CH3 of Val), 
14.5 (SCH3 of Met); (HRMS) (CH3CN) calcd. for C16H24FN2O4S2 [M + H]+: 391.1162,       
found 391.1151. 
 
(S)-1-(4-Fluorophenylsulfonamido)-N-(1-hydroxy-4-methylpentan-2-
yl)cyclohexanecarboxamide 
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O
H
N
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O
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F
O O
H2N OH
2.1.8a
2.1.31
2.1.11i  
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A solution containing 1-(4-fluorophenylsulfonamido)cyclohexanecarboxylic acid 1.800 g   
(5.974 mmol, 1 equiv.) dissolved in DMF (8 mL) kept under N2, added a solution of L-leucinol 
770 mg (6.571 mmol, 1.1 equiv.) dissolved in DMF (2 mL). DIPEA (1.2 mL) (7.169 mmol,          
1.2 equiv.) added followed by the slow addition of HATU 2.498 g (6.571 mmol, 1.1 equiv.) over 
15 min. The solution was stirred for 2 days at room temperature. The reaction mixture was 
partitioned between EtOAc (40 mL) and HCl (40 mL; 1N), and the aqueous phase washed twice 
with EtOAc (40 mL). The combined organic phases were washed with saturated NaHCO3       
(40 mL) and saturated brine (40 mL) and dried with anhydrous Na2SO4 and the solvent removed 
in-vacuo. Flash chromatography on silica (EtOAc/petroleum ether 3:2, Rf = 0.30) gave (S)-1-(4-
fluorophenylsulfonamido)-N-(1-hydroxy-4-methylpentan-2-yl)cyclohexanecarboxamide 1.963 g 
(4.901 mmol, 82%) as a white solid. m.p. 79-80oC; IR ν max (KBr) 1647 (CONH), 1032 
(H2COH); 1H NMR ((CD3)2SO) (300 MHz) δH = 7.99-7.94 (2H, m, ArH), 7.81 (1H, s, NHC of 
Chx), 7.52-7.46 (2H, m, ArH), 7.01 (1H, d, J = 8.4 Hz, NHCH of Leu), 4.63 (1H, t,                  
J = 5.4 Hz, CH2OH of Leu), 3.85-3.75 (1H, m, NHCH of Leu), 3.44-3.40 (1H, m, CH2OH of 
Leu), 3.30-3.22 (1H, m, CH2OH of Leu), 1.85-1.67 (5H, m, CH2’s of Chx and CH(CH3)2 of 
Leu), 1.48-1.24 (8H, m, CH2’s of Chx, and CHCH2CH of Leu), 0.95 (3H, d, J = 6.6 Hz, CH3 of 
Leu), 0.91 (3H, d, J = 6.3 Hz, CH3 of Leu); 13C NMR ((CD3)2SO) δC = 173.1 (CONH of Chx), 
164.0 (d, J = 248.9 Hz, F-C=), 139.8 (d, J = 3.3 Hz, =C-S), 129.5 (2C, d, J = 9.4 Hz, C=C-S), 
116.1 (2C, d, J = 22.6 Hz, F-C=C), 63.5, 62.0, 48.9, 32.9, 24.8, 24.2, 23.4, 22.1, 21.1; (HRMS) 
(CH3OH) calcd. for C19H30FN2O4S, [M + H]+: 401.1910, found 401.1899.  
 
(S)-1-(4-Fluorophenylsulfonamido)-N-(4-methyl-1-oxopentan-2-
yl)cyclohexanecarboxamide 
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(S)-1-(4-Fluorophenylsulfonamido)-N-(1-hydroxy-4-methylpentan-2-
yl)cyclohexanecarboxamide 1.356 mg (3.386 mmol, 1 equiv.) was dissolved in DMSO (10 mL) 
and DCM (14 mL), then DIPEA (2.4 mL) (13.544 mmol, 4 equiv.) added. A separate vial 
containing SO3.Pyr 2.156 mg (13.544 mmol, 4 equiv.) dissolved in DMSO (5 mL) was heated 
and added to the reaction mixture over 3 min and the mixture stirred for 2 hr at room 
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temperature. The reaction mixture was partitioned between EtOAc (25 mL) and HCl (25 mL; 
1N) and the aqueous phase was washed twice with EtOAc (25 mL). The combined organic 
phases where washed with saturated NaHCO3 (25 mL) and saturated brine (25 mL) and dried 
with anhydrous Na2SO4. The solvent was removed in-vacuo to give a yellow solid               
which was recrystallised from EtOAc/petroleum ether 1:1 (Rf = 0.43) to give                  
(S)-1-(4-fluorophenylsulfonamido)-N-(4-methyl-1-oxopentan-2-yl)cyclohexanecarboxamide  
954 mg (2.394 mmol, 71%) as white solid. m.p. 159oC. IR ν max (KBr) 1731 (CHO), 1655 
(CONH); 1H NMR ((CD3)2SO) (300 MHz) δH = 9.40 (1H, s, CHO of Leu), 8.00-7.96 (3H, m, 
ArH and NHCH of Leu), 7.86 (1H, s, NHC of Chx), 7.51-7.48 (2H, m, ArH), 4.02-3.98 (1H, m, 
NHCH of Leu), 1.85-1.70 (5H, m, CH2’s of Chx and CH(CH3) of Leu), 1.63-1.50 (2H, m, 
CHCH2CH of Leu), 1.42-1.25 (6H, m, CH2’s of Chx), 0.97 (3H, d, J = 6.5 Hz, CH3 of Leu), 
0.94 (3H, d, J = 6.5 Hz, CH3 of Leu); 13C NMR ((CD3)2SO) δC = 202.0 (CHO of Leu), 174.0 
(CONH of Chx), 164.0 (d, J = 248.9 Hz, F-C=), 139.7 (d, J = 3.2 Hz, =C-S), 129.6 (2C, d,         
J = 9.3 Hz, C=C-S), 116.1 (2C, d, J = 22.6 Hz, F-C=C), 61.5, 57.0, 36.6 (CHCH2CH of Leu), 
33.4, 32.8, 24.7, 24.0, 23.2, 21.6, 21.1; (HRMS) (CH3CN) calcd. for C19H28FN2O4S [M + H]+: 
399.1754, found 399.1762.  
 
Boc L-tyrosinol [(S)-tert-butyl 1-hydroxy-3-(4-hydroxyphenyl)propan-2-ylcarbamate] 
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2.1.32 2.1.34  
 
A solution of boc L-tyrosine methyl ester 4.425 g (15.000 mmol, 1 equiv.) in EtOH (112 mL) 
and anhydrous THF (75 mL) kept under N2 was cooled to 0oC in an ice bath. LiCl 2.550 g           
(60.00 mmol, 4 equiv.) added followed by granulated NaBH4 2.250 g (60.00 mmol, 4 equiv.) in 
one portion and the mixture stirred for 1 hr. The mixture was heated gently to 40oC in a silica oil 
bath and was stirred for a further 2 days. The reaction mixture was concentrated on a rotatory 
evaporator to half the original volume and was acidified to pH 3 with 10 % citric acid solution 
(30 mL). The mixture was partitioned between EtOAc (50 mL) and citric acid (50 mL) (10%) 
solution and the aqueous phase was washed twice with EtOAc (50 mL. The combined organic 
phases were dried with anhydrous MgSO4. The solvent was removed in-vacuo.                  
Flash chromatography on silica (EtOAc/petroleum ether 1:1, Rf = 0.21) gave boc L-tyrosinol 
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2.807 g (10.580 mmol, 71%) as a white solid. lit. m.p. 120oC125 m.p. 124oC. 1H NMR (CD3OD)               
(300 MHz) δH = 7.03 (2H, d, J = 8.4 Hz, ArH), 6.70-6.67 (2H, m, ArH), 3.70-3.65 (1H, m, 
NHCH), 3.47-3.45 (2H, m, CH2OH), 2.78-2.72 (1H, m, CH2ArH), 2.60-2.55 (1H, m, CH2ArH), 
1.37 (9H, s, C(CH3)3 of boc); (HRMS) (CH3OH) calcd. for C14H22NO4 [M + H]+: 268.1549, 
found 268.1540.  
 
L-Tyrosinol hydrochloride [(S)-1-hydroxy-3-(4-hydroxyphenyl)propan-2-aminium 
chloride] 
 H
N
OH
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Cl- +H3N OH
OH
2.1.34 2.1.35  
 
To boc L-tyrosinol 2.501 g (9.355 mmol, 1 equiv.), HCl/ether (30 mL; 2N) added and the 
mixture stirred for 15 hr at room temperature. The solvent was removed in-vacuo to give           
L-tyrosinol hydrochloride 1.902 g (9.339 mmol, 99%) as a white green solid. m.p. 160oC;         
1H NMR ((CD3)2SO) (500 MHz) δH = 9.52 (1H, s, PhOH), 8.21 (3H, s, NH3+), 7.14 (2H, d,        
J = 5.1 Hz, ArH) 6.84-6.82 (2H, m, ArH), 5.42 (1H, m, CH2OH), 3.60-3.45 (2H, m, NCH and 
CH2OH), 3.30-3.25 (1H, m, CH2OH), 2.92 (1H, dd, J = 13.5 Hz and J = 5.0 Hz, CH2ArH), 2.79 
(1H, dd, J = 13.0 Hz and J = 9.5 Hz, CH2ArH), (HRMS) (CH3OH) calcd. for the free amine 
C9H14NO2 [M + H]+: 168.1025, found 168.1024.  
 
N-(4-Fluorobenzenesulfonyl) L-valine L-tyrosinol [(S)-2-(4-fluorophenylsulfonamido)-N-
(S)-1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl)-3-methylbutanamide] 
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L-Tyrosinol hydrochloride 1.000 g (4.910 mmol, 1.2 equiv.) dissolved in DMF (10 mL) under 
argon, N-(4-fluorobenzenesulfonyl) L-valine 1.126 g (4.092 mmol, 1 equiv.) added and 
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dissolved. Subsequently the solution was treated with DIPEA (1.6 mL) (9.002 mmol, 2.2 equiv.). 
HATU 1.711 g (4.501 mmol, 1.1 equiv.) added slowly over 15 min and was left stirring over 
night. The reaction mixture was partitioned between EtOAc (20 mL) and HCl (20 mL; 1N), the 
aqueous phase was washed twice with EtOAc (20 mL). The combined organic phases were 
washed with saturated NaHCO3 (20 mL) and saturated brine (20 mL) and dried with     
anhydrous Na2SO4 the solvent was removed in-vacuo. Flash chromatography on silica      
(EtOAc/petroleum ether 3:1, Rf = 0.40) gave N-(4-fluorophenylsulfonyl) L-valine L-tyrosinol 
481.1 mg (1.133 mmol, 28%) as a white solid. m.p. 190-192oC (decomp.); IR ν max (KBr) 1643 
(CONH), 1040 (H2COH); 1H NMR ((CD3)2SO, 298 K) (300 MHz) δH = 9.26 (1H, s, PhOH of 
Tyr) 7.89-7.84 (3H, m, FArH and NHCH) 7.75 (1H, d, J = 8.1 Hz, NHCH) 7.42-7.36 (2H, m, 
FArH), 7.03 (2H, d, J = 8.4 Hz, ArH of Tyr), 6.76 (2H, d, J = 8.4 Hz, ArH of Tyr), 4.71 (1H, t,               
J = 5.1 Hz, CH2OH of Tyr), 3.72-3.58 (2H, m, NHCH of Tyr and NHCH of Val), 3.29-3.19 (2H, 
m, CH2OH of Tyr), 2.66-2.59 (1H, m, CH2ArH of Tyr), 2.36 (1H, dd, J = 13.5 Hz and 6.6 Hz, 
CH2ArH of Tyr), 1.93-1.86 (1H, m,CH(CH3) of Val), 0.88-0.86 (6H, m, CH(CH3)2 of Val);    
13C NMR ((CD3)2SO) δC = 169.5 (CONH of Val), 164.1 (d, J = 249.1 Hz, F-C=), 155.7 (HO-C= 
of Tyr), 137.8 (d, J = 2.6 Hz, =C-S), 130.0 (2C, s, HO-C=C-C- of Tyr) 129.6 (2C, d, J = 9.2 Hz, 
C=C-S), 129.0 (CH2-C= of Tyr), 115.9 (2C, d, J = 22.8 Hz, F-C=C), 115.0 (2C, s, HO-C=C of 
Tyr), 62.0, 61.6, 52.8 (NHCH of Tyr), 35.5 (CHCH2ArH of Tyr) 31.1 (CH(CH3)2 of Val), 19.2 
(CH3 of Val), 18.2 (CH3 of Val); (HRMS) (CH3OH) calcd. for C20H26FN2O5S [M + H]+: 
425.1546, found 425.1526. 
 
N-(4-Fluorobenzenesulfonyl) L-valine L-tyrosinal [(S)-2-(4-fluorophenylsulfonamido)-N-
((S)-1-(4-hydroxyphenyl)-3-oxopropan-2-yl)-3-methylbutanamide] 
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To a solution of N-(4-fluorobenzenesulfonyl) L-valine L-tyrosinol 420 mg (0.990 mmol,              
1 equiv.) in DMSO (6 mL) and DCM (10 mL) added DIPEA (0.69 mL) (3.960 mmol, 4 equiv.).        
A separate vial of SO3.Pyr 630.2 mg (3.960 mmol, 4 equiv.) dissolved in DMSO (4 mL) was 
heated and added dropwise to the reaction mixture over 5 min and the reaction stirred for 2 hr at 
room temperature. The reaction mixture was partitioned between EtOAc (10 mL) and             
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HCl (10 mL; 1N) and the aqueous phase was washed twice with EtOAc (10 mL). The combined 
organic phase was washed with saturated NaHCO3 (10 mL) and saturated brine (10 mL) dried 
with anhydrous Na2SO4 the solvent was removed in-vacuo. Flash chromatography on silica 
(EtOAc/petroleum ether 3:2, Rf = 0.23) gave N-(4-fluorobenzenesulfonyl) L-valine L-tyrosinal 
292 mg (0.691 mmol, 70%) as a white solid. m.p. 79oC (decomp.); IR ν max (KBr) 1732 (CHO), 
1659 (CONH), 1043 (ArCOH); 1H NMR ((CD3)2SO) (300 MHz) δH = 9.34 (1H, s, CHO of Tyr), 
9.18 (1H, s, PhOH of Tyr), 8.45 (1H, d, J = 6.9 Hz, NHCH) 8.01 (1H, d, J = 9.6 Hz, NHCH)       
7.89-7.83 (2H, m, FArH) 7.44-7.36 (2H, m, FArH), 7.06-7.00 (2H m, ArH of Tyr), 6.78-6.70 
(2H m, ArH of Tyr), 4.05-4.00 (1H, m, NHCH of Tyr) 3.70 (1H, app t, J = 6.6 Hz, NHCH of 
Val), 2.82 (1H, dd, J = 14.0 Hz and J = 5.6 Hz, CH2ArH of Tyr), 2.71-2.59 (1H, m, CH2ArH of 
Tyr), 1.94-1.87 (1H, m, CH(CH3)2 of Val), 0.90-0.83 (6H, m, CH(CH3)2 of Val); 13C NMR 
((CD3)2SO) δC = 200.0 (CHO of Tyr), 170.6 (CONH of Val), 164.1 (d, J = 248.9 Hz, F-C=), 
156.1 (HO-C= of Tyr), 137.7 (d, J = 3.3 Hz, =C-S), 130.1 (2C, s, HO-C=C-C= of Tyr), 129.7 
(2C, d, J = 9.3 Hz, C=C-S), 127.3 (CH2-C= of Tyr), 115.9 (2C, d, J = 22.6 Hz, F-C=C), 115.2 
(2C, s, HO-C=C- of Tyr), 61.4, 60.2, 59.9, 32.7, 31.0, 20.9, 19.2 (CH3 of Val), 18.0 (CH3 of 
Val); (HRMS) (CH3CN) calcd. for C20H24FN2O5S [M + H]+: 423.1390, found 423.1384. 
 
Ethyl 5-formyl-1H-pyrrole-2-carboxylate and ethyl 4-formyl-1H-pyrrole-2-carboxylate. 
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The synthesis of 5-formyl pyrrole 2-carboxylate ethyl ester was preformed using          
Vilsmeier-Haack formylation116 of pyrrole 2-carboxylate ethyl ester. To a three necked flask 
(250 mL) fitted with a reflux condenser and dropping funnel added DMF (6.2 mL) and the 
solution cooled to 0oC in a ice bath stirring under argon. POCl3 (7.4 mL) (78.98 mmol,             
1.1 equiv.) added slowly over 15 min via a dropping funnel. A separate vial pyrrole                   
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2-carboxylate ethyl ester 10.000 g (71.8 mmol, 1 equiv.) was dissolved in DCE (18 mL) and 
added to the DMF-POCl3 complex slowly over 1 hr. The mixture was heated under reflux at 
120oC in a silica oil bath for 15 min. The reaction mixture was allowed to return to room 
temperature and a solution containing NaOAc.3H2O 48.2 g (359.00 mmol, 5 equiv.) in distilled 
water (80 mL) was slowly added over 5 min. The mixture was heated under reflux at 120oC in a 
silica oil bath for 20 min and was slowly returned to room temperature. The reaction mixture was 
partitioned with ether (200 mL) and the aqueous phase was washed twice more with ether     
(200 mL). The combined organic phase was washed with saturated brine and dried with 
anhydrous MgSO4 the solvent was removed in-vacuo. Flash chromatography on silica 
(EtOAc/petroleum ether 1:3, Rf = 0.25) gave 5-formyl pyrrole 2-carboxylate ethyl ester 6.20 g 
(37.08 mmol, 52%) as a light pink solid. lit. m.p. 72-74oC126 m.p. 75oC; 1H NMR ((CD3)2SO)     
(500 MHz) δH = 13.10 (1H, s, NH of Pyo), 9.80 (1H, s, CHO), 7.03 (1H, t, J = 1.8 Hz, CH of 
Pyo), 6.95 (1H, s, CH of Pyo), 4.39-4.35 (2H, m, OCH2CH3), 1.38 (3H, t, J = 7.0 Hz, 
OCH2CH3); (HRMS) (CH3OH) calcd. for C8H10NO3 [M + H]+: 168.0661, found 168.0659.  
Flash chromatography over silica (EtOAc/pet ether 1:2, Rf = 0.20) gave 4-formyl pyrrole           
2-carboxylate ethyl ester 3.03 g (18.12 mmol, 25%) as a orange solid m.p. 101-102oC127        
m.p. 104-105oC; 1H NMR ((CD3)2SO) (500 MHz) δH = 12.77 (1H, s, NH of Pyo), 9.85 (1H, s, 
CHO), 7.90 (1H, t, J = 1.8 Hz, NHCH of Pyo), 7.22 (1H, s, C=CHC of Pyo), 4.38-4.34 (2H, m, 
OCH2CH3), 1.40-1.36 (3H, m, OCH2CH3); (HRMS) (CH3OH) calcd. for C8H10NO3 [M + H]+: 
168.0661, found 168.0664. 
 
5-Formyl-1H-pyrrole-2-carboxylic acid 
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A two necked flask, (250 mL) fitted with a reflux condenser containing 5-formyl pyrrole           
2-carboxylate ethyl ester 5.32 g (31.82 mmol, 1 equiv.) was treated with a aqueous solution of 
KOH (160 mL; 0.796 N). The mixture was heated to 45oC on a silica oil bath and stirred for 2 hr. 
The reaction mixture was partitioned between EtOAc (50 mL) and HCl (50 mL; 1N), the 
aqueous phase was washed twice with EtOAc (50 mL). The combined organic phases were 
washed with saturated brine (50 mL) and dried with anhydrous MgSO4 the solvent was removed 
in-vacuo to give 5-formyl pyrrole 2-carboxylic acid 4.06 g (29.06 mmol, 91%) as an orange red 
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solid lit. m.p. 202-203oC128 m.p. 211oC (decomp. to carbon); 1H NMR ((CD3)2SO) (300 MHz)       
δH = 9.78 (1H, s, CHO), 7.03 (1H, app t, J = 2.4 Hz, CH of Pyo), 6.93 (1H, app t, J = 2.4 Hz, 
CH of Pyo). 
 
Boc L-valine L-methioninol [tert-butyl (S)-1-((S)-1-hydroxy-4-(Methylthio)butan-2-
ylamino)-3-methyl-1-oxobutan-2-ylcarbamate] 
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To boc L-valine 6.806 g (31.320 mmol, 1.1 equiv.), L-methioninol 3.850 g (28.480 mmol            
1 equiv.) in DMF (40 mL) under argon added DIPEA (10.9 mL) (62.660 mmol, 2.2 equiv.), 
followed by the slow addition of HATU 11.924 g (31.320 mmol, 1.1 equiv.) over 15 min.       
The mixture was stirred for 3 days and partitioned between EtOAc (75 mL) and                  
HCl (75 mL; 1N). The aqueous phase was washed twice with EtOAc (75 mL) and the combined 
organic phases were washed with saturated NaHCO3 (75 mL) and saturated brine (75 mL) and 
dried with anhydrous MgSO4. The solvent was removed in-vacuo to give boc L-valine               
L-methioninol 8.005 g (23.933 mmol, 84%) as a white solid m.p. 91oC; IR ν max (KBr) 1682 
(COOt-Bu), 1655 (CONH), 1042 (H2COH); 1H NMR (CD3OD) (300 MHz) δH = 7.77 (1H, d,     
J = 8.7 Hz, NHCH of Met), 6.55 (1H, d, J = 9.0 Hz, NHCH of Val), 4.03-3.98 (1H, m, NHCH of 
Met), 3.80-3.74 (1H, m, NHCH of Val), 3.56-3.43 (2H, m, CH2OH of Met), 2.61-2.41 (2H, m, 
SCH2 of Met), 2.07-1.88 (5H, m, SCH3 of Met, CH(CH3)2 of Val and CHCH2CH2 of Met),  
1.76-1.65 (1H, m, CHCH2CH2 of Met), 1.44 (9H, s, OC(CH3)3 of boc), 0.95-0.91 (6H, m, 
CH(CH3)2 of Val). 13C NMR ((CD3)2SO) δC = 171.4 (CONH of Val), 155.6 (OCONH), 78.1 
(OC(CH3)3), 63.3 (CH2OH of Met), 60.3 (NHCH of Val), 50.0 (NHCH of Met), 30.8, 30.2, 
30.1, 28.3 (3C, s, C(CH3)3 of boc), 19.4 (CH3 of Val), 18.5 (CH3 of Val), 14.8 (SCH3 of Met); 
(HRMS) (CH3OH) calcd. for C15H31N2O4S [M + H]+: 335.2005, found 335.2013. 
 
L-Valine L-methioninol hydrochloride [(S)-1-((S)-1-hydroxy-4-(methylthio)butan-2-
ylamino)-3-methyl-1-oxobutan-2-aminium chloride] 
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A mixture of boc L-valine L-methioninol 4.000 g (11.959 mmol, 1 equiv.) and HCl/ether         
(50 mL; 2N) was stirred at room temperature for 15 hr. The solvent was removed in-vacuo to 
give L-valine L-methioninol hydrochloride 3.230 g (11.959 mmol, 100%) as a hydroscopic white 
solid. IR ν max (KBr) 1672 (CONH), 1049 (H2COH); 1H NMR (CD3OD) (300 MHz) δH = 8.17 
(1H d, J = 9.0 Hz, NHCH of Met), 4.07-4.02 (1H, m, NHCH of Met), 3.74-3.53 (3H, m, CH2OH 
of Met and CHCO of Val), 2.62-2.46 (2H, m, SCH2 of Met), 2.20-2.09 (1H, m, CH(CH3)2 of 
Val), 2.08 (3H, s, SCH3 of Met), 1.95-1.85 (1H, m, CHCH2CH2 of Met), 1.81-1.71 (1H, m, 
CHCH2CH2 of Met), 1.09 (3H, d, J = 4.5 Hz, CH3 of Val), 1.04 (3H, d, J = 4.5 Hz, CH3 of Val); 
13C NMR (CD3OD) δC = 169.7 (CONH of Val), 64.9 (CH2OH of Met), 60.1 (CHCO of Val), 
52.5 (NHCH of Met), 31.9, 31.8, 31.7, 19.2 (CH3 of Val), 18.2 (CH3 of Val), 15.5 (SCH3 of 
Met); (HRMS) (CH3OH) calcd. for the free amine C10H23N2O2S [M + H]+: 235.1480,          
found 235.1482. 
 
5-Formyl pyrrole 2-carboxylate L-valine L-methioninol [5-formyl-N-((S)-1-((S)-1-hydroxy-
4-(methylthio)butan-2-ylamino)-3-methyl-1-oxobutan-2-yl)-1H-pyrrole-2-carboxamide] 
 
Cl- +H3N
O
H
N
OH
S
H
N
H OH
O O
H
N
H N
H
H
N
OH
OO
O
S
2.2.13
2.2.4
2.1.11k  
To L-valine L-methioninol hydrochloride 3.050 g (11.281 mmol, 1.1 equiv.) in DMF (20 mL) 
kept under argon, added 5-formyl pyrrole 2-carboxylic acid 1.432 g (10.255 mmol, 1 equiv.).         
The solution was treated with DIPEA (4.3 mL) (24.612 mmol, 2.4 equiv.). EDCI.HCl 2.359 g 
(12.306 mmol, 1.2 equiv.) added slowly over 5 min followed by HOBt.H2O 1.884 g          
(12.306 mmol, 1.2 equiv.) added slowly to the mixture over 15 min. The mixture was stirred at 
room temperature for 1 day and partitioned between EtOAc (50 mL) and HCl (50 mL; 1N).    
The aqueous phase was washed twice with EtOAc (50 mL). The combined organic phases were 
washed with saturated brine (50 mL) and dried with anhydrous MgSO4 and the solvent removed 
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in-vacuo. Flash chromatography on silica (MeOH/DCM 1:19, Rf = 0.15,) gave 5-formyl pyrrole               
2-carboxylate L-valine L-methioninol 273 mg (0.768 mmol, 7%) as a yellow orange solid.      
m.p. 148oC; IR ν max (KBr) 1655 (CONH), 1650 (CONH), 1047 (H2COH); 1H NMR (CD3OD) 
(300 MHz) δH = 9.59 (1H, s, CHO of Pyo), 8.02 (1H, d, J = 9.0 Hz, NHCH), 7.01-6.99 (1H, m, 
CH of Pyo), 6.96 (1H, d, J = 3.9 Hz, CH of Pyo), 4.25 (1H, d, J = 8.4 Hz, NHCH of Val),    
4.06-4.00 (1H, m, NHCH of Met), 3.57-3.47 (2H, m, CH2OH of Met), 2.58-2.39 (2H, m, SCH2 
of Met), 2.20-2.05 (1H, m, CH(CH3)2 of Val), 2.01 (3H, s, SCH3 of Met), 1.95-1.84 (1H, m, 
CHCH2CH2 of Met), 1.78-1.65 (1H, m, CHCH2CH2 of Met), 1.04-0.91 (6H, m, CH(CH3)2 of 
Val); 13C NMR (CD3OD) δC = 182.6 (CHO of Pyo), 174.4 (CONH of Val), 163.5 (CONH of 
Pyo), 134.9 (C=C-CHO of Pyo), 126.7 (C=C-CONH of Pyo), 113.7, 109.5, 65.1 (CH2OH of 
Met), 61.0 (NHCH of Val), 52.2 (NHCH of Met), 32.1, 31.9, 31.8, 20.2 (CH3 of Val), 19.6 (CH3 
of Val), 15.6 (SCH3 of Met); (HRMS) (CH3OH) calcd. for C16H26N3O4S [M + H]+: 356.1644, 
found 356.1633. 
 
5-Formyl pyrrole 2-carboxylate L-valine L-methioninal [5-formyl-N-((S)-3-methyl-1-((S)-4-
(methylthio)-1-oxobutan-2-ylamino)-1-oxobutan-2-yl)-1H-pyrrole-2-carboxamide] 
 
 
H
N
H N
H
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N
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H N
H
H
N
H
OO
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2.1.11k 2.1.3k  
 
5-Formyl pyrrole 2-carboxylate L-valine L-methioninol 200 mg (0.563 mmol, 1 equiv.) was 
dissolved in DMSO (6 mL) and DCM (5 mL) and DIPEA (0.39 mL) (2.251 mmol, 4 equiv.) 
added. A separate vial SO3.Pyr 358 mg (2.251 mmol, 4 equiv.) was dissolved in DMSO (3 mL) 
and heated before addition to the reaction mixture. The mixture was stirred at room temperature      
for 2 hr and partitioned between EtOAc (10 mL) and HCl (10 mL; 1N). The aqueous phase was 
washed twice with EtOAc (10 mL). The combined organic phases were washed with saturated 
brine (10 mL) and dried with anhydrous MgSO4 and the solvent was removed in-vacuo.          
Flash chromatography on silica (EtOAc, Rf = 0.61) gave 5-formyl pyrrole 2-carboxylate                  
L-valine L-methioninal 49 mg (0.1386 mmol, 25%) as a yellow solid. m.p. 72oC; IR ν max (KBr) 
1734 (CHO), 1718 (CHO), 1665 (CONH), 1655 (CONH); 1H NMR ((CD3)2SO) (300 MHz)          
δH = 12.82 (1H, s, NH of Pyo), 9.74 (1H, s, CHO of Met), 9.54 (1H, s, CHO of Pyo), 8.72 (1H, 
d, J = 9.0 Hz, NHCH), 8.50 (1H, d, J = 8.4 Hz, NHCH), 7.09 (1H, d, J = 1.8 Hz, CH of Pyo), 
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7.07(1H, d, J = 1.8 Hz, CH of Pyo), 4.50 (1H, t, J = 7.5 Hz, NHCH of Val), 4.36-4.27 (1H, m, 
NHCH of Met) 2.70-2.50 (2H, m, SCH2 of Met), 2.26-2.09 (5H, m, SCH3 of Met, CH(CH3)2 of 
Val) and CHCH2CH2 of Met), 1.95-1.80 (CHCH2CH2 of Met), 1.06 (3H, d, J = 4.2 Hz, CH3 of 
Val), 1.04 (3H, d, J = 4.2 Hz, CH3 of Val); 13C NMR ((CD3)2SO) δC = 200.6 (CHO of Met), 
181.3 (CHO of Pyo), 171.7 (CONH of Val), 159.4 (CONH of Pyo), 134.2, 132.3, 118.3, 113.8, 
58.2, 57.5, 30.3, 29.5, 27.5, 19.4 (CH3 of Val), 18.6 (CH3 of Val), 14.5 (SCH3 of Met); (HRMS) 
(CH3CN) calcd. for C16H24N3O4S [M + H]+: 354.1488, found 354.1485. 
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